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Suhila Sawesi 
AN ONTOLOGY FOR FORMAL REPRESENTATION OF MEDICATION 
ADHERENCE-RELATED KNOWLEDGE: CASE STUDY IN BREAST CANCER 
Medication non-adherence is a major healthcare problem that negatively impacts 
the health and productivity of individuals and society as a whole. Reasons for medication 
non-adherence are multi-faced, with no clear-cut solution. Adherence to medication 
remains a difficult area to study, due to inconsistencies in representing medication-
adherence behavior data that poses a challenge to humans and today’s computer 
technology related to interpreting and synthesizing such complex information. 
Developing a consistent conceptual framework to medication adherence is needed to 
facilitate domain understanding, sharing, and communicating, as well as enabling 
researchers to formally compare the findings of studies in systematic reviews.  
The goal of this research is to create a common language that bridges human and 
computer technology by developing a controlled structured vocabulary of medication 
adherence behavior—“Medication Adherence Behavior Ontology” (MAB-Ontology) 
using breast cancer as a case study to inform and evaluate the proposed ontology and 
demonstrating its application to real-world situation. The intention is for MAB-Ontology 
to be developed against the background of a philosophical analysis of terms, such as 
belief, and desire to be human, computer-understandable, and interoperable with other 
systems that support scientific research.   
The design process for MAB-Ontology carried out using the METHONTOLOGY 
method incorporated with the Basic Formal Ontology (BFO) principles of best practice. 
This approach introduces a novel knowledge acquisition step that guides capturing 
vii 
medication-adherence-related data from different knowledge sources, including 
adherence assessment, adherence determinants, adherence theories, adherence 
taxonomies, and tacit knowledge source types. These sources were analyzed using a 
systematic approach that involved some questions applied to all source types to guide 
data extraction and inform domain conceptualization. A set of intermediate 
representations involving tables and graphs was used to allow for domain evaluation 
before implementation. The resulting ontology included 629 classes, 529 individuals, 51 
object property, and 2 data property. 
The intermediate representation was formalized into OWL using Protégé. The 
MAB-Ontology was evaluated through competency questions, use-case scenario, face 
validity and was found to satisfy the requirement specification. This study provides a 
unified method for developing a computerized-based adherence model that can be 
applied among various disease groups and different drug categories.     
Karl F. MacDorman, Ph.D., Chair 
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CHAPTER ONE: INTRODUCTION AND BACKGROUND   
Despite progress in medical science leading to new therapies for acute, chronic, 
and fatal diseases, such as AIDS and cancers, full benefits of these treatments have not 
been realized (Sawesi, Carpenter, & Jones, 2014). This is primarily due to non-adherence 
leading to poor clinical outcomes, treatment failure, and ineffective therapies (Sedjo & 
Devine, 2011; Williams, Mertz, & Wilkins, 2014). Medication non-adherence—“the 
extent to which patients are not taking their medications as prescribed by their healthcare 
provider (Meichenbaum & Turk, 1987)”—is a major problem that produces an “invisible 
epidemic,” unknown to patients and unrecognized by caregivers, clinicians, pharmacists, 
and healthcare systems as a whole (Haider et al., 2014; Kaufman & Birks, 2009). 
Medication non-adherence is estimated to cause approximately 125,000 deaths and at 
least 10% of hospitalizations annually (Viswanathan et al., 2012). Based on the Centers 
for Disease Control and Prevention’s (CDC) leading causes for the numbers of deaths in 
2017, medication non-adherence would rank as sixth. Between $100-$300 billion in 
annual unnecessary medical costs are attributed to medication non-adherence (Cutler, 
Fernandez-Llimos, Frommer, Benrimoj, & Garcia-Cardenas, 2018; Iuga & McGuire, 
2014; Nasseh, Frazee, Visaria, Vlahiotis, & Tian, 2012; Williams et al., 2014). More than 
1.6 billion annual prescriptions dispensed in the U.S. are not taken as prescribed 
(Williams et al., 2014). And, among patients with chronic diseases, it is even higher. 
These patients require long-term, possibly lifelong medications to control symptoms and 
prevent complications.  
Medication adherence among breast cancer patients exemplifies these challenges. 
Two types of hormone-based therapies, tamoxifen (TAM) and aromatase inhibitors (AIs), 
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have reduced disease recurrence and mortality rates among women with breast cancer, 
provided the regimens are adhered to for at least five years (Nekhlyudov, Li, Ross-
Degnan, & Wagner, 2011). However, studies show that around half of breast cancer 
patients fail to adhere to hormone treatment, risking clinical responses below expected 
standards (Banning, 2012; Chlebowski & Geller, 2007; Doggrell, 2011; Gotay & Dunn, 
2011; Hadji, 2010; Verma, Madarnas, Sehdev, Martin, & Bajcar, 2011). While side 
effects are the main reason for medication non-adherence (Henry et al., 2013; Kadakia, 
Kidwell, et al., 2016; Kadakia, Snyder, et al., 2016; Sawesi,  Carpenter, & Jones, 2014), 
co-morbidity, patient-provider relationship, forgetfulness, and patients’ perceptions and 
beliefs have been cited as contributing to non-compliance: specifically TAM and AIs 
(Sawesi, Carpenter, & Jones, 2014).  
Adherence research has been spurred by the proliferation of information 
technology (IT) innovations in the healthcare system. Medication non-adherence offers 
the health information technology (HIT) community the opportunity to devise tools and 
solutions that assist medication adherence and enhance quality of life and improve 
population health. Several HITs have been used to understand, explore, measure, and 
improve medication adherence. The U.S. Department of Health and Human 
Services (HHS), via the Office of the National Coordinator for Health Information 
Technology (ONC) and the Centers for Medicare and Medicaid Services (CMS), supports 
using HIT applications to improve medication adherence and medication management 
through various programs, such as certified electronic health records (EHRs), the 
Medicare and Medicaid EHR Incentive Program, and adoption of consumer-based tools 
that motivate the patient and caregiver to participate in medication adherence (Williams 
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et al., 2014). Studies reveal that hospital HIT enhances storage and retrieval of patient 
information via electronic health records (EHRs) (Buntin, Burke, Hoaglin, & Blumenthal, 
2011). For example, EHRs enable healthcare providers to assess medication adherence by 
linking electronic prescription information from the e-prescribing system with pharmacy-
fill information. Healthcare providers can also track medication adherence using 
electronic drug monitoring systems (EDMs), such as personal health records (PHRs) and 
patient portals, and use electronic pillboxes and medication event monitoring systems 
(MEMS) (Williams et al., 2014). As a result, a growing volume of heterogeneous data 
(Shaban‐Nejad, Lavigne, Okhmatovskaia, & Buckeridge, 2016) from heterogeneous 
sources store data having different meaning in different formats with the need to move it 
from place to place among healthcare providers, payers, and beneficiaries. 
Although medication adherence varies based on patient demographics, behavioral 
dimensions, the nature of the disease, the type of drug, and its duration, it differs highly 
by heterogenicity in data and clinical terminologies that represent this domain (Bramwell 
et al., 2009; Sawesi, Carpenter, & Jones, 2014). The lack of uniformity in terminology 
used to describe and measure medication adherence behavior and factors impacting a 
patient’s adherence impede the integration, analysis, interpretation, usefulness, and 
synthesis of the medication adherence-related data (Verma et al., 2011). This problem 
leads to fragmented, non-interoperable healthcare information systems in terms of 
comparative effectiveness research (CER). Consequently, it limits data dissemination due 
to underdeveloped domain standards that can facilitate both human and computer 
understanding, analysis, and sharing. The domain of medication adherence behavior has 
many challenges that need to be overcome in order to achieve a standardized, shareable 
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information network that can successfully “interoperate” and allow research and 
treatment to inform one another.  
Inconsistencies in terminology and definitions of medication adherence are a 
challenge. The terms adherence, compliance, persistence, and concordance are often used 
interchangeably (Hugtenburg, Timmers, Elders, Vervloet, & Dijk, 2013). However, each 
has a different meaning/measurement and reflects a variety of views on the relationship 
between patient, healthcare provider, and how the medicine has been filled and taken. 
Medication compliance, for example, is defined as the “extent to which the patient 
follows the recommendations of the prescriber” (Hugtenburg, Timmers, Elders, Vervloet, 
& Dijk, 2013). In this instance, the behavior seems to have a negative association that is 
subservient to prescribers. There is no regard for patient autonomy and self-efficacy, as 
the patient has to comply with medication regimens regardless of their suitability 
(Chakrabarti, 2014). Non-compliance in this context represents the patient’s 
maladaptation behavior when he/she refuses to comply. Failure to comply may not 
always be harmful; while many treatments can cause severe side-effects, non-compliance 
to a medication can be considered a protective behavior. Therefore, while compliance is 
possibly useful in defining and measuring patient behavior, it fails to address all the 
reasons for patient non-compliance.  
Medication adherence, the preferred term, now replaces compliance and is 
defined as the “extent to which medication intake behavior corresponds with the 
recommendations of the healthcare provider (Sabaté, 2003).” This implies that the patient 
can actively choose the most suitable treatment plan (Organization, 2014). This definition 
emphasizes the patient partnership or engagement in the treatment processes and decision 
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making. Thus, the patient will not be blamed for a treatment plan failure if he/she does 
not adhere to the medication regimen. Although this definition addresses the patient’s 
role in treatment decisions, it creates conceptual confusion that generates a measurement 
problem. As it implies the need for agreement between the patient and the healthcare 
provider, it also requires methods to measure this agreement. Moreover, it lacks the 
normative agenda, i.e., whether adhering to medication is good or bad (Chakrabarti, 
2014). Therefore, the term “concordance” has evolved to mean the “normative agenda” 
of taking medication. It is defined as “the agreement between the prescriber and patient 
on the purpose and use of the medication (Vrijens et al., 2012)”; it describes the patient-
prescriber relationship, in which a consensus about how taking medication will be 
reached by including the patient’s perspective and his or her own views on taking 
medication. Although concordance can solve the normative agenda, it creates an ethical 
dilemma for the healthcare provider when a patient’s decision threatens him/herself (i.e., 
patient selects the treatment based on preference, not on scientific evidence). 
“Persistence,” also mentioned in the literature, refers to medication-taking behavior. It 
refers to “the length of time between the first and last dose (Vrijens et al., 2012),” 
implying how long the patient remains on a medication regimen. While these terms are 
used as synonyms, they do not consistently define. They hold different meanings and 
reflect different views about the role of patients in treatment plans, as well as the 
relationship between patients and healthcare providers; they do not include the entire 
range of data sources for adherence—i.e., medication initiation or discontinuation 
behavior (Cramer et al., 2008; Organization, 2014). 
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Medication non-adherence can take a variety of forms; there is no unilateral 
category as to their types. The World Health Organization (WHO), for example, 
classifies medication non-adherence into: (1) Erratic non-adherence (patient forgets dose; 
patient inconsistently follows the health professional’s instructions, such as incorrect 
time, dose, and frequency); and (2) Intelligent non-adherence (patient purposely alters, 
discontinues, or even fails to fill the prescription (Sabaté, 2003)). Williams (2014) 
formalized non-adherence types differently: (1) Primary non-adherence (patient does not 
obtain the prescribed medication), (2) Discontinuation (patient stops taking the 
medication), (3) Compromised execution (medication inconsistent with provider’s 
instructions) (Williams et al., 2014). Another non-adherence category is: (1) Intentional 
non-adherence (patient actively fails to follow prescribed treatment recommendations, 
and (2) Unintentional non-adherence (unplanned behavior for not taking the prescribed 
treatment) (Hugtenburg, Timmers, Elders, Vervloet, & Dijk, 2013).  
Medication non-adherence was also categorized based on factors or determinants 
that contribute to adherence behavior called “dimensions” (Figure 1) by WHO (WHO, 
2003) and is referred to as patient-related factors; therapy-related factors; social and 
economic factors; disease-related factors; and the healthcare system. Munro et al. 
classifies these same factors under four different themes: structural, personal, social 
context, and health service (Munro et al., 2007). Selinger et al. (2013) used different 
categorizations to represent medication adherence: influencing factors through a 
modifiable and non-modifiable category. Among these dimensions, the patient can fall 
into more than one category at a given time. Therefore, since these dimensions are 
potential causes of medication non-adherence, they can help healthcare providers 
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understand the reasons for non-adherence and effectively collaborate with patients to 
overcome barriers (Shah et al., 2009). 
Medication non-adherence can be explained through the use of behavioral 
theories. However, theoretical constructs were found to overlap in many areas, making 
the inconsistent use of terminology involved with determining and deciding which 
theories would be the most precise in explaining the difficulty challenging to the health-
related behavior. For example, the perceived benefits of HBM, named as perceived 
outcome expectancy in SCT; and perceived barriers in HBM, termed as perceived cost in 
self-regulatory theory. Also, the construct of self-efficacy—a person’s belief in his/her 
ability to self-manage and overcome boundaries, used in the Social Cognitive Theory 
(SCT), Protection Motivation Theory (PMT), Theory of Planned Behavior (TPB), Health 
Belief Model (HBM), and Self-Regulation Theory (Leventhal & Cameron, 1987). This 
term holds the same meaning with the phrase, “perceived behavioral control”— meaning 
an individual’s belief about his/her ability to produce a performance that influences 
events that affect his/her life (Ajzen, 2002). Both self-efficacy and perceived behavioral 
control pertain to a belief in one’s ability to perform a behavior and have control over that 
behavior. It does not refer to controlling the outcomes or events. However, “perceived 
behavioral control” in the theory of planned behavior may have been misleading; it has 
been intended to refer to the belief that performing a behavior affords control over 
achievement of an outcome, which is not the intended meaning. It has also been used to 
measure external constraints on behavior, while self-efficacy has been used to measure 
internal control factors (Gustafson et al., 2001). There is a lack of clarity about the 
definition and measurement of these terms and under what category they exist in reality. 
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Many studies either neglect these terms, assuming the reader knows their 
meaning, or inconsistently define them. Examining their nature and under what category 
they exist is essential for data sharing. All medication adherence researchers and 
clinicians pretty much need the same data. This data must have the same meaning and 
context to be understandable and shared. Belief, as an example, is defined in several ways 
in the literature. (i) Belief is a feeling (Hume, 2003): to believe that Tamoxifen will 
prevent the recurrence of breast cancer is to have a special kind of feeling linked with this 
statement. (ii) Belief is a mental state (Davidson, 1989): having the belief that Tamoxifen 
prevents the recurrence of breast cancer is being in a state of belief about this proposition. 
(iii) Belief is something an individual holds (Eynde, Corte, & Verschaffel, 2002): to 
believe that Tamoxifen prevents breast cancer is to have a material entity in the brain 
representing this proposition. (iv) Belief is a metacognitive process in which an 
individual believes in knowledge and knowing (Hofer, 2004): to believe that Tamoxifen 
prevents breast cancer is to believe and know this as fact. The belief is an event or 
episode. Therefore, in order to predict and explain an individual’s behavior and design 
better behavioral intervention, such terms need to be represented consistently in common 
schema in order to be sharable and interoperable. To circumvent these obstacles, such 
diverse information requires the ability to integrate, analyze, interpret, organize, and be 
stored in interconnected computer repositories, so that it would be available to anyone, 
anywhere in the world, at any point in time (Arp, Smith, & Spear, 2015). There is a need 
for some way to explicitly specifying the semantics for each terminology in an 
unambiguous fashion—a novel framework that represents and investigates the existing 
knowledge and hidden patterns from the data.  
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1.1 Problem Statement 
Evidence-based practice needs to produce and access current best evidence to 
understand and make decisions related to better ways to overcome and improve the 
patient medication-adherence problem. The main reasons for collecting medication 
adherence data are to facilitate the conversation among healthcare providers regarding the 
non-adherence issue and the reasons behind this problematic behavior. These reasons 
need to be documented to enable behavioral change. Medication non-adherence 
documentation lexically varies and is represented by numerous semantics (Turchin et al., 
2008). Clinicians, informaticians, and researchers sometimes use terms inconsistently and 
define them imprecisely (Andrade, Kahler, Frech, & Chan, Arnold 2006). Other terms 
lack understanding as to their nature and the categorical classes they subsumed, such as 
in the case of cognitive constructs used in behavioral theories.  
These inconsistencies in definition, measurement, and the reporting of medication 
adherence-related information make it challenging to determine the best interventions and 
treatment plans and impede the evidence-based practice process. Also, using different 
computer technologies to standardize, encode, and store these results creates serious 
obstacles to better access, interoperability, and reusing of data and information (Arp et 
al., 2015). Arp, Smith, and Spear (2015) state, “It is the diversity of data, not the quantity, 
that poses the primary challenge in making use of electronic medical data and 
information (Arp et al., 2015).” Constructing definitions and classifying this 
heterogeneous information in a way that avoids these idiosyncrasies is what is needed to 
improve domain knowledge interoperability and improve consistency in data description.  
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Discussing medication adherence domain, in general, Jack BW (2009) stated, “If 
there was a standard instrument that existed, it would be nice to report adherence in a 
standard way if there was a standard or accepted tool that is used. It would be nice if our 
project used a similar standard, so it means something around the country (Blake, 2016).” 
Complicated knowledge, such as that related to medication adherence mentioned in 
previous sections, presents challenges in information representation. For example, the 
terms beliefs, desires, motives, emotion, and intentions, all lack clarity about what kind of 
entities they are. The term adherence could also be problematic. It may represent 
different ideas, can be understood and used in various contexts, or describes different 
phenomena. 
 Such inconsistent use of terminology would render the term useless in systems 
with the goals of automating information sharing, facilitating re-use of information, and 
supporting building new knowledge. The uniformity of concepts and language used to 
describe medication adherence and theoretical constructs would further enhance 
comparing and combining results and aiding in developing effective and efficient 
intervention strategies to improve medication adherence (Cramer et al., 2008). Uniform 
concepts and language will facilitate communication across medication adherence 
disciplines and among healthcare providers and patients. Accordingly, the problem 
statement is formally stated as:  
Representation of medication adherence-related knowledge using ontology as a 
formal representational tool is needed to facilitate domain understandability, 
interoperability, and comparative effectiveness research. 
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1.2 Proposed Solution 
Representing knowledge related to medication-adherence behavior with ontology 
is proposed as a step toward improving clinical data interoperability, understanding and 
formalizing a knowledge-related domain, and evidence-based care. Consequently, it can 
support the development and implementation of medication adherence applications. At a 
high level, it involves building standard and formal definitions of concepts and their use 
to enable the reuse of derived knowledge and facilitate the connection of databases and 
datasets in the medication adherence domain. 
In past years, considerable research has related to using ontologies as an 
information tool for knowledge representation. They are used to provide a shared 
understanding of a domain, both for computers and humans, by modeling concepts and 
relationships within a domain, enhancing interoperability, and reusing data and 
knowledge (Bailey, McMullin, & Coble, 2001; Bodenreider & Stevens, 2006; Gruber, 
1995; M. Musen, 2008; M. A. Musen, 1999) to support multiple clinical tasks (Beale & 
Heard, 2007; Borycki & Kushniruk, 2006; Dao, Marin, & Tho, 2007; Islam, Brandeau, & 
Das, 2006). However, what has not been explored was representing medication 
adherence-related knowledge based on ontologies. 
1.3 Aims and Objectives 
Based on the aforementioned problem description, specific research aims of this 
dissertation are as follows: 
1- Develop a formal representation of medication adherence-related knowledge using 
breast cancer as a case study. This model represents theoretical constructs that 
influence medication-adherence behavior, methods used to assess medication 
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adherence, and behavioral change intervention using information technology platforms 
to enhance medication adherence.   
a. Identify key foundational medication-adherence behavior-domain sources. 
b. Identify definitions and metrics for terms related to medication-adherence 
behavior. 
c. Develop an intermediate representation of medication adherence domain using 
tables and graphs.    
d. Formalize the conceptual model using the ontology editor Protégé.  
2- Validate the ontological model by experts using the Face Validity Technique.  
1.4 Significance of the Study 
Inconsistencies with representing medication-adherence behavior data pose a 
challenge for humans and computers to use, interpret, and synthesize such complex 
information. Data quality and consistency are important, not only for communicating, 
coordinating, and reporting healthcare, but also for ensuring patient safety (Fenton, 
Giannangelo, Kallem, & Scichilone, 2007). Currently, medication-adherence behavior 
data is siloed, the terms are not standardized, and the information is fragmented across 
different sources. Developing a consistent conceptual framework will enhance the 
consistency and generalizability of medication-adherence research and facilitate domain 
understanding, sharing, and communicating, and enable researchers to formally compare 
study findings in systematic reviews.  
Moreover, such a model can be used to facilitate retrieval and analysis of 
medication-adherence information, automated data annotation and integration, semantic 
interoperability between data sets, and automated reasoning and knowledge generation. 
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Internet searches based on this proposed ontology will be able to retrieve all relevant data 
from different data sources. Also, ontologies are machine-readable and can enable 
automated programs, such as data mining, to intelligently access and analyze information 
and, therefore, derive meaningful data patterns and extract new knowledge. Also, as new, 
hidden relationships are identified among different aspects of medication adherence in 
the knowledge representation process, this will motivate researchers to conduct additional 
studies on these important topics.  
1.5 Rationale 
Studies of patients who fail to take their medication, which can result in serious 
problems, have been documented for decades in the literature. Yet, these studies offer 
few solutions. This kind of behavior increases patients’ chances of worsening their 
disease, increasing the chance of the cancer returning, and very possibly resulting in 
death (Sabaté, 2003). Healthcare providers largely view this behavior as a binary event, 
with two outcomes: patients either take or do not take their medication (Samarth & Grant, 
2009).  
This view of the problem omits the behavioral change aspect. It risks taking an 
authoritarian/paternalistic approach to how we view patients who refuse to adhere to their 
medication regimen. This assumption could reflect patients not complying due to a low 
level of understanding the repercussions of not taking their medications or their simply 
forgetting to take it. While these reasons are accurate in some situations, non-adherence 
is far broader and may not be as obvious to healthcare providers. A key reason to gather 
information about the importance of patients adhering to their medications is to start a 
conversation with a health provider that addresses issues, such as side effects, cost of the 
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medication, and discovering other behavioral and psychological reasons why patients fail 
to comply with their medication regimens. Capturing and understanding these underlying 
reasons, respecting patient choices, and discussing them is necessary in order to help 
patients become medication adherent.  
Building a common language (biomedical ontology) that can be shared across 
different biological and medical domains takes time. It is a difficult process, as 
documented by the scope and collective effort of well-known ontology projects, such as 
Gene Ontology (Harris et al., 2004). Attaining a consensus as to the terms and definitions 
used by different domain experts requires negotiation and ongoing iterations. As a result, 
this project serves as a foundational step towards developing a refined Medication 
Adherence Behavior (MAB-Ontology) that can interact with other ontologies. It is 
designed to serve as a methods model and first-iteration artifact that the domain can 
interact with and refine/improve. In this way, a comprehensive systematic review 
approach needs to use sources rooted in research and practice to grasp the important 
concepts of domain communication. A wide variety of sources, combined with different 
methods designed to fulfill validity criteria, assures that steps taken, and documented 
results provide an accurate approach and meaningful contribution to the effort. 
1.6 Description of the Chapters 
Chapter 2—Includes three reviews: (1) Reasons for non-adherence to tamoxifen 
and aromatase inhibitors for the treatment of breast cancer: a literature review (Sawesi, 
Carpenter, & Jones, 2014). This part discusses the complexity and challenges of 
medication adherence behavior using breast cancer as a case study to narrow down the 
domain. It addresses important factors that impact adherence to adjuvant hormone 
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therapy. (2) The impact of information technology on patient engagement and health 
behavior change: a systematic review of the literature (Sawesi, Rashrash, Phalakornkule, 
Carpenter, & Jones, 2016). This section provides an overview of the different information 
technology platforms used to improve, sustain, and change health-related behavior. (3) 
Ontology and knowledge representation. This section defines ontology, its role in the 
biomedical domain, and the different methodologies used to develop ontologies.  
Chapter 3—Chronicles the methodologies used to construct a formal knowledge 
representation for the Medication Adherence Behavior ontology (MAB-Ontology). It 
describes the steps taken to formalize medication adherence knowledge, the methods 
used to validate this knowledge, and the resulting model.    
Chapter 4—Provides results based on the selected methodology and describes the 
outcome of each step.  
Chapter 5—Links the results to the problem statement, implications, next steps, 
and limitations of the approach. It also recaps conclusions and contributions. 
1.7 Protection of Human Subjects 
This study was approved by the Indiana University Institutional Review Boards 
(IRBs). Human subjects’ protection was required for the validation aim: Face Validity. It 
was designated as Non-Human Subject Research, because it was not subject to FDA or 
common-rule definitions of human subject research. This research involved use of 
informal meeting procedures with committee members not considered subjects for this 
research and did not place them at risk for criminal or civil liability or damage their 
financial standing, employability, or reputation (Appendix 1). 
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CHAPTER TWO: LITERATURE REVIEWS 
This dissertation is primarily informed by three areas of literature: Medication 
adherence behavior, technology adoption to change patient behavior, and knowledge 
representation with ontology. Medication adherence literature provides knowledge about 
factors that affect medication adherence using breast cancer as a case study and the way 
in which these factors are categorized (Sawesi, Carpenter, & Jones, 2014). Biomedical 
informatics technologies literature provides knowledge regarding technology used to 
impact patient behavior, and the behavioral theories have been used to guide the design 
and assess the outcomes (Sawesi, Rashrash, Phalakornkule, Carpenter, & Jones, 2016). 
Ontology and knowledge representation literature provides the foundation required to 
create a formal representation for medication adherence behavior-related knowledge 
using ontology. It reviews the key topics of relevance to biomedical ontologies including: 
philosophical approaches of ontology; ambiguity in medical terminologies; benefits of 
ontology; existing biomedical ontologies; and methodologies used for ontology 
development and evaluation, which informed the methodology used in this dissertation. 
2.1 Reasons for Non-Adherence to Tamoxifen and Aromatase Inhibitors  
2.1.1 Introduction 
Breast cancer is the most prevalent type of cancer among women worldwide 
(Coulter, Parsons, & Askham, 2008). Treatment commonly includes estrogen- 
suppressive or ablative medications. Two types of hormone-based therapies (i.e., 
tamoxifen [TAM] and aromatase inhibitors [AIs]) have been shown to decrease disease 
recurrence and mortality rates (Nekhlyudov et al., 2011). TAM works by inhibiting 
estrogen action, and AIs work by inhibiting the aromatase enzyme–mediated peripheral 
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conversion of androgen to estrogen (Johnston & Dowsett, 2003). TAM is used to treat 
pre-, peri-, or postmenopausal women with hormone receptor–positive breast cancer, and 
AIs are used to treat postmenopausal women with hormone receptor–positive breast 
cancer (Herk-Sukel et al., 2010). 
TAM and AIs have the potential to provide significant levels of clinical benefit if 
patients adhere to the regimens for the pre- scribed time period, which is usually a 
number of years. However, many women with breast cancer do not follow the protocol. 
Intentional and unintentional non-adherence to therapies persists and undermines the 
effectiveness of those therapies (Sedjo & Devine, 2011). Many patients with chronic 
diseases rarely follow their medication regimens, including patients with cancer who may 
be regarded as highly motivated because of the clinical consequences associated with 
non-adherence to the medication (Chlebowski & Geller, 2007). Healthcare providers 
should encourage women with breast cancer to adhere to the recommended dosage of 
TAM or AI at prescribed times each day and over the recommended time period. 
Randomized placebo-controlled research studies testing the efficacy of TAM and AI 
therapies have reported non-adherence as a study limitation (Bramwell et al., 2009; 
Bramwell et al., 2009; Chlebowski & Geller, 2007; Dezentjé et al., 2010; Lin, Zhang, & 
Manson, 2011; Partridge et al., 2008). As a result of the apparent widespread lack of 
adherence, considerable effort has been made to develop interventions that can 
effectively enhance adherence rates. One approach to help increase the chances of 
medication adherence is to use information technology. Health information technology 
can potentially improve the timely and complete information flow between patients and 
healthcare providers, and it can identify and address gaps in patients’ medication usage 
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(Parekh, 2011). Companies have devised many different types of electronic tools (e.g., 
computer-based interactive healthcare programs, short message service [SMS] alerts, 
drug compliance monitors) as a way to ad- dress the problem. Mobile health (mHealth) 
technology provides healthcare providers greater power to ensure adherence and reduce 
the adverse health and economic consequences associated with the problem. Simple 
phone counseling interventions have demonstrated improved adherence to mammography 
and adjuvant chemotherapy (Champion, Skinner, & Foster, 2000; Gotay & Dunn, 2011). 
However, each intervention has its advantages and disadvantages. To achieve the 
therapeutic goals of TAM and AIs when designing an intervention, the reasons for poor 
adherence or non-adherence should be clearly identified to tailor the intervention 
(Grunfeld, Hunter, Sikka, & Mittal, 2005). The purpose of the current systematic review 
is to evaluate the reasons for and factors associated with non-adherence to TAM and AI 
therapies among women with breast cancer. 
2.1.2 Methods 
Defining adherence categories in the current review, medication adherence is 
conceptualized as encompassing medication compliance and persistence. Medi- cation 
compliance was considered to be measured if the study assessed administered medication 
doses per defined period of time or the proportion of the prescribed doses taken in a given 
time interval (Cramer et al., 2008). Patient self-reporting, electronic monitoring, pill 
count, and prescription refill records are common measurement tools related to 
medication compliance. Medication persistence was measured if the study assessed the 
duration from initiation to discontinuation of therapy (Cramer et al., 2008). Medication 
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persistence can be evaluated according to the duration and as a time-dependent rate (e.g., 
the percentage of patients who are still adherent five-years post-treatment). 
1. Search strategy. 
A literature search was conducted using electronic databases (i.e., CINAHL®, 
PsycINFO, and PubMed). The search was limited to English-language studies published 
in peer-reviewed journals from January 1990 to October 2011. Key words and medical 
subject headings initially used to identify relevant studies included breast cancer, 
medication adherence, medication non-adherence, medication compliance, medication 
non-compliance, and medication persistence. Additional relevant key words were 
identified during some of the electronic searches, including breast cancer regimens and 
treatment regimens. All three databases were searched using similar strategies and refined 
according to initial search results from some databases. The authors also searched 
reference lists from all included studies and relevant reviews. Titles and abstracts were 
screened to identify articles included in the review. Full articles from potentially relevant 
studies were then retrieved and assessed for eligibility based on the inclusion criteria. The 
same researcher twice reviewed all included and excluded studies. 
2. Inclusion criteria. 
Inclusion criteria for the review were (a) the study described specific reasons for 
medication non-adherence, (b) the study was written in the English language, (c) 
medication adherence outcomes were specifically reported, (d) participants received 
treatment regimens that included TAM or AIs, and (e) participants had a diagnosis of 
only breast cancer. Studies were excluded from the review if (a) participants had other 
types of cancer, (b) medication adherence outcomes were not reported, (c) the study was 
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written in a language other than English, or (d) the study evaluated adherence to variables 
other than TAM or AI therapy (e.g., appointments kept, chemotherapy, radiation). 
 
Figure 1 Articles Identified During the Search for Relevant Literature 
3. Data extraction. 
From each relevant study, information was extracted into a review table. 
Variables included names of authors, title of the article, year, country of origin, study 
design, study duration, age of participants, sample size, stage of cancer, adjuvant drugs 
used, gender, adherence measures, adherence outcomes, and reasons for non-adherence. 
Titles and abstracts identified using search term and screened 
(n=7,638)
Full copies retrieved and assessed for eligibility (n=334)
Potentially relevant (n=24)
Articles included in the final 
study (n=26)
Articles added by spooling reference lists 
(n=2)
Articles excluded (n=310) Nonspecific barriers (n=128) 
Ovarian cancer (n=11) Other drugs used (n=60) No 
adherence measure (n=102) Not English language (n=6) 
Different title duplicate (n=1) Unclear results (n=1)
Articles excluded (n=7,304) Duplicated 
publications
21 
2.1.3 Results 
The three electronic databases yielded 7,638 research articles (CINAHL = 6,035, 
PsycINFO = 978, PubMed = 625) (Figure 1). After manual screening of the articles’ titles 
and abstracts, a total of 7,304 articles were excluded; 2,513 were duplicate publications, 
and 4,791 were irrelevant. Of the remaining 334 full articles retrieved for eligibility, 24 
met the inclusion criteria and were included in the review. Reference lists of the 24 
articles were reviewed, and two more articles were identified for a total of 26 articles 
used. The majority of the included studies were conducted in the United States (n = 14) 
and published from 2001-2011 (n = 25). With the exception of two studies that included 
men, all other studies were conducted with only female participants because of the nature 
of the breast cancer diagnosis. Sample sizes varied greatly, ranging from 26-22,160 
participants. Participants’ ages ranged from 16-95 years, and the study duration ranged 
from 12 months to five years. Most studies evaluated the reasons for non-adherence to 
TAM therapy exclusively (n = 15). Only two studies evaluated non-adherence to AIs 
exclusively. Nine studies included both types of adjuvant therapies. Studies primarily 
used self-report questionnaires and abstraction of the patients’ medical records to collect 
data on non-adherence. Two studies collected adherence data through direct interviews 
with participants, and two studies evaluated the reliability of data-collecting tools with 
suggestions for using an additional confirmatory assessment tool (Atkins & Fallowfield, 
2006) (Lash, Fox, Westrup, Fink, & Silliman, 2006).  
Reasons for non-adherence were grouped into five dimensions (i.e., patient-
related factors, therapy-related factors, healthcare system factors, socioeconomic factors, 
and disease factors) based on the World Health Organization (2003) report on medication 
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adherence. Seventeen individual themes of medication factors were recorded in 26 
studies (Table 1). 
1. Patient-related factors. 
Six patient-related factors were found, including patients’ beliefs toward TAM 
and AIs, patients’ knowledge about the disease, forgetfulness, smoking, age, and race or 
ethnicity. Negative beliefs and patients’ negative perceptions related to TAM and AIs 
contributed to failure to initiate the medications’ regimen (Fink, Gurwitz, Rakowski, 
Guadagnoli, & Silliman, 2004; Grunfeld et al., 2005; Lash et al., 2006; Oguntola, Adeoti, 
& Akanbi, 2011; Pellegrini et al., 2010). In a study conducted by Pellegrini et al. (2010) 
to assess women’s perceptions and experience toward adjuvant TAM therapy, the women 
who were interviewed about their TAM regimen had branded the TAM therapy as 
“hormone treatment” and “anti-hormonal.” In that scenario, the women cited their past 
negative experiences with hormone-based contraceptives as the primary reason for their 
refusal to initiate or adhere to ongoing TAM therapy. A lack of information (e.g., how the 
disease develops, effective ways to manage the disease, specific information about the 
medication prescribed such as dose specification, duration specification, timing 
specification) was found to be a significant barrier in medication adherence (Pellegrini et 
al., 2010; Ziller et al., 2009). Forgetfulness was acknowledged as the single most 
important factor in medication non-adherence (Atkins & Fallowfield, 2006; Grunfeld et 
al., 2005; Kirk & Hudis, 2008; Murthy, Bharia, & Sarin, 2002; Waterhouse, Calzone, 
Mele, & Brenner, 1993). One study found that patients who smoked were less likely to be 
adherent to the therapy (Maurice, Howell, Evans, O’Neil, & Scobie, 2006). Twelve 
articles found that patients younger than age 45 years or older than age 85 years exhibited 
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higher rates of TAM non-adherence (Atkins & Fallowfield, 2006; Hershman et al., 2010; 
Huiart, Dell'Aniello, & Suissa, 2011; Kahn, Schneider, Malin, Adams, & Epstein, 2007; 
Ma et al., 2008; McCowan et al., 2008; Neugut et al., 2011; Oguntola et al., 2011; Owusu 
et al., 2008; Partridge, Wang, Winer, & Avorn, 2003; Sedjo & Devine, 2011; van Herk-
Sukel et al., 2010). In Nekhlyudov et al.’s (2011) study, women older than age 60 years 
were found to be less compliant than other age groups. Five studies found that minority 
patients were less adherent than their Caucasian counterparts (Bhosle, 2007; Hershman et 
al., 2010; Ma et al., 2008; Neugut et al., 2011; Partridge et al., 2003). 
2. Therapy-related factors. 
Four therapy-related factors (i.e., therapy duration, side effects, additional 
prescribed medications, and perceived interference) were found to help explain why 
women with breast cancer failed to adhere to adjuvant TAM and AI therapies. The long 
duration of therapy interfered with medication persistence. In one study, patients found a 
five-year TAM regimen to be too long (Bramwell et al., 2009). Nine of the studies found 
that unpleasant side effects (e.g., hot flashes, vaginal bleeding, interrupted menstrual 
cycles, nausea with vomiting, body weakness) altered patients’ compliance (Bramwell et 
al., 2009; Demissie, Silliman, & Lash, 2001; Fink et al., 2004; Grunfeld et al., 2005; 
Kahn et al., 2007; Kirk & Hudis, 2008; Lash et al., 2006; Oguntola et al., 2011; Owusu et 
al., 2008). Two studies found that an increased number of prescriptions was associated 
with an increased adherence rate (Lash et al., 2006; Maurice et al., 2006). Those results 
contradicted two other studies that found that a greater number of daily doses and number 
of concurrent medications were associated with non-adherence (McCowan et al., 2008; 
Neugut et al., 2011). One study found that patients who perceived that TAM or AI 
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treatment interfered with their lifestyles and abilities to function normally led to ceasing 
treatment (Bramwell et al., 2009). 
3. Healthcare system factors. 
Only one healthcare system factor was found. The patient/ provider relationship 
appeared to play a significant role in adherence to TAM and AIs. A good relationship 
between the patient and healthcare provider was found to have a positive impact on 
adherence rates (Güth et al., 2008; Kahn et al., 2007; Kirk & Hudis, 2008; Partridge et 
al., 2003; Pellegrini et al., 2010; Sedjo & Devine, 2011). 
4. Socioeconomic factors. 
Four socioeconomic factors (i.e., medication cost, work complexity, religious 
practices, and marital status) have been observed as reasons for poor adherence to TAM 
and AIs. Cost of medications may be significant enough to cause unintentional non-
adherence among patients with economic problems (Kirk & Hudis, 2008; Neugut et al., 
2011; Oguntola et al., 2011; Sedjo & Devine, 2011). In one study, a burdensome work 
schedule was associated with decreased adherence rates. Type of occupation also was a 
rea- son for medication non-compliance because being outside of the home and traveling 
may have altered adherence rates (Oguntola et al., 2011). Religious practices were found 
to be a reason for non-adherence, because fasting on specific days during the year 
prevented patients from adhering to their treatment (Murthy et al., 2002). Two studies 
found marital status to be a barrier for medication adherence; being unmarried was 
associated with a higher probability of medication non-adherence and having a family 
support network was reported to be a facilitator of adherence (Hershman et al., 2010; 
Neugut et al., 2011). 
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5. Disease-related factors. 
Two disease-related factors (i.e., comorbidities and disease stage) were found. 
Comorbid illnesses, such as diabetes and hypertension, are a common problem that may 
cause poor adherence to TAM and AIs therapies (Hershman et al., 2010; Neugut et al., 
2011; Oguntola et al., 2011; Owusu et al., 2008; Partridge et al., 2003; Sedjo & Devine, 
2011; Herk-Sukel et al., 2010). In two studies, the patients’ stage of breast cancer was 
found to be a significant reason for non-adherence to TAM or AIs, with greater non-
adherence associated with later disease stages (Ma et al., 2008; Oguntola et al., 2011).   
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Table 1 Studies Assessing Reasons for Non-adherence to TAM or AIs 
 
Study 
 
Design 
 
Length 
(Years) 
 
Sample 
Non-adherence Rate  
Measure  
TAM 
 
AI 
Atkins & Fallowfield, 
2006 
Semi structured 
interview 
– 131 patients with a median age of 59.4 years 54% 61% SR 
Bhosle, 2007 Retrospective cohort 1 206 pairs of patients with stage I–IV cancer, 
with a median age of 66.6 years 
34% 29% MPR 
Bramwell et al., 2009 Randomized, 
controlled trial 
5 672 patients with stage I, II, and IIIA cancer, 
with an age range of 29–58 years 
31% – RxRR 
Demissie et al., 2001 Prospective cohort 3 303 patients with stage I–II cancer, aged 55 
years or older 
15% – SR 
Fink et al., 2004 Cohort 2 597 patients with stage I–III cancer, aged 65 
years or older 
17% – SR 
Grunfeld et al., 2005 Survey 2.75 110 patients with a median age of 56.3 years 13% – MARS-
5 
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Güth et al., 2008 Follow-up 5 325 patients (n = 206 TAM) with stage I–III 
cancer, with a median age of 67.3 years 
11% MR 
Hershman et al., 2010 Cohort 4.5 8,769 patients with stage I–III cancer, with a 
median age of 62 years 
30% 28% 
(year 1) 
50% 
(year 5) 
RxRR 
Huiart et al., 2011 Cohort 5 13,479 participants with age of 62 years 31% 19% MPR 
Kahn et al., 2007 Prospective cohort 4 881 patients with stage I–II cancer, with an age 
range of 21–80 years 
21% – SR 
Kirk & Hudis, 2008a Survey – 542 patients (n = 7 male) with stage I–IV 
cancer, with an age range of 21–80 
43% SR 
Lash et al., 2006 Follow-up 5 462 patients with stage I–IIIA cancer, aged 65 
years or older 
31% – SR 
Ma et al., 2008 Retrospective cohort 5 1,769 patients aged 54 years 37% – SR, 
RxRR 
Maurice et al., 2006 Case-control trial 5 533 patients aged 48 years 29% – MEMS 
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McCowan et al., 2008 Cohort 5 2,080 patients with stage I–IV cancer, with a 
median age of 61.4 years 
20% – RxRR 
Murthy et al., 2002 Survey 5 53 patients 62% – SR 
Nekhlyudov et al., 
2011 
Cohort 5 2,207 patients with early-stage cancer, aged 18 
years or older 
> 70% MPR 
Neugut et al., 2011 Retrospective cohort 2 22,160 patients with early-stage cancer, aged 50 
years or older 
– 9%–
10% 
RxRR 
Oguntola 
et al., 2011a 
Cohort 1 115 patients (n = 6 male) with stage I–IV 
cancer, aged 45 years or younger and 65 years 
or older 
25% – SR 
Owusu et al., 2008 Cohort 5 961 patients with stage I–IIB cancer, aged 65 
years or older 
49% – RxRR 
Partridge et al., 2003 Cohort 4 2,378 patients with early-stage cancer, aged 75 
years 
25% (year 
1) 
50% (year 
4) 
– RxRR 
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Pellegrini et al., 2010 Qualitative, semi- 
structured interview 
– 34 patients with early-stage cancer, aged from 
35–65 years 
18% – SR 
Sedjo & Devine, 2011 Retrospective cohort 1 13,593 patients, with a median age of 55.5 years – 23% MPR 
van Herk-Sukel et al., 
2010 
Cohort 5 1,451 patients with stage I–IIIA cancer, aged 35 
years or younger and 70 years or older 
              44%–51% 
 
RxRR 
Waterhouse et al., 1993 Prospective cohort 5.8 26 patients with stage I–IV cancer, aged from 
42–86 years 
17% PC; 
29% 
MEMS 
– SR, PC, 
MEMS 
Ziller et al., 2009 Retrospective cohort 1 100 patients (n = 72 AIs, n = 65 TAM, n = 39 
ANA) 
0% SR; 
20% MPR 
0% SR; 
31% 
MPR 
SR, 
MPR 
a Studies included male participants. AI—aromatase inhibitor; ANA—anastrozole; MARS-5—Medication Adherence Report Scale; MEMS—
Medication Event Monitoring System; MPR— medication possession ratio; MR—medical record; PC—pill count; RxRR—prescription refill 
records; SR—self-report questionnaire; TAM—tamoxifen.  
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2.1.4 Discussion 
 Most published studies reviewed the reasons for non-adherence to adjuvant TAM 
but not AIs. No single study independently explained the reasons for non-adherence to 
the therapies because factors contributing to non-adherence are multifaceted. No single 
factor can clearly explain non-adherence. Nurses play a key role in addressing identified 
contributing factors. Nurses can help patients find financial aid to fill prescriptions, 
manage side effects, improve self-management of comorbidities, facilitate the 
patient/provider relationship, and help patients identify strategies to address forgetfulness 
or change perceptions and beliefs. At a global level, certain therapies may become more 
important predictors of non-adherence. For example, most patients with breast cancer 
living in developed countries have adequate access to medications because most have 
medical or commercial insurance coverage, suggesting that cost may not be a detrimental 
factor. However, in a study done in an African population, financial constraints and side 
effects were the most viable reasons for non-adherence (Oguntola et al., 2011). When 
designing health interventions to improve adherence, the relative weight of each factor 
should be carefully assessed and considered within a larger environmental context.  
The importance of decision making in TAM and AI adherence should not be 
underestimated. One study found that patients with breast cancer who are given adequate 
medical support are more likely to adhere to recommended regimens (Kahn et al., 2007). 
Nurses can help facilitate patient-centered healthcare services, which may positively 
influence adherence. In addition, nurses can support patients’ involvement in the 
decision- making process to initiate TAM therapy. 
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The main limitation in almost all of the reviewed studies was that most data were 
self-reported. Waterhouse et al. (1993) questioned the validity of the method, citing it as 
relatively subjective and erroneous. In an effort to investigate adherence behavior to oral 
TAM, Waterhouse et al. (1993) argued that conventional methods of collecting non-
adherence data, such as self-reporting and pill counting, significantly overrate the extent 
to which patients adhere to their regimens and suggested the use of microelectronic 
monitoring to track patients’ adherence behaviors. That monitoring system can be used to 
obtain confirmatory or complementary data. The integration of microelectronics into the 
TAM drug package can effectively and continuously monitor patient interaction with the 
drug package. Although it does not guarantee data on drug entry into the body, it can 
effectively provide data on missed doses and dosage timing. In a study of 26 patients on 
TAM, comparisons were made using three parallel measuring tools: patient self-reporting 
questionnaires, remain- der pill counting, and the Medication Event Monitoring System 
(MEMS) (Waterhouse et al., 1993). MEMS includes a microprocessor in the cap of a 
bottle that records each time it is opened; date, time, and duration of bottle openings are 
downloaded for later retrieval on a computer. TAM adherence data collected from 
patients’ self-reporting was highest, followed by remainder pill counting, with MEMS 
data indicating the lowest adherence. Those findings suggest that conventional self-
reporting and remainder pill counting may not be the most reliable methods. In the 
current review, it became apparent that some factors related to non-adherence were much 
more important than others. However, the reasons for non-adherence to TAM and AI 
breast cancer therapies are multifaceted because no single study established an 
independent factor that effectively explained the frequently observed non-adherence to 
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the two most common breast cancer therapies. The authors’ findings indicate that many 
barriers to adherence could be amenable to change if targeted with mHealth 
interventions. Implementing mHealth has the potential to enable behavior change and 
improve health outcomes (Free et al., 2013; Qiang, Yamamichi, Hausman, Altman, & 
Unit, 2011; Thirumurthy & Lester, 2012). The cost of mobile phone use has declined 
dramatically, and availability of easy-to-use software programs has increased. For 
example, SMS reminders may readily help patients to adhere to treatment by overcoming 
forgetfulness. SMS alerts can reach across geographic boundaries and be used to educate 
and improve patient knowledge. mHealth interventions designed by nurses or other 
healthcare professionals can be viewed as a way to support patients and healthcare 
providers in a convenient and cost-effective way (Mair, Hiscock, & Beaton, 2008). 
2.1.5 Limitations  
Limitations of the current review include a focus on English- language articles 
and its focus on only TAM and AI for breast cancer treatment in the adjuvant setting. The 
focus on English-language articles may have omitted some relevant reports. Use of TAM 
for breast cancer prevention was not explored, and additional factors may exist that 
uniquely affect non-adherence in that context. 
2.1.6 Conclusion 
Despite the proven benefits of TAM and AIs for breast cancer treatment, many 
patients with breast cancer adhere poorly to recommended regimens and others decline to 
initiate the therapies. Reasons for non-adherence are multifaceted, but a number of 
factors (e.g., patient/provider relationship, forgetfulness, fear of side effects, burden, 
additional prescribed medications, treatment interfering with lifestyle, scheduling 
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problems, patient beliefs and knowledge) may be improved by using mHealth 
interventions. Future studies should be performed that incorporate health information 
technology to evaluate the necessary steps and measures that can be taken to address the 
barriers to adherence. 
2.2 The Impact of Information Technology on Behavior Change 
2.2.1 Introduction 
Patient engagement is currently considered the cornerstone of the healthcare 
system revolution for its positive impact on health outcomes and healthcare costs 
(Barello, Graffigna, Vegni, & Bosio, 2014; Coulter et al., 2008). A growing body of 
evidence demonstrates that lack of patient engagement is a major contributor to 
preventable deaths. In fact, it is estimated that 40% of deaths in the United States are 
caused by modifiable behavioral issues, including smoking, obesity, poor blood sugar 
control, poor blood pressure control, inadequate exercise, medication non-adherence, and 
neglect in attending follow-up medical appointments (Parekh, 2011). As a result, patients 
must be encouraged to become more involved with managing their own care. Frequent, 
real-time communication and feedback are essential in supporting health behavior change 
and empowering patient engagement in the healthcare process (Sundiatu, Shonu, 
Thomas, & Angela, 2012). However, the traditional model of care delivery, a face-to-face 
interaction with an expert or trusted healthcare provider, can be implemented only with a 
small number of patients and thus has limited impact and limited reach (Bickmore & 
Giorgino, 2004). In an effort to reach and engage larger numbers of patients, researchers 
and clinicians have begun exploring the role of information technology (IT) platforms in 
patient engagement and health behavior change interventions (Bickmore & Giorgino, 
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2004; Vollmer et al., 2011). It is assumed that face-to face interaction in the traditional 
model can be mimicked by peer-to-peer or peer group support in social media. 
IT platforms are being embraced as a way to enhance patient engagement in the 
healthcare process, improve quality of care, support healthcare safety, and provide cost-
effective health services for patients (Or & Karsh, 2009; Sutcliffe et al., 2011; Vollmer et 
al., 2011; Webb, Joseph, Yardley, & Michie, 2010). Numerous IT platforms are used to 
motivate patient engagement in health behavior change including short message service 
(SMS)-capable mobile devices, Internet-based interventions, social media, and other 
online communication tools (de Jong, Ros, & Schrijvers, 2014; Martyn & Gallant, 2012; 
Winbush, McDougle, Labranche, Khan, & Tolliver, 2013). Previous systematic reviews 
have evaluated the potential benefit of IT platforms in managing different health 
conditions and how these platforms have been used to actively engage patients and 
change unhealthy patient behavior. A systematic review conducted to assess the 
effectiveness of IT platforms on physical activity and dietary behavior change found that 
51% of studies showed positive results, although a significant proportion of the studies 
showed no significant effect (Norman et al., 2007). The reviewed interventions tended to 
focus on specific technology (e.g., desktop applications), while mobile devices, such as 
mobile phones and text messaging devices were not included. Similarly, Webb et al. 
reviewed 85 studies on the impact of Internet-based interventions on health behavior 
change and found small but significant effects on health-related behavior, especially with 
regards to interventions grounded in behavioral theory. Although the review mentioned 
that the effectiveness of Internet-based interventions was enhanced by using additional IT 
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methods, such as text messaging (SMS), it did not focus on the distinction between these 
different interventions (Webb et al., 2010). 
In addition, a meta-analysis performed to investigate the effectiveness of Web-
based interventions on health behavior changes found that Web-based interventions 
improve patient outcomes. This particular meta-analysis, however, referred only to Web-
based interventions in specific problem areas and focused on a relatively narrow range of 
technologies (Wantland, Portillo, Holzemer, Slaughter, & McGhee, 2004). A recent 
systematic review that investigated the effectiveness of the IT platform on self-
management among diabetic patients showed positive effects in 74% of studies (El-
Gayar, Timsina, Nawar, & Eid, 2013). Another research study showed that successful 
health behavior interventions may contribute to understanding of health behavior theories 
and their appropriate use (Glanz & Bishop, 2010). Mobile-based interventions and web-
based interventions developed based on health behavior theories are more likely to 
effectively change patient health behavior and maintain behavior change than non-theory-
based interventions (DiClemente, Crosby, & Kegler, 2009; Ellis et al., 2004; Patrick et 
al., 2014; Webb et al., 2010).  
Basing IT interventions on behavior theories can help test and detect why 
interventions succeed or fail (Rothman, 2004). Health behavioral theories can identify 
key determinants of the target behaviors and identify behavior change strategies essential 
to obtain desired health outcomes; this knowledge can then be transformed into specific 
behavioral strategies that patients can adapt in their daily life (Rothman, 2004). 
Conclusions drawn from these reviews are important; they provide insights but no clear 
answers about the effectiveness of IT platforms on patient engagement and behavior 
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change. They do not address which interventions are used most or are most effective with 
which theory or model when it comes to improving patients’ health behaviors and patient 
engagement. IT platforms generally can have high potential benefits and some proven 
effects; however, specific components in several health conditions associated with 
success remain unclear. To better understand how to build a successful intervention that 
can engage patients to change their behavior meaningfully, we performed a systematic 
review. Review aims were to systematically determine (1) the impact of IT platforms 
used to promote patient engagement and to effect change in health behaviors and health 
outcomes, (2) behavioral theories or models applied as bases for developing these 
interventions and their impact on health outcomes, (3) different ways of measuring health 
outcomes, (4) usability, feasibility, and acceptability of these technologies among 
patients, and (5) challenges and research directions for implementing IT platforms to 
meaningfully impact patient engagement and health outcomes. 
2.2.2 Methods 
1. Search strategy and data source. 
Electronic literature searches were performed using four databases: PubMed, Web 
of Science, PsycINFO, and Google Scholar. Google Scholar was searched because it had 
sufficiently wide coverage to be used instead of several databases (Howland, Wright, 
Boughan, & Roberts, 2009; Kennedy et al., 2012; Walters, 2007). The reference lists of 
retrieved articles from searches were screened for additional articles. Searches used the 
following medical subject headings (MeSH) terms in various combinations: patient 
engagement, health, promotion, behavior, digital, technology, email, Internet, web-based, 
cell phone, social media, computer, and intervention. 
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2. Inclusion and excluding criteria. 
The following criteria were used to select the articles: (1) all types of study 
designs published in scientific journals between 2000 and December 2014 were included, 
excluding conference proceedings, book chapters, reviews, dissertations, and protocols. 
(2) Studies that evaluated and reported the impact of health information technology 
platforms on patients’ health outcome, (3) studies that focused on disease management 
rather than more general health promotion including but not limited to patient education, 
symptom monitoring, medication adherence, diet, and physical activity, (4) studies that 
addressed patient engagement and health-related behavior change through the use of IT 
platforms such as social networking sites, mobile telephony, video and teleconferencing, 
email, SMS, and electronic monitoring, (5) studies that explored different factors 
affecting patient engagement and health behavior change were excluded, (6) studies that 
were published in languages other than English were excluded, (7) studies where the 
patient was not the main actor (i.e., studies that were clinician-focused), and (8) the 
methodological quality of articles was evaluated to establish their inclusion in the review 
using 10 items adopted from Critical Appraisal Skills Program (CASP) (Campbell et al., 
2003; Trust, 2002). The criteria that were used in the quality assessment included (1) 
study name, (2) aims clearly stated, (3) appropriate research design, (4) appropriate 
recruitment strategy, (5) theories clearly stated, (6) usability tested within the study, (7) 
patient engagement part of study, (8) appropriate data collection method, (9) data analysis 
sufficiently rigorous, and (10) findings clearly stated. After the completion of the 
methodological quality assessment, the studies that met the criteria for the categories of 
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“good” were reviewed (i.e., bad=0-33%, satisfactory=34-66%, and good=67-100%) 
(Davids & Roman, 2014). 
3. Data extraction. 
Two investigators independently reviewed the titles and then abstracts. The same 
investigators read and screened for full text eligibility. Data extraction was carried out by 
one reviewer and was rechecked for accuracy by another reviewer. The reasons for 
exclusion were recorded. Discrepancies were resolved by joint probability of agreement 
(0.98) (El-Gayar et al., 2013). A meta-analysis was not feasible due to the varying data 
collection methods and outcome measures. Therefore, eligible studies were broken down 
and evaluated in a narrative format using some statistical analysis when feasible and 
summarized systematically according to the following key information abstracted from 
them: study details (including author name, year, country, and study design); study 
characteristics (including sample size and condition/disease); intervention details 
(including technology used and duration); and outcome details (including direct and 
indirect assessment methods); and impact of intervention, usability assessment, patient 
engagement, and theory used in interventions classified according to Leventhal 
(biomedical model, behavioral learning, communicative, cognitive theory, and self-
regulative) (De Geest & Sabaté, 2003; Leventhal & Cameron, 1987; Munro, Lewin, 
Swart, & Volmink, 2007). The outcomes variable was classified into (1) positive impact 
in which health information technology platform was associated with improvement in 
one or more aspects of care and (2) no impact or no noticeable improvement or change in 
health outcomes. This was assessed based on the overall conclusion made by the authors 
of each study. Most studies used statistical methods to test hypotheses or describe 
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quantitative findings. Patient engagement was measured based on the overall conclusion. 
This was usually measured by timed patient log-ins, communication with the healthcare 
provider via secure message, or data download. 
2.2.3 Results 
1. Search and selection results. 
Figure 2 shows the flow chart that describes the process of identifying the 
relevant literature. A separate comprehensive search using four databases yielded 2235 
articles. Following removal of duplicates, our search identified 786 potentially relevant 
articles. These were scanned keeping 219 papers for full reading at full text level, of 
which 59 were screened and rejected, leaving 160 studies to be included in the review. 
Ten additional papers were included from the reference lists of retrieved articles. A total 
of 170 articles matched the initial search criteria.
 
Figure 2 Flow Diagram of Included and Excluded Studies 
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2. Article characteristics. 
Different categories of IT platforms were identified including Internet-based 
interventions (50.6%, 86/170), mobile-based interventions (25.9%, 44/170), social media 
(9.4%, 16/170), video game technology (3.5%, 6/170), and telemonitoring (10.6%, 
18/170). Publication years ranged from 2000 to 2014, with an overall increase in articles 
published more recently (21.8%, 37/170 in 2014). The majority of studies were 
implemented in the United States (54.7%, 93/170). With respect to the different targeted 
disorders, hormonal disorders were most frequently targeted (22.4%, 38/170 studies, e.g., 
diabetes). The literature was dominated by randomized controlled trials (65.9%, 
112/170). The duration of these studies ranged from 1 week to 48 months, and sample 
sizes ranged from 1-22,337 subjects. Articles included in this review were categorized in 
five topics based on study aims: impact of IT platform on health outcomes, patient 
engagement in health behavior change, theory of health behavior, ways to assess health 
outcomes, and usability assessment (Table 2). 
Table 2 Summary of the Review Results Based on Types of IT Platforms. 
Health condition, n (%) 
 
Internet 
(n=86) 
Phone 
(n=44) 
Video- 
game 
(n=6) 
Social 
network 
(n=16) 
Tele-
monitoring 
(n=18) 
Bone, joint, and muscle disorders 3 (3)     
Brain, spinal cord, and nerve disorders 7 (8) 1 (2) 2 (33) 1 (6) 1 (6) 
Cancer 5 (8) 2 (5) 1 (17) 2 (13) 2 (11) 
Disorders of nutrition and metabolism 13 (15) 4 (9) 1 (17) 2 (13) 1 (6) 
Ears, nose, and throat disorders  1 (2)    
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Eye disorders     1 (6) 
Health hazard 5 (6) 6 (14)    
Heart and blood vessel disorders 5 (6) 3 (7)   6 (33) 
Hormonal disorders 20 (23) 11 (25)  4 (25) 3 (17) 
Immune disorders 4 (5) 5 (11)  1 (6) 1 (6) 
Lung and airway disorders 2 (2) 1 (2) 1 (17) 1 (6) 1 (6) 
Mental health disorders 12 (14) 4 (9) 1 (17) 2 (13) 2 (11) 
Skin disorders  1 (2)  1 (6)  
Women’s health issues 3 (3) 1 (2)    
Not specified 7 (8) 4 (9)  2 (13)  
Country, n (%) 
Australia 7 (8) 5 (42)    
Austria     1 (6) 
Bangladesh  1 (2)    
Canada 4 (5)    2 (11) 
Chile 1 (1)     
China  1 (2)    
France  1 (2)    
Germany 3 (3)     
Israel    1 (6)  
Italy 1 (1) 1 (2)    
Japan 1 (1)   1 (6)  
Kenya  1 (2)    
Korea 1 (1) 1 (2)   1 (6) 
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Malaysia  1 (2)    
Netherlands 4 (5)  1 (17)  2 (11) 
New Zealand  2 (5)    
Norway  1 (2)    
Poland     1 (6) 
Russia  1 (2)    
Slovenia 1 (1)     
South Korea 2 (2) 4 (5)    
Spain  1 (2)   1 (6) 
Sweden 2 (2)     
Switzerland     1 (6) 
Taiwan 1 (1)     
United Kingdom 5 (6) 7 (16) 1 (17)  1 (6) 
United States 53 (62) 14 (32) 4 (67) 14 (88) 8 (44) 
Victoria  1 (2)    
Vietnam  1 (2)    
Study design, n (%) 
Randomized controlled trial 55 (64) 34(30) 2 (33) 7 (44) 14 (78) 
Case study 2 (2) 1 (2) 2 (33) 2 (13)  
Cohort study 10 (12) 4 (5) 1 (17) 1 (6) 3 (17) 
Cross-sectional analysis 8 (9) 1 (2)  5 (31) 1 (6) 
Quasi-experimental trial 11 (13) 4 (5) 1 (17) 1 (6)  
Ways to measure health outcomes, n (%) 
Direct 28 (33) 20 (45) 3 (50) 1 (6) 6 (33) 
Indirect 58 (67) 24 (55) 3 (50) 15 (94) 12 (67) 
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Impact of technology, n (%) 
Yes 75 (87) 41 (93) 6 (100) 13 (81) 16 (89) 
No 11 (13) 3 (7)  3 (19) 2 (11) 
Usability assessment, n (%) 
Yes 38 (44) 8 (18) 1 (17) 8 (50) 3 (17) 
No 48 (56) 36 (82) 5 (83) 8 (50) 15 (83) 
Patient engagement, n (%) 
Yes 68 (79) 38 (86) 6 (100) 13 (81) 16 (89) 
No 18 (21) 6 (14)  3 (19) 2 (11) 
Theory of behavior change, n (%) 
Biomedical theory (chronic model) 1 (1)    1 (6) 
Behavioral learning theory 3 (3)     
Communication theories  5 (6) 5 (11) 2 (13)   
Cognitive theories  40 (47)  9(20) 2 (33) 2 (13) 1 (6) 
Self-regulatory 6 (7)  1 (17) 2 (13)  
Not specified 31 (36) 30 (69) 3 (33) 10 (63) 16 (88) 
Sample size, n Min. 1 2 6 51 
 Max. 13564 22337 375 1754 
Duration Min. 1 m 1 m 1 m 1 w 
 Max. 48 m 16 m 3 m 36 m 
 n/s 3 1 1 3 
 m=month, w=week, n/s=Not specified.  
3. Impact of information technology platforms on health outcome. 
Overall, IT platforms have been shown to improve health behavior among 
different disease categories (88.8%, 151/170), although the majority of the positive 
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impact has been shown among hormonal disorders (20.6%, 35/170) (Table 3). Among 
studies utilizing Internet-based platforms, 87% (75/86) of studies showed a significant 
impact on health outcomes. Studies also showed that the use of Internet-based tailored 
weight control programs was correlated with significant increases in weight loss (Adachi 
et al., 2007; Johnston, Massey, & DeVaneaux, 2012) and walking distance (P<.05) 
(Napolitano et al., 2003).  
Similarly, mobile-based platforms showed significant effects on health outcomes 
(91%, 40/44). For example, a study examined use of text messages among patients with 
diabetes and found a significant decrease in HbA1C level, improved medication 
adherence, and decreased in emergency service use (Arora, Peters, Burner, Lam, & 
Menchine, 2014). Social media showed a positive impact on health outcomes (81%, 
13/16). For example, one study indicated that Twitter usage among cancer patients was a 
valuable medium for sharing information, discussing treatments, and also acted as a 
psychological support (Sugawara et al., 2012). The use of Facebook has also been found 
to help improve asthma care (Winstead-Derlega et al., 2012).  
As such, this review found that 100% (6/6) of studies had a positive impact on 
patient health behavior when implementing a video game as an intervention to change 
health behavior. A study concluded that video games can be implemented successfully 
among hyperfunctional voice disorder as a “voice therapeutic protocol,” a voice and 
speech therapy program including a set of vocal tasks using syllable repetitions and 
chanting of songs and phrases (King, Davis, Lehman, & Ruddy, 2012).  
Furthermore, the literature showed that telemonitoring improved health outcomes 
(89%, 16/18). One telemonitoring-based study assessed the effects of a glucose 
 45 
monitoring system on HbA1c levels in diabetic patients and found that usage of this 
system was correlated with a significant decrease in HbA1c (P=.001) (Tildesley, 
Mazanderani, & Ross, 2010). Another study evaluated the impact of home-based 
telemonitoring on patients with heart failure and showed a significant correlative 
improvement in patients’ health outcomes (Kwon et al., 2004; Scherr et al., 2009).  
 In contrast, 11% of studies (19/170) showed no impact of using IT platforms on 
health behavior. Among studies using Internet-based platforms, 13% (11/86) did not find 
significant results. One study using a Web-based behavior change program found no 
differences in smoking abstinence rates at 3- and 6-month follow-up assessment 
(Danaher, Boles, Akers, Gordon, & Severson, 2006) and no maintenance of weight loss 
in an Internet-based intervention group compared to the study’s control group (Steele, 
Mummery, & Dwyer, 2007). Also, 7% of (3/44) mobile phone studies reported non-
significant impact (Arora et al., 2014; Benhamou et al., 2007; Chen, Fang, Chen, & Dai, 
2008; Song et al., 2013). Two mobile phone platform studies did not find a significant 
reduction in HbA1c level among diabetic patients when SMS text messaging was used to 
manage their healthcare (P<.10) (Arora et al., 2014; Sugawara et al., 2012).  
Moreover, 18% (3/16) of studies showed undesirable effects from using social 
media (Kaplan, Salzer, Solomon, Brusilovskiy, & Cousounis, 2011; Thackeray, 
Crookston, & West, 2013; Winstead-Derlega et al., 2012). For instance, Kaplan et al. 
found that psychiatric patients who participated in Internet peer support reported higher 
levels of distress compared to those who did not participate (Kaplan et al., 2011). The 
literature shows that 12% (2/18) of telemonitoring studies had no effect on health 
outcomes. One particular study found significant changes in neither readmission rate 
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(Wakefield et al., 2008) nor medication adherence (Ramaekers, Janssen-Boyne, Gorgels, 
& Vrijhoef, 2009) among patients with heart failure. 
Table 3 Impact of IT Platforms Among Different Disorders 
Disorders Internet 
 
Mobile Social 
Media 
Tele-
monitoring 
Video 
game 
   
 Yes No Yes No Yes No Yes No Yes T 
Yes 
T 
No 
T 
Bone, joint, 
and muscle 
3(3)         3 
(2) 
 3 (2) 
Brain, 
spinal cord 
& nerves 
7(8)  1(2)   1 
(6) 
1(6)  2 (33) 11 
(6) 
1 
(1) 
12 
(7) 
Cancer 5 
(6) 
 2 
(5) 
 2 
(13) 
 2 
(11) 
 1 (17) 12 
(7) 
 12 
(7) 
Nutrition 
and 
metabolism 
10 
(12) 
3 
(3) 
4 
(9) 
 2 
(13) 
 1 
(6) 
 1 (17) 18 
(11) 
3 
(3) 
21 
(12) 
Ears, nose 
& throat 
   1 
(2) 
      1 
(1) 
1 (1) 
Eye       1(6)   1(1)  1 (1) 
Health 
hazard 
4 
(5) 
1 
(1) 
6 
(14) 
      10 
(6) 
1 
(1) 
11 
(6) 
Heart and 
blood 
vessel 
4 
(5) 
1 
(1) 
3 
(7) 
   4 
(22) 
2 
(11) 
 11 
(6) 
3 
(2) 
14 
(8) 
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Hormonal 19 
(22) 
1 
(1) 
9 
(20) 
2 
(5) 
4 
(25) 
 3 
(17) 
  35 
(21) 
3 
(2) 
38 
(22) 
Immune 
system 
2 
(2) 
2 
(2) 
5 
(11) 
  1 
(6) 
1 
(6) 
  8 
(5) 
3 
(2) 
11 
(6) 
Lung and 
airway 
2 
(2) 
 1 
(2) 
 1 
(6) 
 1 
(6) 
 1 (17) 6 
(4) 
 6 (4) 
Mental 
health 
11 
(13) 
1 
(1) 
4 
(9) 
 2 
(13) 
 2 
(11) 
 1 (17) 20 
(12) 
1 
(1) 
21 
(12) 
Not 
specified 
5(6) 2 
(2) 
4 
(9) 
 1 
(6) 
1 
(6) 
   10 
(6) 
3 
(2) 
13 
(8) 
Skin   1(2)  1(6)     2(1)  2 (1) 
Women’s 
health 
3 
(3) 
 1 
(2) 
      4 
(2) 
 4 (2) 
Total 75 
(87) 
11 
(13) 
41 
(93) 
3 
(7) 
13 
(81) 
3 
(19 
16 
(89) 
2 
(11) 
6 
(100) 
151 
(89) 
19 
(11) 
170 
(100) 
T=Total, Yes=positive impact, No=no impact 
4. Patient engagement. 
In total, 82.9% (141/170) of studies reported improvement in patient engagement 
after using IT platforms (Table 4). Among Internet-based interventions, 79% (68/86) of 
studies reported a high level of patient engagement. For example, a research study 
reported that human immunodeficiency virus patients used the Internet-based 
intervention a majority of the time to access information and manage their health 
(Andrade et al., 2005; Shaw & Gant, 2002). Among studies using mobile-based 
interventions, 86% (38/44) reported improvement in patient engagement. One mobile-
based intervention study found that text messaging enhanced successful engagement of 
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diabetic patients in their own healthcare. Patients were able to use this study’s text 
message system for clinical data queries and communicating with healthcare providers 
(Franklin, Greene, Waller, Greene, & Pagliari, 2008). Similarly, 81% (13/16) of studies 
reported that social media was helpful in improving patient engagement. One study found 
that Facebook provided a forum for reporting personal experiences, asking questions, and 
receiving direct feedback for people living with diabetes (Thackeray et al., 2013). 
Another study showed that social media was helpful to individuals with lower patient 
activation (Magnezi, Bergman, & Grosberg, 2014; McKay, Glasgow, Feil, Boles, & 
Barrera, 2002; McKay, King, Eakin, Seeley, & Glasgow, 2001). In addition, it was found 
that video games could enhance patients’ active participation in the healthcare process 
(100%, 6/6). One video game-based study demonstrated that a health-based video game 
could help build an effective client-therapist relationship, help structure sessions, and 
improve patient engagement in the therapeutic process (Coyle, Doherty, & Sharry, 2009; 
Jelsma, Geuze, Mombarg, & Smits-Engelsman, 2014).  
Likewise, the literature showed that telemonitoring has been particularly useful 
for improving patient engagement remotely (88.8%, 16/18) (Chan, Callahan, Sheets, 
Moreno, & Malone, 2003; Galiano-Castillo et al., 2014; Gray et al., 2000; Kinney et al., 
2014; Meiland et al., 2014; Price & Gros, 2014; Španiel et al., 2008), as traditional point-
of-care-based ways to monitor patients are costly and difficult to implement (Weinstock 
et al., 2010). Overall, analysis showed significant correlations between patient 
engagement in healthcare and the impact of IT platforms (χ2 =39.8836, P˂.001). Only 
Internet-based platforms had a significant association between patient engagement and 
impact of technology on outcomes (χ2 =28.2558, P˂.001).  
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Table 4 Impact of IT Platforms on Patient Engagement 
Engagement Internet 
 
Mobile Social Media Tele-monitoring Video game    
 Y N Y N Y N Y N Y T Yes T No T 
Yes 66 
(88) 
2 (18) 36 
(88) 
2 (67) 12 (92) 1 (33) 15 (94) 1 (50) 6 (100) 135 (63) 6 (32) 141 
(83) 
No 9 (12) 9 (82) 5 (12) 1 (33) 1 (8) 2 (67) 1 (6) 1 (50)  16 (37) 13 (68) 29 (17) 
Total 75 
(100) 
11 
(100) 
41 
(100) 
3 13 
(100) 
3 (100) 16 
(100) 
2 (100) 6 (100) 151 
(100) 
19 
(100) 
170 
(100) 
Y=Yes, N=No, Yes=positive impact, No=no impact. 
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5. Behavior theory 
Overall results showed that 47.0% (80/170) of the literature explicitly referenced 
theory (Table 5). Among Internet-based interventions, 64% (55/86) of studies mentioned 
the use of behavior theories. Cognitive theories dominated this category (47%, 40/86). 
Further, 32% (14/44) of mobile-based intervention studies reported use of behavior 
theories. Cognitive theories were also the most widely used among this category (30%, 
13/44) (Brendryen & Kraft, 2008; Franklin et al., 2008; Franklin, Waller, Pagliari, & 
Greene, 2006; Gold, Lim, Hellard, Hocking, & Keogh, 2010; Granholm, Ben-Zeev, Link, 
Bradshaw, & Holden, 2011; Hurling et al., 2007; Rodgers et al., 2005; Song et al., 2013; 
Stacy, Schwartz, Ershoff, & Shreve, 2009).  
Moreover, 38% (6/16) of social media studies used behavior change theory. 
Social support, cognitive, and self-regulatory theories were the only models used in this 
category (Gabriele, Carpenter, Tate, & Fisher, 2011; Gustafson et al., 2001; Kaplan et al., 
2011; Magnezi et al., 2014; Simon et al., 2011; Winstead-Derlega et al., 2012). The 
analysis showed 50% (3/6) of video-game platforms used behavior change theories, 
where the cognitive and self-regulatory theories are the only used (Bingham, Lahiri, & 
Ashikaga, 2012; Kato, Cole, Bradlyn, & Pollock, 2008). Only 11% (2/18) of 
telemonitoring studies used biomedical and cognitive theories (Green et al., 2008; Read, 
2014). Literature showed that 89% (71/80) of studies with behavior theories had a 
significant impact on health outcomes. Only 11% (9/80) of telemonitoring studies 
explicitly referenced the use of behavior theories and showed no impact of technology on 
health outcomes.  
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The result failed to show any relationship between using behavior theory and the 
impact of technology on health outcomes (χ2 =0.008, P=.977). The analysis also found 
no significant correlative relationship between behavior theory and patient engagement in 
healthcare (χ2 =0.3055, P=.580479). However, there was a significant relationship 
between patient engagement and Internet-based interventions using behavior theories (χ2 
=7.314, P=.0068) (Table 6).  
6. Methods to measure health outcomes. 
Most studies used indirect ways (such as self-reports) to measure health outcomes 
(65.9%, 112/170). The literature showed that 57.6% (98/170) of studies showed a 
positive impact of IT platforms when the health outcomes were assessed using indirect 
ways. For example, self-reporting was used to assess whether a text message could 
increase smoking cessation (Rodgers et al., 2005), reduce methamphetamine use among 
human immunodeficiency virus patients (Reback et al., 2012), and to assess medication 
adherence among patients with congestive heart failure (Ramaekers et al., 2009). The 
analysis showed no significant association between ways to measure health outcomes and 
technology impact (χ2 =0.5793, P=.446603) (Table 7). 
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Table 5 Impact of IT Platforms and Theories of Health Behavior 
Behavior theory Internet Mobile Social Media Tele-monitoring Video-
game 
   
 Y N Y N Y N Y N Y T Y T N T 
Biomedical theory 1 (1)      1 (6)   2 (1)  2 (1) 
Behavioral learning theory 2 (2) 1 (1)        2 (1) 1 (1) 3 (2) 
Communication 4 (5) 1 (1) 1 (2)  1 (6) 1 (6)    6 (4) 2 (1) 8 (5) 
Cognitive theory  36(42) 4 (5) 12(27) 1 (2) 2 (13)  1 (6)  2 (33) 53(31) 5 (3) 58 (34) 
Self-regulatory 5 (6) 1 (1)   2 (13)    1 (17) 8 (5) 1 (1) 9 (5) 
Reported theory 48(56) 7 (8) 13(29) 1 (2) 5 (31) 1 (6 2 (2)  3 (50) 71(42) 9 (5) 80 (47) 
Theory not reported 27(31) 4 (5) 28(64) 2 (5) 8 (50) 2 (13) 14(78) 2 (11) 3 (50) 80(47) 10 (6) 90 (53) 
Total 75 
(87) 
11 
(13) 
41 
(93) 
3 (7) 13 
(81) 
3 (19) 16 
(89) 
2 (11) 6 (100) 151 
(89) 
19 
(11) 
170 
(100) 
T=Total, Y=Yes, N=No, Yes=positive impact, No=no impact. Social cognitive theory (TPB, SOC, TTM, self-efficacy, information 
motivation, and behavioral skill). V-Game=video-game. 
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Table 6 Patient Engagement and Theories of Health Behavior  
 Patient Engagement, n (%) 
Behavior theory Internet 
 
Mobile Social Media Tele-monitoring Video- 
game 
   
 Y N Y N Y N Y N Y T Y T N T 
Biomedical theory 1 (1)      1 (6)   2 (1)  2 (1) 
Behavioral learning 
theory 
2 (2) 1 (1)        2 (1) 1 (1) 3 (2) 
Communication 5 (6)  1 (2)  2 (13)     8 (5)  8 (5) 
Cognitive theories 30 (35) 10 (12) 11 (25) 2 (5) 2 (13)  1 (6)  2 (33) 46 (27) 12 (7) 58 (34) 
Self-regulatory 4 (5) 2 (2)   2 (13)    1 (17) 7 (4) 2 (1) 9 (5) 
Total of used theory 42 (49) 13 (12) 12 (27) 2 (5) 6 (38)  2 (11)  3 (50) 65 (38) 15 (9) 80 (47) 
Theory not reported 26 (30) 5 (2) 26 (59) 4 (9) 7 (44) 3 (19) 16 (89) 2 (11) 3 (50) 76 (45) 14 (8) 90 (53) 
Total 68 (79) 18 (15) 38 (86) 6 (14) 13 (81) 3 (19)  2 (11) 6 (100) 141 
(83) 
29 
(17) 
170 
(100) 
T=Total, Y=Yes, N=No, Yes=positive impact, No=no impact, Cognitive theory=(TPB, SOC, TTM, self-efficacy, information 
motivation, and behavioral skill).
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Table 7 Impact of IT Platforms and Methods to Measure Health  
 Methods to Measure Health Impact of Information Technology Platforms, n (%) 
Outcomes Internet 
 
Mobile Social Media Tele-monitoring Video 
game 
   
 Y N Y N Y N Y N Y T Y T N T 
Direct  25 
(29) 
3 (3) (41) 2 (5) 1 (6)  6 (33)  3 (50) 53 
(31) 
5 (3) 58 (34) 
Indirect 50 
(58) 
8 (9) 23 
(52) 
1 (2) 12 
(75) 
3 (19) 10 (56) 2 (11) 3 (50) 98 
(58) 
14 (8) 112 (66) 
Grand Total 75 
(87) 
11 
(13) 
41 
(93) 
3 (7) 3 (81) (19) 16 (89) 2 (11) 6 (100) 151 
(89) 
19 
(11) 
170 (100) 
T=Total, N=No, Yes=positive impact, No=no impact
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7. Usability assessment. 
Only 33.5% (57/170) of studies assessed the usability of IT platforms. Of those, 
the majority were considered by authors to be usable (89%, 51/57). Specifically, 75% 
(28/37) of Internet-based IT intervention studies showed positive health outcomes with 
usable interventions (Agarwal, Anderson, Zarate, & Ward, 2013; Bantum et al., 2014; 
Barnabei, O'Connor, Nimphius, Vierkant, & Eaker, 2008; Botts, Horan, & Thoms, 2011; 
Boudreaux et al., 2012; Buhrman et al., 2013; Claborn, Leffingwell, Miller, Meier, & 
Stephens, 2014; Feldman, Murtaugh, Pezzin, McDonald, & Peng, 2005; R. Glasgow et 
al., 2011; Glynn, Randolph, Garrick, & Lui, 2010; Gustafson et al., 2005; Gutierrez, 
Kindratt, Pagels, Foster, & Gimpel, 2014; Hasin, Aharonovich, & Greenstein, 2014; 
Irvine, Gelatt, Seeley, Macfarlane, & Gau, 2013; Iverson, Howard, & Penney, 2008; 
Krishna et al., 2003; Lee, Gray, & Lewis, 2010; Lewis, Gray, Freres, & Hornik, 2009; 
Lorig, Ritter, Laurent, & Plant, 2006; Osborn, Mayberry, Wallston, Johnson, & Elasy, 
2013; Pandolfi et al., 2014; Rooke, Gates, Norberg, & Copeland, 2014; Ross, Moore, 
Earnest, Wittevrongel, & Lin, 2004; Steele et al., 2007; Urowitz et al., 2012; Van den 
Berg et al., 2007; Villegas et al., 2014; Winzelberg et al., 2000). In one study that gauged 
usability, Steele et al. performed a 3-month randomized controlled trial among 192 
participants and found an Internet-based physical activity behavior change program to be 
usable, feasible, and acceptable among inactive participants (Steele et al., 2007). Mobile-
based interventions also showed 75% (6/8) of usable interventions had a positive impact 
on health outcomes (Brendryen & Kraft, 2008; Harris et al., 2010; Hasin et al., 2014; 
Shrier, Rhoads, Burke, Walls, & Blood, 2014; Song et al., 2013; Tran & Houston, 2012).  
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In one study, SMS was found to be useful in helping patients to remember to take 
their medications and be engaged in treatment planning (Harris et al., 2010). SMS-based 
intervention was also found to be useful in promoting communication with healthcare 
providers by delivering, receiving health information, generating questions, and seeking 
information related to health conditions (Song et al., 2013). Moreover, 87% (7/8) of 
studies reported that the usability of social media-based interventions was positively 
correlated with good impact on health outcomes (Fisher & Clayton, 2012; Greene, 
Choudhry, Kilabuk, & Shrank, 2011; Magnezi et al., 2014; McKay et al., 2002; Sugawara 
et al., 2012; Thackeray et al., 2013; Winstead-Derlega et al., 2012). One particular social 
networking-related study found that online health-related social networking was useful 
and acceptable in chronic disease management (Magnezi et al., 2014).  
In addition, one study reported the usability assessment in the video-game 
category and found that it was usable and had a positive impact among patients with 
hyperfunctional voice disorders (King et al., 2012). Overall, the analysis also found that 
telemonitoring also showed similar results (100%, 3/3). One telemonitoring-based study 
found that telecommunication-based reminder tools are useful for improving medication 
adherence (Boland et al., 2014). Although our results failed to report any relationship 
between usability of IT platforms and the impact on health outcomes (P=.1065), they 
showed significant association between usability and patient engagement in healthcare 
(P=.0216) (Fisher’s exact test) (Tables 8-9). 
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Table 8 Impact of IT Platforms and Usability  
 Impact of Information Technology Platforms, n (%) 
Usability Internet 
 
Mobile Social Media Tele-monitoring Video 
game 
   
 Y N Y N Y N Y N Y T 
N 
T 
N 
T 
Usable 28 (33) 4 (5) 6 (14) 2 (5) 5 (31) 2 (13) 3 (17)  1 (17) 43 (25) 8 (5) 51 (30) 
Not usable 1 (1) 4 (5)   1 (6)     4 (2) 2 (1) 6 (4) 
Total of assessed 
usability 
29 (34) 8 (9) 6 (14) 2 (5) 6 (38) 2 (13) 3 (17)  1 (17) 12 (7) 45 (26) 57 (34) 
Not assessed 
usability 
46 (53) 3 (3) 35 (80) 1 (2) 7 (44) 1 (6) 13 
(72) 
2 (11) 5 (83) 7 (4) 106 (62) 113 
(66) 
Grand total 75 (87) 11 
(13) 
41 (93) 3 (7) 13 
(81) 
3 (19) 16 
(89) 
2 (11) 6 (100) 19 (11) 151 (89) 170 
(100) 
T=Total, N=No, Yes=positive impact, No=no impact.  
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Table 9 Patient Engagement and Usability 
 Impact of Information Technology Platforms, n (%) 
Usability Internet 
 
Mobile Social Media Tele-monitoring Video- 
game 
   
 Y N Y N Y N Y N Y T Y TY T 
Usability assessed 
(usable) 
26 (30) 6 (7) 7 (16) 1 (2) 5 (31) 2 (13) 3 (17)  1 (17) 41 (24) 9 (5) 51 (30) 
Usability assessed (not 
usable) 
1 (1) 4 (5)   1 (6)     2 (1) 4 (2) 6 (4) 
Total usability assessed 27 (31) 10 (12) 7 (16) 1 (2) 6 (38) 2 (13) 3 (17)  1 (17) 43 (25) 13 (8) 57 (34) 
Not assessed 41 (48) 8 (9) 31 (70) 5 (11) 7 (44) 1 (6) 13 (72) 2 (11) 5 (83) 97 (57) 16 (9) 113 (66) 
Grand total 68 (79) 18 (21) 38 (86) 6 (14) 13 (81) 3 (19) 16 (89) 2 (11) 6 (100) 141 (83) 29 
(17) 
170 
(100) 
T=Total, N=No, Yes=positive impact, No=no impact
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2.2.4 Discussion 
1. Impact of IT platforms on health outcomes. 
Overall, this review indicated that IT platform-based health interventions had a 
great impact on patients’ health outcomes in the United States and in other nations. IT-
based health interventions have been viewed as driving positive health behavior change 
through patient engagement with most technology platforms. IT-based health 
interventions also provide necessary information and advice and counseling related to 
certain diseases and conditions, such as mental disorders (Bond, Burr, Wolf, & Feldt, 
2010; Buhrman, Fältenhag, Ström, & Andersson, 2004; Christensen, Griffiths, & Jorm, 
2004; Herbst et al., 2014; Houston, Cooper, & Ford, 2002; Kerr et al., 2008; Rotondi et 
al., 2010; Roy & Gillett, 2008), asthma (Baptist et al., 2011; Bingham et al., 2012; Chan 
et al., 2003; Krishna et al., 2003; Nguyen et al., 2008; Ostojic et al., 2005), obesity 
(Johnson & Wardle, 2011; Johnston et al., 2012; Kornman et al., 2010; Napolitano et al., 
2003; Park & Kim, 2012; Kevin Patrick et al., 2009; Petersen, Sill, Lu, Young, & 
Edington, 2008; Steinberg et al., 2014; Tate, Jackvony, & Wing, 2006; Turner-McGrievy 
& Tate, 2014; Ware et al., 2008), smoking (Boudreaux et al., 2012; Bramley et al., 2005; 
Brendryen & Kraft, 2008; Danaher et al., 2006; McKay, Danaher, Seeley, Lichtenstein, 
& Gau, 2008; Richardson et al., 2013; Rodgers et al., 2005; Strecher et al., 2008), 
diabetes (Bell, Fonda, Walker, Schmidt, & Vigersky, 2012; Cho et al., 2006; Fonda, 
McMahon, Gomes, Hickson, & Conlin, 2009; Kim & Jeong, 2007; Kim & Kim, 2008; 
McCarrier et al., 2009; McMahon et al., 2005; Meigs et al., 2003; Quinn et al., 2008; 
Ralston et al., 2009; Rami, Popow, Horn, Waldhoer, & Schober, 2006; Smith et al., 2004; 
Tasker, Gibson, Franklin, Gregor, & Greene, 2007; Weppner et al., 2010; Winbush et al., 
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2013; Yoon & Kim, 2008), sleep disorder (Espie et al., 2012), hypertension (Kiselev, 
Gridnev, Shvartz, Posnenkova, & Dovgalevsky, 2012; Park & Kim, 2012; Park, Kim, & 
Kim, 2009), cancer (Bantum et al., 2014; Galiano-Castillo et al., 2014; Ginsburg et al., 
2014; Gustafson et al., 2001; Gustafson et al., 2005; Kato et al., 2008; Kinney et al., 
2014; Lee et al., 2010; Lewis et al., 2009; McCann, Maguire, Miller, & Kearney, 2009; 
Sugawara et al., 2012; Zernicke et al., 2014), thereby encouraging healthy living (Adachi 
et al., 2007; Christensen et al., 2010; Gabriele et al., 2011; Johnston et al., 2012; Oh, 
Jorm, & Wright, 2009; Tate et al., 2006). Moreover, these interventions enable patients to 
be engaged in self-monitoring, thereby directing patients toward healthy eating, 
enhancing attendance rate (Downer, Meara, & Da Costa, 2005; Farmer, Brook, 
McSorley, Murphy, & Mohamed, 2014; Kay-Lambkin, Baker, Lewin, & Carr, 2011; 
Liew et al., 2009; McInnes et al., 2014; Sims et al., 2012; Stockwell et al., 2012; Strecher 
et al., 2008), improving medication adherence (Glasgow et al., 2012; Heisler et al., 2014; 
Heyworth et al., 2014; Kay-Lambkin et al., 2011; Meglic et al., 2010; Parr, Kavanagh, 
Young, & Mitchell, 2011; Santschi, Wuerzner, Schneider, Bugnon, & Burnier, 2007; 
Vilella et al., 2004), increasing knowledge about disease and treatment (Arora et al., 
2014; Christensen et al., 2004; Feldman et al., 2005; Heisler et al., 2014; Irvine et al., 
2013; Kato et al., 2008; Krishna et al., 2003; Kulkarni, Wright, & Kingdom, 2014; 
Pandolfi et al., 2014; Rotondi et al., 2010; Song et al., 2013; Vaart et al., 2014; Wakefield 
et al., 2008), and enhancing exercise use (Aikens, Zivin, Trivedi, & Piette, 2014; Bantum 
et al., 2014; Bentley & Richardson, 2014; Claborn et al., 2014; Glasgow et al., 2011; 
Helander, Kaipainen, Korhonen, & Wansink, 2014; Hunter et al., 2008; Jelsma et al., 
2014; Johnson & Wardle, 2011; Keyserling et al., 2014; Kim & Kang, 2006; Kiselev et 
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al., 2012; Kornman et al., 2010; Napolitano et al., 2003; Nguyen et al., 2008; Kevin 
Patrick et al., 2009; Petersen et al., 2008; Plotnikoff, McCargar, Wilson, & Loucaides, 
2005; Steinberg et al., 2014; ter Huurne, Postel, de Haan, Drossaert, & DeJong, 2013; 
Turner-McGrievy & Tate, 2014; Ware et al., 2008; Zernicke et al., 2014). Online 
coaching by specialists enables patients to recover quickly, ensuring that the pain they 
experience is reduced (Buhrman et al., 2013; Trautmann & Kröner-Herwig, 2008), and 
doctor-patient communications are made readily available (Furber et al., 2011; Greysen, 
Khanna, Jacolbia, Lee, & Auerbach, 2014; Idriss, Kvedar, & Watson, 2009; Lancioni et 
al., 2012; Lee, Yeh, Liu, & Chen, 2007; McCann et al., 2009; Schnall, Wantland, Velez, 
Cato, & Jia, 2014; Sciamanna et al., 2006; Simon et al., 2011). 
Apart from Internet-based technologies, mobile phone technologies have been 
used extensively to engage patients and ensure there is patient health behavior change. 
Mobile phone technologies engage patients by using SMS to contact them and provide 
necessary health information. This technology can be very effective and efficient, since it 
is less expensive and therefore more people can afford it. Studies have shown that 
patients can receive health-related information, receive reminders of their healthcare 
attendance, as well as be encouraged to adhere to their treatment (Granholm et al., 2011; 
Green et al., 2008; Harris et al., 2010; Lester et al., 2010; Winstead-Derlega et al., 2012). 
Social media outlets, such as Twitter and Facebook, can ensure patients get and 
exchange necessary health information (Sugawara et al., 2012; Thackeray et al., 2013). 
Video game and telemonitoring technologies served a similar purpose; these technologies 
tried to engage patients in order to provide necessary health information and provided a 
platform for helping patients adhere to treatment and helped patients actively become 
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involved in the treatment process. These technologies are of great importance to patients 
as well as helpful to healthcare providers, therefore ensuring effectiveness and efficiency. 
Although several studies demonstrated the positive impact of IT platform usage, others 
showed no impact (Arora et al., 2014; Benhamou et al., 2007; Claborn et al., 2014; Glynn 
et al., 2010; Gutierrez et al., 2014; Habibović et al., 2014; Helander et al., 2014; Kaplan 
et al., 2011; McCarrier et al., 2009; McInnes et al., 2013; McKay et al., 2008; Phillips et 
al., 2014; Ramaekers et al., 2009; Schweier et al., 2014; Steele et al., 2007; Thackeray et 
al., 2013; Wakefield et al., 2008; Williamson et al., 2006; Winstead-Derlega et al., 2012; 
Womble et al., 2004). This could be due to the timing of the follow-up assessments 
ranging from one extremely short follow-up timing (1 week) to a relatively long-term 
follow-up timing (48 months). The lack of consistency in follow-up timing made it 
unclear as to how long these effects on patient health last. 
Moreover, the technology adoption rate may decline after a certain time period, 
thus diminishing its effectiveness after significant results at the beginning of the study. 
This occurred in a study by Williamson et al. who found that after two years of an IT-
based intervention, the decrease in body weight did not differ between the intervention 
and control group (Leventhal & Cameron, 1987). Similarly, another research study found 
a slow decline in HbA1c at 3 months follow-up (1.22%) versus (1.09%) six month 
follow-up (Kim & Song, 2008; Kim & Jeong, 2007). Therefore, designing and evaluating 
IT platforms may become a significant challenge because researchers are dealing with a 
large volume of interventions that have different impacts on patient health behavior. 
Thus, several issues need to be addressed if such interventions are to be evaluated or 
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assessed, such as length of intervention, type of technology, usability of the technology, 
application of behavior theory, and how health outcomes are measured. 
2. Patient engagement in healthcare using IT platforms. 
Our review showed that IT platforms are playing a significant role in patient 
engagement. This review implies that higher patient participation in condition self-
management was correlated with greater improvement in health outcomes. Many studies 
have shown that patients who actively participated in healthcare experience better health 
outcomes compared to less involved patients. One specific study showed a significant 
association between patient engagement using the Internet and weight loss at 6 months 
(P˂.001) (Green et al., 2008). Another study reported that a text messaging could 
enhance patient engagement (Arora et al., 2014). Social networks can also be particularly 
helpful to individuals with lower patient activation (Magnezi et al., 2014).  
Despite the evidence regarding the importance of patient engagement, it is 
challenging to draw solid conclusions. Many of the studies conducted qualitative surveys 
to measure patient engagement or relied solely on the number of times patients logged in 
or uploaded data to determine their engagement. However, system log-ins and upload and 
download data are not engagement. Patient engagement is basically about interaction and 
participation in managing one’s health to achieve desired goals. Therefore, further 
research is needed to determine the best ways to measure patient engagement. 
3. Association between usability of IT platforms and their impact. 
The review found limited levels of evidence supporting the correlation between 
usability and impact of technology on health outcomes (P=.1065). Several factors may 
hinder the positive impact of technology on health outcomes other than usability issues. 
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Patients’ willingness to participate in managing their healthcare could be one of the main 
reasons. The review found a significant relationship with patient engagement and impact 
of technology. It found also a significant positive correlation between patient engagement 
and usability of IT platforms. Even though the aim of this study was not to discover 
determinants of patient engagement, several issues were identified including unequal 
access to technology, technical issues, poor interface design, suboptimal message content, 
privacy and confidentiality issues (Baptist et al., 2011; Fisher & Clayton, 2012; Sims et 
al., 2012; Thackeray et al., 2013; Tran & Houston, 2012; Walker et al., 2011; Womble et 
al., 2004), and patients’ self-perceived health illiteracy. The latter issue was seen in social 
media, where patients think such a discussion should be restricted to healthcare 
professionals (Thackeray et al., 2013). Also, the majority of technologies rely on patient-
provider engagement from both sides to exchange information and manage health 
conditions, such as in two-way SMS, thus increasing burden on providers as well as 
patients. Moreover, in some countries like Sweden, information dissemination can be 
restricted by legal and ethical regulations for online patient-provider communication 
(Nordgreen et al., 2010). Therefore, more research on the usability and acceptability of 
these technologies and discovering the different factors that impact patient engagement 
and their meaningful use will be required in the future. 
4. Association between technology impact and intervention grounded in behavior change 
theories. 
This review found that only a limited number of specific behavioral theories and 
models were referenced among multiple articles inferring a theoretical design. This could 
imply that several IT interventions are designed in an ad hoc way, without using any 
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1 theoretical frameworks. This finding supports the results of a previous study showing the 
majority of mobile-based interventions used for improving medication adherence and 
disease management were developed without a theoretical basis (Riley et al., 2011). The 
review failed to detect any relationship between (1) behavioral theories and impact of 
technology or (2) theories and patient engagement. This could imply that existing 
theories/model were not developed to be used with these technologies. The review found 
a significant association between patient engagement in Internet-based interventions and 
use of behavior theories in these interventions (χ2 =7.3144, P=.00684). This could imply 
that existing theories or models may have limited applicability. However, it was difficult 
to draw a clear conclusion whether or not using theory influenced intervention 
effectiveness. Possible reasons for the lack of theory may include the investigator not 
citing the theory, researchers’ lack of knowledge of the theories, struggling to define 
appropriate theories, poorly operationalized theories, an absence of good evaluation 
methods and usability testing, and theories containing overlapping constructs and 
inconsistent use of terminology. For example, the construct of self-efficacy can be found 
in Social Cognitive Theory, Protection Motivation Theory, the Theory of Planned 
Behavior, the Health Belief Model, and Self-Regulation Theory. In addition, the 
simplicity of the interventions could be another reason for not including behavior 
theories. For example, reminding patients to take their treatment through text message 
appears simple and consistent with the “cue to action” constituent of many health 
behavior theories or models, but these theories were not always described. Our findings 
of the lack of association between use of theory and outcomes was based on the theory 
description within each published article and should be interpreted cautiously. 
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5. Association between methods measure health outcomes and the technologies impact. 
Overall, slightly more than half of the reviewed articles had a positive impact 
when assessed with patient questionnaires, patient self-reports, pill counts, rates of 
prescription refills, assessment of patients’ clinical response, and electronic medication 
monitors. Even though the way to measure health outcomes is an important factor in 
determining the impact of technology, the review failed to detect any relationship 
between methods used to measure health outcomes and the impact of technology. 
Therefore, further study is needed to replicate our results, because for each approach, 
there are different assumptions related to what data to collect, how to collect that data, 
and how to make decisions about success. Indirect methods may overestimate patient 
adherence. For instance, metformin treatment adherence can be monitored either by 
recording the number of times the medication bottle was opened, or alternately, 
adherence could be gauged by metformin plasma levels. Both health behaviors are part of 
the same behavioral class to control blood sugar levels. However, measuring metformin 
in blood is more effective at measuring adherence than recording the time when the bottle 
is opened because patients may open and close the bottle without taking any medication. 
2.2.5 Limitations 
Our review included some limitations. First, due to the heterogeneity of the 
research studies and the fact that some data were not available for certain types of 
interventions and their characteristics, some statistical tests could not be performed, 
hindering optimal quantitative assessment. Second, we excluded studies not written in 
English; this criterion might have omitted certain relevant research. Third, the majority of 
studies were performed in the United States, which limits generalizability of findings. 
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Finally, because of possible publication bias toward positive findings, our review may 
overestimate the actual impact of these technologies. 
2.2.6 Implications 
The results from this review reveal several practical applications worthy of future 
study: (i) Information technology platforms: It would be valuable to further evaluate IT 
platform-based interventions to form a more coherent picture of their effectiveness in 
encouraging patient engagement for the purpose of enhancing lasting health behavior 
change. A study with a long-time frame may be useful to draw a clear conclusion on the 
effectiveness of these technologies and to determine the best ways to guarantee positive 
long-term effects in patients, Also, due to low availability of studies meeting our criteria, 
we could not provide or conclude relationships between factors. Therefore, we 
recommend doing another review when there are more studies available in future. In 
future, we can increase the quality of the review by limiting sample size and study time 
frame. IT platform interventions reviewed in this study are mutually inclusive; they use 
different labels and contexts to describe the same concepts and lack of formal definitions. 
Therefore, a common framework for analyzing these concepts is needed. A framework 
with an ontological approach may serve this purpose. (ii) Patient engagement: The 
outreach and engagement period prior to the intervention enrollment are critical to the 
success of any intervention. Therefore, studies should consider that when implementing 
the interventions. A study assessing determinant of patient engagement is highly 
recommended. (iii) Usability. Assessment of user satisfaction toward IT platforms and 
their usability of these platforms are needed and could be done through qualitative 
evaluations of user opinions of the respective IT platform(s). (iv) Behavioral theories: 
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The literature also needs to focus more on referencing, selecting, and implementing 
behavioral theory to achieve the best possible impact. Reporting accurate information 
about interventions is essential to assessing the effectiveness of these interventions and 
facilitating their successful implementation. Also, new theories are needed to better 
understand how patients can participate and facilitate health behavior change, theories 
building on past conceptual and focus only on one aspect, a triangulation model would 
provide internally logical and comprehensible perception to achieve these goals.  
(v) Methods measure outcomes: It would be valuable to further examine how different 
types of measurement could affect patient outcomes reported in the study. A comparison 
between direct and indirect methods could be helpful to draw a clear conclusion.  
2.2.7 Conclusion 
Based on our review, there is moderately strong evidence that IT platforms can 
engage patients in healthcare and improve health outcomes. The usefulness and 
acceptability of IT platforms can have great power in engagement and outcomes. Studies 
grounded in behavior theory appeared to show a positive impact on patient health 
behavior. To exploit the full potential of IT platforms in healthcare, new theories may be 
needed to better understand how patients can participate and facilitate health behavior 
change. Selecting appropriate ways to measure health behavior change and developing a 
common framework to analyze and understand the different components of IT platforms 
and their safety, effectiveness, efficiency, and acceptability will also be of great 
importance. 
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2.3 Ontologies and Knowledge Representation 
Based on the review in section 2.1, medication-adherence behavior is multi-
factorial in its origin and is affected by interaction between individuals and situation 
factors (Sawesi, Carpenter, & Jones, 2014). Section 2.2 discussed the vast amount of 
information produced as a result of advancements in medication adherence in information 
technology. For medication adherence research activities to be ultimately effective in 
understanding, changing, or modifying such complex behavior, there needs to be 
knowledge aggregation from different resources, such as literature, clinical study results, 
and databases.  
Currently, no single system capably covers the medication adherence domain 
completely. A fundamental reason for this gap relates to the inconsistency and lack of a 
strategy for representing knowledge related to the medication adherence domain. 
Medication adherence is measured in a variety of ways (e.g., self-report vs. drug 
concentration in body fluid). Although these represent different constructs or entities, 
they are labeled as medication adherence. Also, medication adherence and medication 
persistence are used interchangeably (Aronson, 2007) when they refer to different 
phenomena. Moreover, different labels can be used to refer to the same meaning, such as 
in case of some theoretical constructs (e.g., self-efficacy, perceived behavioral control, 
and locus of control). Therefore, developing an interoperable and standardized 
framework that enables the scientific community to contribute equally to the 
representation of the medication-adherence knowledge domain is necessary. 
Knowledge representation is a surrogate for something tangible or intangible in 
the real world. It is a medium of human expression and computation (Blobel, 2006). It 
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facilitates our understanding, communicating, sharing, organizing, thinking, and 
reasoning about the thing in the real world (Davis, Shrobe, & Szolovits, 1993). 
Knowledge representation in biomedical informatics refers to electronic models of real-
world phenomena; an example is that knowledge representation represents patient-related 
information in electronic health records (EHRs). 
To solve any problem or discover knowledge in a domain, the first step is to 
represent that knowledge in a way that it can be understood and shared by humans and 
computers (Chandrasegaran et al., 2013). An ontology is a form of knowledge 
representation about the real world or a part of it. It is one strategy that has been used in 
biomedical science to support knowledge aggregation. It is organized in hierarchical 
structures of a set of entities describing a domain that can be used as a foundation for 
knowledge base (Salem & Alfonse, 2008).  
2.3.1 What is an Ontology?  
Philosophically, the term “ontology” refers to the study of kinds of things that 
exist and their relation to each other. Barry Smith (2003) defined it as a “science of what 
is, of the kinds and structures of objects, properties, events, processes, and relations in 
every area of reality (Smith, 2003).”  
In information science, Gruber defines ontology as a specification of 
conceptualization (Gruber, 1995). Although Gruber’s definition has been accepted by 
most ontological engineers, his concept-centric view assumed as a matter of course that 
ontology represents what is in humans’ minds, not what exists in reality. Ontology 
primarily concerns describing reality in its most general sense (Arp et al., 2015). 
Therefore, to avoid being misleading, this dissertation defines ontology as a formal 
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description of knowledge within a domain as a set of entities/terms on an abstract level 
and relations between those entities. An ontology, as applied in areas of biomedical 
science, is perceived as a given role in capturing a reality about a domain and allowing 
shareability and reusability of domain knowledge. 
2.3.2 Ontology’s Impact on the Biomedical Field 
Applications for ontologies are broad, as they show value within a domain (Zhang 
& Bodenreider, 2007), across health systems (Anagnostakis, Tzima, Sakellaris, Fotiadis, 
& Likas, 2005), and in the facilitation of bench research to patient care (Tenenbaum et 
al., 2011). According to the National Center for Biomedical Ontology (NCBO), an 
ontology enables data aggregation, improves searching, and detects new associations that 
previously went undetected (Musen et al., 2012). A select number of studies have 
measured ontology’s impact on biomedical research and patient care. Ontology’s impact 
includes, but is not limited to: (1) understanding patient perception, (2) acquiring 
knowledge, (3) understanding patient behavior, (4) allowing the domain knowledge to be 
independent of technology, (5) structuring a relational database, and (6) standardizing or 
formalizing the domain. Each area is discussed below. 
An ontology could be used to better understand patients’ perceptions. In turn, 
these perceptions could then be transformed into a framework structure (Meghani & 
Houldin, 2007). In the same paper, ontology was used to acquire knowledge about how 
patients describe their cancer pain and learn how patients view pain (Meghani & Arkene, 
2007). A study by McGrath (2002) also looked at how ontology was used to attain 
knowledge of an interesting domain through oral interviews (McGrath, 2002). A study by 
Brown (2006) demonstrated similar use for ontology. Brown’s research team used an 
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ontology to better comprehend how patients waited for liver transplants (Brown, Sorrell, 
McClaren, & Creswell, 2006). A study by Bickmore, Schulman, and Sidner (2011) 
demonstrated that ontology has been used successfully to represent changes in health 
behavior. This study covered the Trans-theoretical Model, Motivational Interviewing as 
Applied to Exercise (walking) Promotion, and Diet (fruit and vegetable) Promotion 
(Bickmore, Schulman, & Sidner, 2011). Another study used an ontology to design 
computerized behavioral protocols to help individuals improve their behaviors (Lenert, 
Norman, Mailhot, & Patrick, 2005). 
An ontology framework can also allow the domain knowledge to be independent 
of technology. This means that it can operate on multiple platforms, using a variety of 
capabilities (Farion et al., 2009). The ontology knowledge model allows for 
differentiation between logic knowledge and software design; it embodies a set of 
concepts and how they correlate into a hierarchical format that can be referenced in 
reasoning rules in machine learning. As a result, when knowledge is changed, reasoning 
changes without any work being done to the software system. Doyle, Ma, Groseclose, 
and Hopkins (2005) realized the benefits of ontologies and instituted the ontological 
knowledge base for public health surveillance. As a result of these characteristics, 
ontology benefits data sharing in Electronic Health Records (EHR). Ontology separates 
technology and medical knowledge. It allows patients’ information to be shared across 
health institutions, irrespective of EHRs’ operation or technology. 
Ontology has played a significant role in linking a study’s domain knowledge to 
standard terminology systems. The terminology servers Unified Medical Language 
System (UMLS), Systematized Nomenclature of Medicine (SNOMED), and Logical 
 73 
 
Observation Identifiers Names and Codes (LOINC) are considered well-structured 
systems that, according to Cole (2004), offer standardized communication, 
documentation, and classification of health and medical vocabularies (Cole, Kanter, 
Cummens, Vostinar, & Naeymi-Rad, 2004). Despite these systems being built on a 
standard structured framework, in terms of their concepts, they are inconsistent and 
incompatible (Bolbel, Engel, & Pharow, 2006). A study by Ahmadian, Cornet, & Keizer 
(2009) investigated whether SNOMED CT adequately described the terms used in pre-
operative assessment guidelines. These authors determined that 71% of the guidelines 
matched SNOMED, while 69% of 39 not-fully covered concepts violated a minimum of 
one SNOMED CT format. These researchers stated that ontology could potentially serve 
as a solution for formalizing SNOMED CT’s guidelines. And, in Doan’s 2009 research, 
ontology was instituted to examine the conceptual classifications of infectious diseases 
that were not presented in terminology systems (Doan, Kawazoe, Conway, & Collier, 
2009). Fried et al. (2003) reported that no terminological systems, including current 
ICD10, READ, SNOMED, UMLS, or MeSH, supplied sufficient granularity of content 
or domain completeness for metadata in multimedia data within the Cardio domain 
(Friedl et al., 2003). Another example of ontology used in the terminology domain was 
found in a study by Elkin et al. (2005). In this instance, ontology contributed to building 
terminology structure for an automated system that provided clinical notes with 
classification in negation and propagation. When using ontologies, these terminology 
domains can share and integrate existing definitions and terminologies across multiple 
health levels (Pappa, Telonis, & Stergioulas, 2006). This is a requirement for semantic 
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interoperability, particularly in terms of knowledge representatives and terminologies 
(Blobel, 2007). 
Medical ontology differs from those mentioned above in that ontology that is 
intended for terminology servers is built on static structures designed for knowledge 
reference. Its databases are built on language concepts; whereas, medical ontology 
merges all pertinent concepts, which, according to Jovic, Prcela, & Gamberger (2007), 
relate to five factors: diagnostics, treatment, clinical procedures, patient data, and 
outcome prediction. Ontology, in the environment of medicine/patient care, needs to 
consider temporal changes and factors, particularly when they apply to EHRs, because 
EHRs are patient-centered, longitudinal, comprehensive, and prospective (Garde, Knaup, 
Hovenga, & Heard, 2007). In addition, current ontology models need to be reusable and 
easily adapt to new changes. Furthermore, because stakeholders are present in medicine, 
ontologies need to be classified, based on their design purpose. 
Other studies showed that ontologies are viable as a new tool to implement a 
knowledge framework that connects systems. Medicine is a complex system and 
ontologies can play a significant role, where studies need to focus on a special knowledge 
domain. To connect knowledge frameworks to a larger structure, ontologies must bridge 
similar interests. In a study by Capozzi and Lanzola (2009), in Italy, telemedicine was 
successfully built on a platform and was used for patients with Type I diabetes. Ontology 
served as pivotal knowledge that allowed for interaction connecting EMRs and domain 
knowledge of the study. Another researcher, Abidi (2009), showed ontology as allowing 
for specific clinical pathways to be computerized in prostate cancer. This researcher 
based ontology on the hypothesis of extending and blending nodes that served as 
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interclass intersections (Abidi, Butler, & Hussain, 2008). Abidi’s study merged three 
unique clinical pathways into a single one. Comparably, in instances of heart failure, the 
developed ontology merged data from the ECG signal and heart image (Chiarugi et al., 
2008). 
An additional benefit of ontology is that it standardizes or formalizes the domain 
(Haschler, Skonetzki, Gausepohl, Linderkamp, & Wetter, 2004; Sobrado, Juan, Iker, 
Juan, & Diego, 2004). There is a difference between standardization and integration. It is 
the number of models that connect to the designs. With standardization, ontology can 
connect a significant number of models; it can also be designed without using any 
existing ontology. Lusignana (2003) incorporated ontologies into a study that developed a 
general quintessential theory for the subspecialty of Primary Care. In a study by Pellegrin 
et al., (2007), researchers built a method that represented and observed combined 
activities that occurred within the patient’s management that team members could use to 
prepare for accreditation. However, no common guidelines were established for 
observation; therefore, the ICU team used ontologies to develop a framework for task 
observation. In turn, Haschler et al. (2004) went further and created an expanded 
oncology framework, known as HELEN, which was used to create clinical guidelines. 
This expanded framework served not only as a method for standardization, but it also 
became an adaptable process to change environments. Colantonio (2008) stated that 
ontology was constructed as a way to formalize the domain of chronic heart failure. The 
study further indicated that a main benefit of ontologies is that they allow for 
information-sharing across stakeholders and facilities. Fernandex (2004) indicated that 
ontology supports cardiology’s conceptual frameworks in that it allows for a variety of 
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stakeholders and healthcare groups to exchange knowledge management and 
communication, with no need for any specific domain to be matched to a standard 
ontology (Fernandez et al., 2004; Goossen, Goossen-Baremans, & Van Der Zel, 2010). 
Ontologies not only influence medical terminology, public health, and medicine, 
they also have an impact on healthcare management. Ontologies, when used by 
healthcare organizations, can fulfill many reference or guideline roles. Organizations 
and/or health facilities require their own ontology guidelines. Often they are not 
compatible with other facilities. A study by Dang et al. (2008) includes an ontological 
knowledge framework that addresses a variety of responsibilities, ranging from 
administrative to patient-care related. This framework captures all the critical knowledge 
needed to document complex personal events, ranging from patient care to insurance 
policies and drug prescriptions (Dang, Hedayati, Hampel, & Toklu, 2008). This differs 
from previous examples of ontologies, because it addresses a business perspective; yet, 
ontologies are also applicable to business rules and healthcare policies, and are applicable 
in the context of personalized patient care when supporting the composition and 
execution of an adaptive workflow system. This system incorporates functionalities that 
enable users to monitor and control the patient process and maintain any historical 
process data for future reference without relying on IT support. This study proposed 
creating an adaptive workflow system that could be managed by users without knowing 
the technical aspects. Furthermore, the software that was developed incorporated 
ontology’s meta-data to gain an understanding of the specific domain’s environment and 
its rules. In this instance, the process rules were separated from the business rules that 
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allowed this adaptive workflow system to bridge the healthcare needs and IT technology 
of any hospital environment as its first achievement. 
2.3.3 Ontology Developing Approach 
Considering the discussed benefits of ontology in the biomedical domain, several 
principles and methodologies have been proposed to build ontology. However, no 
specific standardized methods exist for developing an ontology (Smith et al., 2007), 
compared to ISO standards (Ceusters, Smith, & Goldberg, 2005). Ontological 
engineering, the field that studies methods and methodologies for building and using an 
ontology, is relatively young and has no standard methodologies built in or proven 
principles to guide ontology development (Pattuelli, 2011). Ontologies are as unique as 
the domains they represent. Both a collaborative approach and a development trajectory 
are common features in ontology development (Bug et al., 2008; Cimino et al., 2009; 
Tudorache et al., 2010). This section discusses different methods used to build 
ontologies.  
1. Methodology by Uschold and King (Jones, Bench-Capon, & Visser, 1998). The first 
methodology implemented for ontology developed by Uschold and King in 1995 
based on experience as a result of developing an Enterprise Ontology—“an ontology 
for enterprise modeling processes.” It encompasses four steps:  
a. Purpose identification: Identifying the purpose of the ontology, its domain, and 
intended users.  
b. Ontology building: This step has three sub-processes: (i) Ontology capture-in, 
where key concepts and ideas from the ontology domain will be captured using 
bottom-up, top-down, or middle-out. (ii) Coding–Represents knowledge explicitly 
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captured from the previous step. (iii) Integrates existing ontologies–using the 
existing ontology.  
c. Ontology evaluation: Makes technical judgment of the created ontology. 
d. Ontology Documentation: Establishes a guideline for ontology documentation 
according to the purpose of the ontology.  
2. TOVE Methodology (Grüninger & Fox, 1995): Based on experience gained through 
developing TOVE project ontology for the business domain by Gruninger and Fox in 
1995, it involves several steps.  
a. Motivating scenario–may be a story problem or examples not addressed by existing 
ontologies.  
b. Developing competency questions–a set of natural language questions used to 
measure the scope of the ontology.  
c. Coding–specifies informal questions in a formal language.  
d. Axioms specification–uses first-order logic using axioms to define terms and 
constraints for the property.  
e. Evaluation–assesses competency by defining the condition under which answers to 
the competency questions are complete. 
3. METHONTOLOGY method (Fernández-López, Gómez-Pérez, & Juristo, 1997): 
Developed within the Laboratory of Artificial Intelligence at the Polytechnic 
University of Madrid. Used when developing ontologies from scratch. It includes 
several activities and techniques to carry out these activities.   
a. Project management activity–involves three steps. (i) Planning–describes the tasks, 
methods, and time needed to perform an ontology. (ii) Control–ensures that planned 
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tasks are completed, as intended. (iii) Quality assurance–guarantees the quality of 
the ontology is satisfactory. 
b. Development-oriented activities–involves several steps: (i) Specification: identifies 
the ontology’s purpose, intended user, and required degree of formality. (ii) 
Conceptualization: Uses informal representation to represent domain terms (i.e., 
concept, instances, relations). (iii) Formalization: transforms the informal model 
into a formal one. (iv) Implementation: Codifies the ontology in a formal language. 
(v) Maintenance: updates and corrects the ontology.  
c. Support activities: this step includes a series of activities carried out simultaneously 
with development-oriented activities. It includes: (i) Knowledge acquisition: text 
analysis, expert interview, or other sources of knowledge. (ii) Evaluation: performs 
an ontology validation and verification. (iii) Integration: for uniformity across 
ontologies, definitions from other ontologies should be incorporated. (iv) 
Documentation: completed activities should be documented in order to control 
changes. (v) Configuration management: records all versions of the documentation. 
4. KBSI IDEF5 Methodology (Jones et al., 1998): Proposed to assist in building, 
modification, and maintenance of ontologies. It involves general procedures with a 
set of guidelines:  
a. Organizing and scoping: the purpose and requirement of ontology.  
b. Data collection: the raw data required to build the ontology is acquired using a 
typical technique, such as protocol or expert interview.  
c. Data analysis: extracts the ontology from the results of the previous step.  
d. Initial ontology development: initial description of kinds, relations, and properties. 
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e. Ontology refinement and validation: proto-concept refined and tested iteratively. 
5. The CYC methodology (Corcho, Fernández-López, & Gómez-Pérez, 2003): 
Developed by Lenat and Guha in 1990, it is based on experience from developing the 
CYC knowledge base. This method consists of two phases.  
a. Manual knowledge codification: extracts knowledge by hand from different related 
resources.  
b. Machine knowledge acquisition: new common-sense knowledge in this phase will 
be acquired with the help of natural language or machine-learning tools. 
6. 101 Methodology (Noy & McGuinness, 2001): Developed by Noy and Deborah, this 
methodology involves several steps:  
a. Domain specification: determines the domain and scope of an ontology using 
competency questions.  
b. Considers reusing an existing ontology.  
c. Enumerates important terms in the ontology.  
d. Defines classes and their hierarchy using top-down, bottom-up, or a combination. 
e. Defines properties of classes. 
f. Defines facets of the slot.  
g. Defines instances. 
7. UPON Methodology (Iqbal, Murad, Mustapha, & Sharef, 2013): Derived from a 
unified software development process (UP), this methodology is use-case driven and 
consists of cycles, phases, iterations, and workflows. Each cycle contains four phases 
(inception, elaboration, construction, and transition). Each phase splits into iterations 
that contain five workflows.  
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8. The SENSUS-Based Methodology (Iqbal, Murad, et al., 2013): Based on the 
experience development of SENSUS Ontology, this methodology was developed at 
the Information Sciences Institute Natural Language Group. It includes terms from 
both a high- and medium-levels of abstraction and encompasses several steps:  
a. Terms taken as seed. 
b. Terms linked by hand to the SENSUS. 
c. All concepts from seed to root.  
d. Adds any terms relevant within the domain.  
e. Adds the subtree under the node for nodes that have a large number of paths. 
9. On-To-Knowledge (Corcho et al., 2003): Based on usage scenarios, this methodology 
includes identification of goals intended to be achieved: 
a. Feasibility–identifies the problem and why an ontology is needed.  
b. Kickoff–a semi-formal description of the ontology created from different sources, 
including by a domain expert.  
c. Refinement–refining the semi-formal ontology created in the previous step by 
considering relevant knowledge sources: top-down and bottom-up approaches.  
d. Evaluation–technology evaluations; user satisfaction evaluation; and ontology 
evaluation, using OntoClean as an example.  
e. Application–testing develops an ontology in the productive system.  
f. Ontology maintenance.    
2.3.4 Methodologies Comparison 
The scarcity of a standard methodology is one of the greatest issues in 
constructing an ontology. As a result, several criteria have been proposed to analyze and 
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compare methodologies used for ontology building. This comparison would be 
considered systematically-guided ontology building. A comparison of the nine 
methodologies mentioned in the previous section was carried out based on criteria 
developed by Fernández-López, & Asunción (2002), Gómez-Pérez, Fernández-López, & 
Corcho (2006), and as elaborated by Iqbal et al. (2013). The criteria is presented in Table 
10 below and involves: (1) Type of development–there are three: namely, stage-based 
model (suitable when purpose and requirement are not clear), evolving prototype model 
(suitable when requirement needs modification over time), guidelines (focusing only on 
recommended tips or rules to make a better decision). (2) Support collaborative 
construction–when a team or group work on a single ontology simultaneously without 
restriction). (3) Support reusability–use of an existing ontology to prevent reinventing the 
wheel and focusing on quality, not quantity. (4) Interoperability–using upper-level 
ontology to facilitate communication between systems. (5) Application dependency–
keeps in mind building on the basis of application. (6) Life-cycle recommendation–a set 
of stages through which the ontology moves during its specified life. (7) Strategy for 
identifying concepts–involves three types: namely, bottom-up, top-down, and middle-out 
approaches. (8) Details of the methodology–information on activities and techniques used 
in ontology development.  
Results of the comparison show that the majority of methodologies are evolving 
prototype models, except for Enterprise mode and TOVE. They are stage-based models 
that are best when there is a clear purpose. The evolving prototype is suitable when the 
requirement is not clear initially and needs modification over time. The analysis shows 
that all the methodologies are isolation construction, except SENSUS, as the method 
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supports collaboration construction. Reusability is supported by all the methodologies 
except On-To-Knowledge. Seven of the methodologies are application-independent, 
wherein the designer has no assumption in mind regarding use of the ontology during the 
specification stage. METHONTOLOGY, UPON, and On-To-Knowledge proposed a life-
cycle recommendation wherein the ontology moves during its life. Strategy for 
identifying the concept–Enterprise model, TOVE, METHONTOLOGY, UPON, 
SENSUS, and On-To-Knowledge all support the middle-out approach in identifying 
concepts that are candidates for ontology inclusion. Only METHONTOLOGY provides 
sufficient details pertaining to techniques and activities used in the ontology development 
process. This is considered one reason for the high adoption rate of this method in 
ontology building.
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Table 10 The Criteria for Methodology Selection 
Methodologies Type of 
development 
Collaborative 
construction 
Reusability 
support 
Degree of 
application 
dependency 
Life 
cycle  
Strategies 
for concept 
selection 
Methodology 
details 
Inter-
operability 
support 
Enterprise model 
approach 
Stage-based No Yes Application semi-
independent 
No Middle-out 
strategy 
Some details No 
TOVE Stage-based No Yes Application 
independent  
No Middle-out 
strategy 
Some details No 
METHONTOLOGY Evolving 
prototype 
No Yes Application 
independent 
Yes Middle-out 
strategy 
Sufficient 
details 
No 
KBSI IDEF5 Evolving 
prototype 
No Yes Application 
independent 
No Not clear Some details No 
CYC Methodology Evolving 
prototype 
No  Yes Application 
independent 
No Not clear Some details No 
101 Methodology Evolving 
prototype 
No Yes Application 
independent 
No Developer’s 
consent 
Some details No 
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UPON Evolving 
prototype 
No  Yes Application 
independent 
Yes Middle-out 
strategy 
Some details No 
SENSUS Does not 
mention any 
Yes Yes Application semi-
independent 
NO Bottom-up Some details Yes 
On-To-Knowledge Evolving 
prototype 
No No Application 
independent 
Yes Middle-out 
strategy 
Some details No 
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2.3.5 Principles of Ontology Design  
A comprehensive methodology for ontology development should involve 
principles to confirm the quality of the proposed ontology. Arp, Smith, and Spear 
highlighted in their book, Building Ontology with Basic Formal Ontology, (2015), the 
general principles that need to be kept in mind when developing an ontology(Arp et al., 
2015). These principles are: (1) Realism–refers to the general feature of reality in the 
form of universals and relationships between these universals. (2) Perspectivism–the 
occurrence of several accurate descriptions of reality. (3) Fallibilism–the ability to revise 
an ontology. (4) Adequatism–a represented entity that should be taken seriously on its 
own, and is not considered to be reducible to another entity. (5) Reusability–refers to use 
of the existing ontology. (6) Balance utility and realism–refers to the fact that an ontology 
could be developed without restriction on its utility, as a short-term utility may impact its 
long-term utility. (7) Open-ended process–the ontology should be designed so that it can 
be expanded and modified over time. (8) Low-hanging-fruit–refers to defining general 
terms first, then represents more complex terms. For interoperability and reusability, the 
Open Biological and Biomedical Ontologies Foundry (OBO) and the NCBO(Smith et al., 
2007) have developed “Best practices” in ontology design. The guidelines include several 
principles for collaborative, coordinated development and integration of biomedical 
ontologies (Smith et al., 2007). OBO Foundry Principles include: (1) Format–a common 
formal language. (2) URI–classes and relations should have Uniform Resource Identifiers 
(URIs). (3) Versioning–discloses ontology versioning through metadata to reflect 
changes made. (4) Documentation–on an ontology website, documents the ontology in 
sufficient quality and detail. (5) Users–shows evidence for multiple independent users. 
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(6) Authority locus–serves as a responsible leader and developer team/mechanism for 
contact and feedback. (7) Maintenance–the ontology should be maintained with 
appropriate regularity, rigorous quality, and a funding source. (8) License–the ontology 
should be openly available via the OBO foundry. (9) Content delineation–classes and 
relations should have clearly delineated content of acceptable precision. (10) Content 
coverage–a sufficient number of concepts and terms to cover domain. (11) Content 
Quality–both formal correctness and correctness of content. (12) Textual definition–
textual and formal definitions for all class terms. (13) Naming conventions. (14) 
Relations–one method that represents relations by using an upper-level ontology, such as 
Basic Formal Ontology (BFO). (15) Conserved URIs–guarantees interoperability.   
2.3.6 Upper-Level Ontology 
Biomedical ontologies have increased dramatically based on escalating methods 
developed for their construction. The majority of these methods, however, do no support 
interoperability and knowledge sharing. As a result, many ontologies were built in 
isolation and without their intent to be integrated with other ontologies. Many lack formal 
definitions and are not based on formal logic. Using an upper ontology offers the highest 
level structural template related to interoperability between represented domains(Arp et 
al., 2015). As a unifying upper ontology, BFO was developed for biomedical domain 
ontologies. It ensures that all ontologic classes/entities are placed in the correct kind of 
hierarchy. Because of BFO’s generality and the small size of its structure, many large 
projects and biomedical ontologies use BFO’s as their upper-level ontology(Arp et al., 
2015). This means that other ontologies are interoperatable through BFO(Bug et al., 
2008). More information on BFO entities will be discussed in the next chapter.  
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Summary 
The literature was reviewed to evaluate factors impacting medication adherence 
and clarify how these factors relate to adherence behavior to enhance behavior change 
interventions. The review found medication adherence to be multidimensional 
and dynamic—impacted by intrapersonal, interpersonal, and contextual factors, thus 
making behavior change a complex problem. This complexity requires robust approaches 
for organizing and curating knowledge effectively to facilitate the accumulation and 
comparison of findings in the literature. Effectively accumulating knowledge is hindered 
by the inconsistent use of terminology and categorization. Although the literature adopted 
WHO dimensions to categorize factors that influence medication adherence, this category 
is not suitable for a computation representation of these factors, because of (i) a lack of 
uniformity in class categorization (e.g., side effects were represented in one study under 
patient-related, while in another study, it fell under medication-related); (ii) discrepancies 
in class hierarchy with some factors grouped directly with the main class (e.g., severity of 
disease fit under disease-related), while others had sub-categories (e.g., age under 
demographic-related); and (iii) lack of a concrete definition for the categories. It is 
essential to categorize and structure these factors to study complexity of medication 
behavior, allocate resources, and plan interventions. The resulting ontology can be used 
for decision support in medication adherence management programs.   
Next, information technology platforms used to improve patients’ behavior were 
reviewed. Although various platforms were used to improve patients’ behavior, there was 
a need to understand causes of that behavior. The review examined behavioral theories or 
models that were applied to develop these interventions and their impact on health 
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outcomes. The literature review, however, shows that many articles are atheoretical or 
their theories are unspecified. Among studies that implemented theories, often theoretical 
constructs that describe the same concepts were unlabeled, concepts were found to lack 
formal definitions, and theories included overlapping constructs and inconsistent use of 
terminology. Such inconsistencies may limit the behavioral theories’ application and 
evaluation, which impedes development of new theories.  
Finally, biomedical informatics research related to ontology development was 
reviewed; it showed that ontology plays a significant role in analyzing, structuring, and 
implementing domain knowledge due to its ability to capture a common understanding. It 
was also used to facilitate the interoperability of heterogeneous information sources and 
enhanced communication between people and systems, as it provided terms, definitions, 
and relationships among these terms. The reviews discussed various methodologies and 
principles that were proposed and used to build and validate ontologies. They provided a 
brief comparison that would be helpful in deciding which approach would be more 
suitable to build the medication adherence behavior ontology. This section highlighted 
the importance of creating an ontology that can integrate and interoperate with other 
ontologies to facilitate knowledge sharing among experts.  
 
 
 
 
 
 90 
 
CHAPTER THREE: GUIDING PRINCIPLE FOR ONTOLOGY DEVELOPMENT 
Behavioral ontologies are difficult to engineer due to the vast and complex nature 
of behavior knowledge (Fabrigar, Petty, Smith, & Crites Jr, 2006). The instability of 
behavioral knowledge and constant changing in the behaviorist’s understanding of this 
domain add further complications. Ontology development is a collaborative, iterative, 
and ongoing process, which implies involvement of various people with different 
viewpoints, making it difficult to define (Bilder et al., 2009). Although Medication-
Adherence Behavior ontology (MAB-Ontology) represents the work and effort of a 
single author, it is designed to promote engagement with other biomedical ontology 
projects. MAB-Ontology is foundational, extensible, and requires continuing cooperation 
and curation to age gracefully (Cimino, 1998).  
As described in chapter two section 2.3.3, no single methodology exists for 
developing ontologies. However, some criteria can be useful in guiding the methodology 
selection. Based on the criteria represented in Table 10, the METHONTOLOGY and 
UPON methodologies were considered the best candidates for developing the 
medication-adherence behavior ontology (MAB-Ontology). Both methods are 
application-independent, meaning there is no need for pre-assumption regarding their use 
to which the ontology will be put into knowledge-based systems. Moreover, they clearly 
recommend the life cycle that identifies a set of stages through which the ontology moves 
during its lifetime. They also adopt the middle-out approach to determine the most 
relevant terms as a first step before generating and specifying them. Unlike UPON, 
METHONTOLOGY provides adequate information about how information is gathered, 
organized, and evaluated through the ontology development life cycle. It also provides 
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sufficient detail on steps related to updating and correcting the implemented ontology. 
Moreover, METHONTOLOGY uses a set of intermediate representations (IR) to 
summarize knowledge into graphics and tables that can be understood by both 
domain experts and ontology developers. Although METHONTOLOGY and UPON 
methodologies support re-usability and make use of existing ontologies, they fail to 
support interoperability between systems.  
Therefore, METHONTOLOGY was selected as the most suitable methodology 
for guiding development of the MAB-Ontology. In fact, modeling a domain requires a 
customized approach based on the domain’s nature and purpose of the ontology to 
specify and represent the domain (Smith et al., 2007) and flexibility of the 
METHONTOLOGY methods, which allow its adoption to match the needs of the 
development of the medication-adherence behavior ontology (Prieto Ferrero, Lloret, & 
Palomar, 2014). It allows for the incorporation and use of upper-level ontology—the 
Basic Formal Ontology (BFO). Using BFO and following its principles is to guide 
domain ontology development and to support interoperability between the developed 
ontology and other ontologies (Arp et al., 2015). As a result, these methods entail six 
steps that have been adopted to develop a medication-adherence behavior ontology 
(Figure 3):  
1. Domain specification by defining its purpose and scope. 
2. Knowledge acquisition of a given domain. 
3. Knowledge structuring and organizing within a set of Intermediate Representations 
(IRs). 
4. Model Integration with the upper-level ontology and reusing existing ontologies.  
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5. Ontology concretization in a computer-tractable representational artifact (i.e., 
using formal language). 
6. Ontology Evaluation during each phase of the process and between phases of the 
life cycle Methods Overview 
 
Figure 3 MAB-Ontology Methodology Overview 
3.1 Domain specification  
Domain specification is the first step in ontology building, wherein the purpose 
and scope of the ontology is defined. Defining use and scope of an ontology is essential 
to determining the ontology’s complexity and the approach adopted for its development. 
The cost and complexity of building an ontology could vary, according to its use(Sang, 
2009). This step is divided into three parts: (i) definition of the purpose of the ontology, 
including domain use and intended users; (ii) the approach taken for ontology building; 
and (iii) the scope of the ontology, including a set of terms represented.   
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3.1.1 The Purpose of the Ontology 
This step precisely defines the goal the ontology of medication adherence domain 
for which it was created, its intended uses, and a scenario of use.  
3.1.2 Approaches for Ontology Building 
Three types of ontology building approaches existed; namely: The top-down 
approach, where the building process start with the most generic concepts and move to 
more specific concepts. The bottom-up approach, where the process moves from specific 
concepts to high-level abstractions (Francesconi, Montemagni, Peters, & Tiscornia, 
2010). And, the middle-out approach, which is a combination of both approaches. It is an 
integration of theoretical modeling and text analysis that balances the level of detail, 
which, in turn, acquires knowledge, as needed (Fernández-López et al., 1997). 
3.1.3 Scope of the Ontology 
The scope of the ontology which is discussed in the next chapter (i.e., chapter 
four), is defined by using competency questions and use-case scenario. Competency 
questions are a list of natural language questions formulated on the motivation scenario 
(Grüninger & Fox, 1995). Use-case scenario uses to demonstrate an ontology application 
and is defined as an artifact that describes the expectation of the proposed ontology that 
should be satisfied after development (Grüninger & Fox, 1995; Iqbal, Mustapha, & 
Mohd. Yusoff, 2013). Both motivation scenario and competency questions are considered 
documents for the requirement specification; they are used to guide the scope of the 
ontology. That is why they are utilized to test the efficacy of ontology in answering those 
questions and solving the scenario problem.   
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3.2 Knowledge Acquisition 
Knowledge acquisition involves identification of data, interpretation of this data 
(information), and analyzing and structuring this information (knowledge) for 
representation purposes (Mendonça, Coelho, de Andrade, & Almeida, 2012). It is an 
essential step for building an ontology. Through this step, insights into how medication 
adherence is realistically represented can be identified and modeled. To this end, resource 
availability is determined through exploring several areas of domain knowledge. This 
process is an iterative; it involves cycles of reviewing the literature and extracting 
information, as needed. Additional terms may be necessary to ensure the hierarchy’s 
completeness.  
3.2.1 Knowledge Sources 
Several knowledge sources were investigated to ensure consistency, objectivity, 
and better quality of the developed ontology. (1) Scientific papers: Literature related to 
medication-adherence behavior that were systematically reviewed. The motivation 
behind using scientific papers was that they provide comprehensive and objective 
information on a complex and broad topic, such as medication-adherence behavior, 
which is beyond a single human expert (Ogundele, Moodley, Seebregts, & Pillay, 2015). 
Also, the rigorous process that a scientific paper went through before publication 
guarantees its validity as a source of knowledge used to build medication-adherence 
behavior. Moreover, scientific papers reflect complexity of the domain and its different 
perspectives, while also serving as a diverse representation of what the ontology intended 
to solve. Additionally, medical practice and decision making informed by knowledge was 
derived from clinical papers, which enhances ontology adoption and use. (2) Textbooks 
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also served as sources of domain understanding and modeling in this project, because 
they provided solid grounding in the subject and a basis for terms and definitions (Boyce 
& Pahl, 2007). (3) Online repositories of formal ontologies were perused to identify 
relevant terms in order to enhance ontology reusability and prevent reinventing the 
wheel: Ontobee- http://www.ontobee.org/, OBO Foundry-http://www.obofoundry.org/, 
and Bioportal- https://bioportal.bioontology.org/. (4) Domain-related experts were also 
consulted to strengthen understanding of domain content.   
3.2.2 Source Selection  
Sources were identified and clustered into categories based on project scope and 
aims. The first category was coded “Medication Adherence Assessment Literature,” 
which included key articles that describe different methods used to measure medication 
adherence. Category two was coded “Determinants of Medication Adherence Literature,” 
as this broad project will narrow in scope, based on a disease type. Therefore, only 
literature that discussed adherence to endocrine therapy among breast cancer patients was 
reviewed (chapter two, part one). Theories used to understand and change medication 
adherence were reviewed, collected, and grouped under “Theory of Behavioral Change.” 
“Medication Adherence Data Standard” was the code given to the: (a) taxonomy or 
categories for factors affecting medication adherence, such as five dimensions of the 
World Health Organization (WHO) category (Organization, 2014); (b) taxonomy used 
for medication adherence interventions, such as a Behavior Change Technique (BCT) 
project (Michie et al., 2013); and (c) taxonomy of medication adherence, such as 
Ascertaining Barriers to Compliance Project (ABC) (Vrijens et al., 2012). The sources 
under this category were analyzed for possible inclusion at this stage. The fifth category 
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was coded “Medication Adherence–Related Terms,” in which BioPortal, OBO Foundry, 
and Ontobee were reviewed to determine relevant terms and concepts used in similar 
conditions or situations. This step was taken to initially follow the principle of the OBO 
Foundry to ensure interoperability with existing ontologies and obtain feedback on the 
upper-level grouping, the level of granularity and terminology structure. Finally, domain 
experts—committee members—were consulted to enhance understanding of domain 
content. This diversity in the sources guaranteed domain knowledge saturation, as it 
elicited a vast set of terms from diverse source types that were carefully scrutinized for 
clear understanding.  
3.2.3 Searching Strategy  
1. Medication Adherence Assessment Literature Search Strategy. 
Several electronic databases were employed to search Boolean phrases, namely 
“PubMed, Embase, and EBSCO.” CINAHL and PsycINFO were included when 
searching the EBSCO database (Figure 4). Conferences, dissertations, book chapters, 
letters, commentaries, reviews, case series, and case reports were not included in this 
category. Reference to related articles were also examined. MeSH index terms were used 
and included—(adherence OR compliance OR persistence OR concordance) AND 
(Tamoxifen OR Aromataze Inhibitors OR adjuvant hormone therapy) AND (adult OR 
elderly OR Women OR Men OR Female OR Male) AND (breast cancer) AND 
(assessment OR measurement OR direct assessment OR indirect assessment OR 
subjective assessment OR objective assessment OR monitoring device OR electronic 
device OR self-monitor OR self-monitoring OR drug monitoring OR self-administration 
OR reminders OR management OR process outcomes OR managing OR administration 
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OR drug administration schedule OR medication possession ratios OR self-report OR gap 
OR measurement). A comprehensive search strategy was implemented to avoid missing 
potentially relevant information. An article was included if the study abstract was 
available, the study’s design and methods were clearly described, or the article measured 
adherence among breast cancer patients as a primary outcome. Articles reporting clinical 
outcomes as indicators of medication adherence were not included, because many other 
factors, other than adherence, could influence clinical outcomes. If an article reported 
medication adherence or a persistence rate and that described methods used to calculate 
adherence levels, it was included. The search was conducted for English-language 
publications between 2000 and 2017. The feature, Endnote, was used to sort and remove 
duplicates. Relevant terms were extracted and inserted in a structured sheet using 
Microsoft Excel. Terms were organized based on source type.  
 
 Figure 4 Medication Adherence Assessment Literature 
 98 
 
2. Determinants of Medication Adherence Literature Search Strategy.  
The searching strategy for the factors impact medication adherence among breast 
cancer women was discussed in chapter two section 2.1.   
3. Theory of Behavioral Change Literature.  
Two strategies were implemented to search for theories used for medication 
adherence: First, a systematic review was carried out to investigate the theories/model 
used to understand, sustain, or modify long-term medication adherence (Figure 5). 
MEDLINE, CINAHL, PsycINFO, ScienceDirect, and ERIC, were searched using the 
Medical Subject Headings (MeSH) terms “adherence [OR] compliance to medication 
[AND] theories [OR] models [AND] chronic disease” from the start date of each 
database through August 31, 2017. Chronic disease categories were chosen, because of 
their high global burden (Hamine, Gerth-Guyette, Faulx, Green, & Ginsburg, 2015). 
Eligibility criteria for this review included: (i) Titles and abstracts were searched 
in an effort to limit search specificity and minimize the volume of literature, because 
behavioral theories are a broad and complex domain. Thus, theory or model needed to be 
mentioned explicitly in the title or abstract. (ii) Studies eligible for inclusion needed to 
mentioned theory about medication adherence behavior (i.e., studies using theory to 
understand medication adherence, determine factors impacting medication adherence, or 
reference designed interventions that increased/sustained medication adherence). (iii) 
Articles failing to show a clear methodology were excluded. (iv) Narrative reviews, 
descriptive studies, books, case-studies, letters, reports, conferences, commentaries, 
theses, and dissertations were not included at this stage. (vi) Search strategy related to 
publication date was not restricted to a specific date. All articles were included up to the 
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date of the search—August 31, 2017. (vii) If medication adherence proved to be the 
outcome, those articles were selected. (viii) Studies were excluded if they used theoretical 
constructs from different theories to create frameworks, such as theoretical Domain 
framework. Data extraction included: author(s), journal, country of study, type of study 
(intervention, evaluation, review), study design (qualitative, quantitative, mixed 
methods), diseases category, behavior measured (direct, indirect, subjective, objective), 
theory name, constructs name, measurement of adherence and theoretical constructs, 
stage of adherence (initiation or continuation), and theory role (guiding intervention, 
understanding determinant of behavior, evaluation of behavior or intervention).  
Once a list of medication adherence theories was extracted from the review 
implemented in the previous step, the second strategy was conducted. This step included 
a manual search in Google for each theory or model, reviewing it for originality (Figure 
6). The goal of reviewing the original theory or model was to investigate the relationship 
between theoretical constructs and whether the first author defined measurement criteria. 
Out of 12 books, two textbooks qualified for inclusion as a guide for theoretical 
constructs extract: ABC of Behaviour Change Theories(Michie, West, Campbell, Brown, 
& Gainforth, 2014) and Cognitive and Behavioral Theories in Clinical 
Practice.(Kazantzis, Reinecke, & Freeman, 2010). Two out of four behavioral-related 
websites browsed for behavioral theories and theoretical constructs were selected—Grid-
Enabled Measures Database https://www.gembeta.org/Public/Home.aspx and Nursing 
Theories a companion to nursing theories models 
http://currentnursing.com/nursingtheory/.  
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Figure 5 Theory of Adherence Change Literature 
 
 
Figure 6 Theory of Adherence Change Among Books and Websites 
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Adherence not an outcome (n=407). Theory/model 
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4. Medication Adherence Data Standard.  
This step included analyzing WHO’s five dimensions to medication adherence 
(Sabaté, 2003); the Behavior Change Technique (BCT) project (Michie et al., 2013); and 
the Ascertaining Barriers to Compliance Project (ABC) (Vrijens et al., 2012) to 
determine possible relevant classes and relationships. WHO’s five dimensions included 
patient-, disease-, medication-, socioeconomic-, and healthcare system-related medication 
adherence. Each dimension represents several interacting constructs. BCT includes 93 
intervention strategy categories to improve medication adherence. All the terms 
extracted–12 categories–related to medication adherence were considered for inclusion in 
this step. The ABC project was also considered. The names and definitions/descriptions 
related to medication adherence behavior were extracted for further analyses and 
inclusion consideration.   
5. Medication Adherence–Related Terms.  
Three ontology repositories namely, Bioportal, Ontobee and OBO Foundry, were 
searched for relevant terms to determine how data was standardized in similar or related 
domains and what similar classifications and relationships existed. They were then 
nominated for inclusion. If a term was represented differently between two ontologies, 
both representations were extracted for further analysis in the next step. 
6. Tacit Knowledge.  
A discussion with the committee members was conducted to acquire the domain 
terminologies and understand information and data structures. Information was collected 
by writing notes and taking a picture of knowledge presented on the blackboard or on 
paper. The information was then transcribed and analyzed. 
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3.2.4 Source Analysis 
Select sources were analyzed using a systematic approach involving questions 
applied to all source types. These questions were designed to guide data extraction and 
inform domain conceptualization. The framing questions were broadly outlined to 
capture general information in the same way that conceptualization captures high-level 
domain knowledge. Using the same questions against each source type ensured 
generalizability and strengthened the knowledge that was covered. If information was 
missed in one source type, another would address it.  
The following questions were created to reflect project aims: 
1. How is medication adherence described/defined in the source type? 
2. How is medication adherence measured in the source type?  
3. How is medication adherence impacted by the source type? 
4. How is intervention described in the source type and what does it contain? 
5. What are critical themes and concepts regarding MAB research in this source type?   
The answers to the above questions were analyzed and categorized against each 
source type in a structured data sheet to abstract the summary of general terms from the 
different sources. For example, phrases, such as “initiation non-adherence,” appeared in 
several articles. This implies that this term was an important domain concept to be 
included in the knowledge representation step. To ensure relevance, authoritative source 
selections were nominated for each source type. For example, the phrase, “Initiation non-
adherence,” was included as a source of “Medication Adherence Assay Literature” source 
type, as was found in a paper by Cramer et al. (2008). When the terms were extracted, an 
OBO/BFO principle for building ontology followed (chapter two part three). The 
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principle of low-hanging fruit was adopted whenever possible, wherein, more general and 
simple universal terms and their relations were extracted first, then more complex terms 
were identified (Arp et al., 2015). 
3.3 Knowledge Structuring Using Set of Intermediate Representations 
This step’s title changed from “Knowledge Conceptualization” as named in 
METHONTOLOGY method to “Knowledge Structuring.” Because the term 
“conceptualization,” could be misleading, as it may refer to cognitive representation. The 
term “concept” was defined as “unique units of thought (Arp et al., 2015).” Based on this, 
the definition of “medication adherence,” for example, would be “unique units of thought 
in which the patient correctly follows the medical advice.” The representational model of 
medication-adherence behavior, however, represents the reality; for example, scientific 
papers, books, and databases, but not what was in the developer’s mind. The goal of the 
ontology is to describe the reality that corresponds with the general terms used by 
scientists, not to the concept that is in people’s minds (Arp et al., 2015).  
To this end, a set of intermediate representations involving tables and graphs were 
developed to bridge the gap between reality of the domain and languages in which the 
ontology was formalized. This step allowed for domain evaluation before 
implementation. A resulting structure describes the problem and its solution in terms of 
domain vocabulary identified independent of any implementation language. Several 
activities were involved in this step.  
3.3.1 Building a Glossary of Terms 
The glossary included all terms, their synonyms, definitions/descriptions, and 
types (e.g., type/universal, relation, instance). A summary of relevant terms or phrases 
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extracted from all source types, which were represented in the data structure sheet, were 
merged, analyzed, collected, and listed in a “glossary” using “Microsoft Excel Sheet” to 
facilitate the analysis. “Merging” refers to grouping or putting all synonyms together to 
remove redundancies, as different terms may describe the same entity. For instance, 
terms, such as a drug, medicine, and regimen, refer to the same word, “medication.” 
“Analyzing” includes two steps; it specifies parts of speech (verb versus noun) and 
defines the exact meaning of terms. To specify terms as parts of speech, an object-
subject-predicate strategy was carried out (more information in the next section). Since a 
term can have multiple meanings, it was examined carefully. For example, “treatment” 
may refer to a medication/drug or a process of care, such as surgery. Therefore, 
medication adherence or medication-taking behavior, for example, cannot be a subclass 
of treatment unless both terms specified and carefully defined.  
BFO principles for ontology design were followed when building the glossary of 
terms. The definition was borrowed from an equivalent entry into another ontology. If no 
matching or equivalent definitions existed, a dictionary-based definition, books, or 
literature was consulted, or a creative definition was applied. To adopt or give a 
definition to terms, the definition must explain, clearly and coherently, the important 
distinguishing features that make the term what it is. Some definitions lack clarity and are 
not coherent, such as the case for “European,” where it is defined in SNOMED as 
“European is an ethnic group.” The “is-a” means it is a “subtype of.” Therefore, every 
instance of European must reference an ethnic group (Arp, 2010). Also, the definition 
may be circular, meaning a term is defined in the definition. For example, the term 
“coping behavior quality” in Ontology of Biological Attributes at 
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https://bioportal.bioontology.org/ontologies/OBA means “coping behavior quality” is 
defined as the “quality of coping behavior.” The term, “Expectancy,” listed in the 
National Cancer Institute Thesaurus at http://purl.bioontology.org/ontology/NCIT, is 
defined as “something expected, especially the value.” “Desire” is also defined as “a 
desire to have an act occur,” according to the Health Level Seven Reference 
Implementation Model, Version 3 at http://purl.bioontology.org/ontology/HL7. Another 
problem with the definition is confusion around its perception versus reality. An example 
found in BRIDG was an “adverse event is an observation of a change in the state of a 
subject that is assessed as being untoward (Arp, 2010).” These kinds of definitions lead to 
confusion between what exists in reality and what is a subjective mental representation. 
Additionally, another mistake that could occur if the term is defined based on its 
ontology-use, such an error being found in the Medical Subject Headings (MeSH) 
database, where “National Socialism” was defined as “a MeSH Descriptor,” created 
confusion with National Socialism as an actual political movement (Arp, 2010). 
In order to avoid these types of problems, an Aristotelian definition was adopted 
when the definition was formulated or even adopted, wherein “A is B, which is C.” A is a 
child (subclass_of) B in the taxonomic hierarchy and C refers to the defining 
characteristic of what elects those Bs that are As. For example, a human (A) is an animal 
(B) who is rational (C). Here, the distinction was made about all other sibling classes 
(child_ of B), such as a Cat is an animal, but is not rational. So, for someone to be a 
member of a class of humans, it is necessary and sufficient to be an animal and rational. 
Anything that fulfills these conditions is a human. Any intersubstitutable terms having 
this definition were followed. For example, “breast cancer is_a cancer located in the 
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breast,” (Schriml et al., 2011) where cancer is defined as “a disease of cellular 
proliferation that is malignant and primary, characterized by uncontrolled cellular 
proliferation, and local cell invasion and metastasis (Schriml et al., 2011). Therefore, 
breast cancer is “a disease of cellular proliferation that is malignant and primary, 
characterized by uncontrolled cellular proliferation, local cell invasion, and metastasis 
that is located in the breast.” The inspiration behind using an Aristotelian definition is to 
provide a consistent format for definitions’ representation, thus facilitating 
interoperability and reusability regardless of the domain at issue. Also, it facilitates the 
computational inferences that are essential for researchers using computational systems 
(Arp, 2010). 
3.3.2 Knowledge Representation Using Triplet 
The terms extracted from the previous step are represented in the triplet of 
“subject, predicate, and object.” Subject refers to the entity to be described (i.e., what or 
whom the sentence is about); predicate defines the type of relation that exists between the 
subject and object; it always contains a verb, tells something about the subject, and 
connects the subject with the object. And the object is an entity or value describing the 
subject through the relation that connects them (Christophe, Bernard, & Coatanéa, 2010). 
Anything can be described using this simple triple. The subject of one triple could 
become an object of another triple, or vice versa. The entities can participate in different 
relations and play different roles in these relations. For example, the predicate “title” 
associates this dissertation (the subject) with its title, “An Ontology for Formal 
Representation of Medication Adherence: Case Study in Breast Cancer” (the object).    
 107 
 
3.3.3 Building the MAB Hierarchy 
After the terms have been selected, defined in the glossary, and represented in 
triplets, a hierarchy among the terms was developed. All terms were grouped into either 
types, instances, or relations. Term levels in hierarchy were specified (i.e., if the general 
universals/types are defined initially, such as medication adherence, then more specific 
terms were created, such as initiation adherence and implementation adherence. Every 
instance of implementation adherence also served as an instance of medication 
adherence. Terms at the lower level need to adhere to all characteristics that are asserted 
to be true in the ontology from their parents. “A is B.” Class B is a subclass of A, if and 
only if each instance of Class B is also an instance of Class A (Gómez-Pérez, Fernández, 
& Vicente, 1996). As mentioned previously, this inheritance ensures logical consistency 
when the terms are defined and guarantees clear differentiations among the levels of 
abstractness within the ontology and the likelihood of automated reasoning (Arp, 2010). 
Since the Basic Formal Ontology (BFO)—an upper-level (formal, domain-neutral) 
ontology, is used to support creation of a lower-level domain ontology, “Medication 
Adherence Behavior ontology (MAB-Ontology),” some definitions need to be adjusted. 
For, example, Belief is a disposition that is realized by process. A disposition is a class 
under the realizable entity in BFO. The BFO framework for an MAB-Ontology contains 
MAB-Ontology terms mapped to or defined based on BFO neutral terms and relations 
between terms. Based on the BFO, the terms and relation can be primitive or defined.  
1. Primitive and defined terms 
Primitive terms are basic to our understanding of reality. They cannot be defined 
in a non-circular fashion; instead, they should be elucidated or exemplified or use an 
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axiom to be explained (Arp et al., 2015). For example, “entity” in BFO is defined as 
anything that exists or has existed or will exist, such as medication, the process of taking 
medication, the patient who takes medication, and information that resulted from 
assessing medication-taking behavior.  
Defined terms are those terms defined by using primitive terms or other 
previously-defined terms. For example, “breast cancer” can be defined as “a thoracic 
cancer that originates in the mammary gland.” (Schriml, 2016) Such a definition is built 
from another predefined term, “thoracic cancer,” which, in its term, is defined as “an 
organ system cancer located in the thoracic cavity that develops in the different types of 
cells within the lungs, as well as less common cancers of the esophagus, trachea, or chest 
wall.” (Schriml, 2016) BFO-defined terms are based on an Aristotle’s definition adopted 
when building the glossary in the previous step, wherein A=Def. B, which differentiates 
Ds. A is the term to be defined, B is an immediate parent in the hierarchy, and D is the 
differentiating criteria specifying what it is about certain Bs in virtue of which they are 
As. For example, “medication adherence management” is a planned process of 
monitoring and supporting patient adherence to medication by healthcare systems, 
providers, patients, and their social networks. “Consciousness raising” is a type of 
management of the adherence process; it is defined as a “management of the adherence 
process in which the patient was provided with information, feedback or confrontation 
about the causes, consequences, and alternatives for problem behavior.”  
2. Primitive and defined relations  
Primitive relations are those relations that cannot be defined and must be accepted 
as primitive, such as “instance of” relation. This type of relation holds some particulars 
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(i.e., individual) and some universals (i.e., type). This relation cannot be defined. Its 
meaning, however, can be elucidated by example or axiom. This relation takes the form 
of “a” is_instance_of “A” in which “a” represents an individual or a particular in class 
“A.” For example, “missed dose” is_instance_of “medication adherence” and 
“medication possession ratio” is_instance_of “medication possession measurement. More 
types of primitive relations will be discussed in the next section. (ii) Defined relations are 
those explained or defined by using other primitive or defined relations or terms. For 
example, “A” is_a “B” =def. A and B are universals, and for all of a (if a is an 
instance_of A, then a is an instance_of B). Therefore, breast cancer is_a thoracic cancer. 
Breast and thoracic cancer are universals for all breast cancer instances (if ductal 
carcinoma in situ is_instance_of breast cancer, then ductal carcinoma in situ 
is_instance_of thoracic cancer). 
3.3.4 Hierarchy of MAB-Ontology Based on BFO 
Based on BFO, entities in reality are classified into two general groups: 
continuant entities and occurrent entities, as shown in Figure 7. 
 
Figure 7 The Hierarchy for BFO 
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3.3.4.1 Occurrent Entities 
Occurrent entities unfold themselves in time or they are the instantaneous 
boundaries of such entities (for example, a beginning or an ending), or they are temporal 
or spatiotemporal regions, where such entities occupy_temporal_regions or 
occupy_spatiotemporal_regions (Arp et al., 2015). Occurrent entities are categorized into 
four types: process, temporal region, process boundary, and spatiotemporal region. For 
purposes of this dissertation, only process and temporal region are defined.  
1. Process 
Process is an occurrent entity that exists in time by occurring or happening. It has 
temporal parts, such as a beginning, middle, and end, and always depends on some or at 
least one material entity (Arp et al., 2015). An example is a process of medication 
adherence, or the process of measuring medication adherence. Being has temporal parts, 
which means that there is no instance in time during which this process would exist as a 
whole. Instead, it unfolds along a series of temporal parts, such as taking medication in 
the morning, taking it in the evening, or the first minute of taking medication. The formal 
definition is: P is a process = Def. p is an occurrent that has temporal proper parts, and for 
some time, t, p s-depends_on some material entity at t (Smith et al., 2012). 
2. Temporal Region 
Temporal region is an occurrent entity that is a part of time, as defined relative to 
some reference frame. Temporal region with extent is a one-dimensional temporal region. 
If it is not with extent, it is a zero-dimension temporal region. The temporal region does 
not have a closure axiom, because the subclasses do not exhaust all possibilities (Smith et 
al., 2012)—for example, five years of continuously taking Tamoxifen. 
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3.3.4.2 Continuant Entities 
Continuant entities are those “entities that persist, endure, or continue to exist 
through time while maintaining their identity.” (Arp et al., 2015) A person is a continuant 
entity who persists his/her identity through time, no matter what happens throughout 
his/her life. He/she may gain weight, lose weight, lose a leg, or gain an artificial leg, yet 
he or she still perseveres an identity through time. Continuant entities categorize into 
independent, specific-dependent or generic-dependent continuants, as shown in Figure 7. 
1. Independent Continuant Entities 
Independent continuant entities do not depend on other entities. They are the 
bearer of specific and generic dependent entities (Arp et al., 2015) and are categorized 
into two types: namely, material and immaterial entities. A person is an example of an 
independent continuant who bears the patient role at a specific time. A person bears a 
biological sex (female or male). Breast cells bear cancer. A Medication Event Monitoring 
System (MEMS) (Sterns, Hughes, Masstandrea, & Smith, 2014) bears the function of 
recording the time and date each time the container is opened and closed. A pharmacy or 
hospital computer bears record of medication refills as a PDF or another format. Formal 
definition: B is an independent continuant = Def. b is a continuant that is such that there 
is no c and no t, such that b s-depends_on c at t (Arp et al., 2015). 
a- Material Entities: Material entities are independent continuant entities that have a 
portion of matter as part (Arp et al., 2015), such as a person, the chest of a person, cell, 
a collection of cells, MEMS, or Drug.   
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b- Immaterial Entities: Immaterial entities are independent continuant entities that 
contains no material entities as parts (Arp et al., 2015), such as the surface of a cell or 
the surface of an organ.  
2. Dependent Continuant Entities 
Dependent continuant entities are continuant entities that depend on other existing 
entities in order to exist (Arp et al., 2015), such as in the previous example. For the role 
of being a patient to exist, it must be someone who exists and has this role at a time when 
he/she is sick. For a patient record or file to exist, there must be a computer or other 
technology that exists to bear this file. Dependent continuants are two types: specific or 
generic dependent continuants. 
a- Specific Dependent Continuant Entities 
Specific dependent continuants are dependent continuant entities (i.e., realizable 
entities and qualities) that depend on one or more specific independent continuants to 
exist and they cannot migrate from one bearer to another. If this independent continuant, 
upon which it depends ceases to exist, then this specific independent continuant entity 
will also cease to exist (Arp et al., 2015). For example, a function of MEMS is to record 
the date and time when Lori opens and closes the cap. It will not exist if the MEMS did 
not exist. Lori’s low education level will not exist if she did not exist. Formal definition: 
B is a specifically-dependent continuant = Def. b is a continuant and there an independent 
continuant c that is not a spatial region and, as such, b s-depends_on c at every time of t 
during the course of b’s existence (Arp et al., 2015). (i) Realizable entities: Realizable 
entities are specifically dependent continuant entities that inhere in or have an 
independent continuant entity as their bearer, and whose instances require process in 
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order to be realized (manifested, executed, actualized) (Arp et al., 2015), as shown in 
Figure 8. For example, the role of being a patient, the function of MEMS, or the 
disposition certain people have to develop breast cancer. (1) Role: Role is an external, 
grounded, realizable entity that inheres in specific dependent entities (the bearer) under 
special physical, social, or institutional sets of circumstances (i.e., external to the bearer) 
in which this bearer’s physical makeup does not have to be changed if the role ceased to 
exist (Arp et al., 2015). For example, the role of being a patient under certain 
circumstances, such as being under the care of a physician or healthcare provider. Once 
this role has ceased treatment, the person’s physical make does not change. Formal 
definition: b is a role that means: b is a realizable entity and b exists, because there is 
some single bearer that is in some special physical, social, or institutional set of 
circumstances in which this bearer does not have to be and b is not such that, if it ceases 
to exist, then the physical makeup of the bearer is thereby changed (Smith et al., 2012). 
(2) Disposition: Disposition is an internal, grounded, realizable entity, a specific 
dependent entity that inheres in independent continuant entity (the bearer) under special 
physical circumstances (i.e., internal to the bearer) wherein the bearer’s physical makeup 
has to be changed if the disposition ceases to exist (Arp et al., 2015). For example, the 
disposition to have breast cancer or breast cells or tissues under certain physical 
circumstances (e.g., a gene mutation). If the breast cancer ceased to exist, the physical 
makeup of breast cells or tissues would change. Formal definition: b is a disposition 
means: b is a realizable entity and b’s bearer is some material entity and b is such that, if 
it ceases to exist, then its bearer is physically changed, and b’s realization would occur 
when and because this bearer is in some special physical circumstances. Therefore, this 
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realization would occur in virtue of the bearer’s physical makeup (Smith et al., 2012). 
Function: Function is a disposition that exists in virtue of the bearer’s physical makeup 
and this physical makeup is something the bearer possesses, because it came into being, 
either through evolution (in the case of natural biological entities) or through intentional 
design (in the case of artifacts), in order to realize processes of a certain type (Arp et al., 
2015). For example, an aromatase inhibitor’s function, such as Anastrozole (i.e., drug 
class), is to interfere with the action of aromatase, in order to reduce the production of 
estrogenic steroid hormones. In turn, the function of MEMS is to record the date and time 
the medication is taken every time the patient opens the cap. (ii) Quality: Quality is a 
specifically dependent continuant that, unlike a realizable entity, does not require any 
further process in order to be realized (Arp et al., 2015). For example, the patient’s age, 
biological sex, level of education, the size of the tablet, the color of the tablet, and the 
taste of the tablet. The quality of a ridged entity means that if an entity is a quality at any 
time that it exists, then it is a quality every time that it exists. Formal definition: b 
quality_of c at t = Def. b is a quality and c is an independent continuant that is not a 
spatial region, and b s-depends_on c at t (Smith et al., 2012). 
b- Generically Dependent Continuant Entities 
Generically dependent continuant entities rely on one or more independent 
continuant entities (i.e., they can migrate from one bearer to another), which can serve as 
their bearer (Arp et al., 2015). For example, a PDF file that contains a medication refill 
date and time from a pharmacy computer can migrate to a hospital computer. For this file 
to exist, there must be some physical storage device where it was saved (in this case, 
either a pharmacy computer, hospital computer, or physician’s laptop). Formal definition: 
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B is a generically-dependent continuant = Def. b is a continuant that g-depends_on for 
one or more other entities (Smith et al., 2012). 
 
Figure 8 The Realizable Entity Hierarchy for BFO 
3.3.5 Building Relations 
The hierarchies defined in the previous step are connected via relations. Besides 
the “is_a” relations that are applied to build the hierarchy, further relations used to define 
BFO were adopted from the BFO 2 reference (relation ontology (RO)) (Smith et al., 
2012) for building the MAB-Ontology. Based on BFO, three types of relations were used 
at this level: relations that hold between two universals, such as a “belief about capability 
‘is_a’ belief;” relations that hold between instance and universal, such as “this patient 
‘is_instance of’ patient;” or relations that hold between two particles, such as “this leg 
is_part of this patient.” Having these kinds of relations allows for use of the ontology in 
combination with information about particulars in the world to reason about those 
particulars. The outcome of this step is to build a table of relations. It involves relation 
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name, definition, source of the relation (domain), target of the relation (range), inverse 
relation, and relation property or characteristics.   
3.3.5.1 Relations/Property Characteristics 
1) Reflexivity: to say that relation R is reflexive is to say anything A bears relation R to 
something else. B also bears that relation to itself (Smith et al., 2012). For example, 
“knows” is a reflexive relation. Lori knows her physician, Jacob. Then Lori must know 
herself, too. If relation “is_a” is reflexive relation and a person is_a human, then the 
person must be a person, too. Relation “being the same age as” is reflexive, and with Lori 
“being the same age as” her physician, Jacob, at t, then Lori must be the same age as 
herself at t.  
2) Symmetry: to say that a relation R is symmetric is to say that if A stands in relation R 
to B, then B also stands in R to A (Smith et al., 2012). For example, if relation 
adjacent_to is symmetric (on the instance level) and cell1 is adjacent_to cell2, then cell2 
must be adjacent_to cell1.  
3) Transitivity: to say that relation R is transitive is to say that if A stands in relation R to 
B, and B stands in relation R to C, then A also stands in relation R to C(Smith et al., 
2012). For example, if a relation is_a transitive, and medication adherence is_a behavior, 
and behavior is_a process, then medication adherence is_a process, too. 
4) Antisymmetric: To say that relation R is antisymmetric is to say that if A bears R 
relation to B and B bears R relation to A, then A and B are identical (Smith et al., 2012). 
If not, then they cannot hold this relation. For example, if part_of relation is 
antisymmetric, and cognitive process is part_of emotional process, then cognitive process 
and emotional process are identical (in this case, they cannot be identical). 
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3.3.5.2 MAB-Ontology Relation Based on BFO 
This section represents some of the relations used in MAB-Ontology. A complete 
list of the included relations is tabulated in the next chapter.  
1) “is_a” relation: is relation used to relate subtypes in BFO to their parent type and can 
be transitive, reflexive, or antisymmetric. This relation is defined using primitive relation 
“instance_of.” For example, medication adherence is_a medication-taking behavior. 
Every instance_of medication adherence is_instance of medication-taking behavior. For 
example, a missed dose is_instance of medication adherence, then it is an instance_of 
medication-taking behavior. Formal definition: A is_a B=Def. for every instance of a, if a 
is an instance_of A, then a is an instance of B (Smith et al., 2012). 
2) “instance_of relation”: a relation that holds between particulars and universals/types. It 
is used to relate instance to the continuant and occurrent universals/types as follows: 
c instance_of C at t means: that the particular continuant entity c instantiates the universal 
C at t (Smith et al., 2012). For example, a high school diploma is an instance of 
educational level. p instance_of P means: that the particular occurrent entity p instantiates 
the universal P (Smith et al., 2012). For example, a missed dose is an instance of 
medication adherence.  
3) “part_of” relation: a relation used to relate two continuants or two occurrents and can 
be transitive, reflexive, or antisymmetric. b continuant_part_of c at t =Def. b is a part of c 
at t and t is a time and b and c are continuant (Smith et al., 2012). For example, questions 
are part of a questionnaire. b occurrent_part_of c =Def. b is a part of c and b and c are 
occurrents (Smith et al., 2012). For example, the cognitive process is part of the 
emotional process.  
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4) “specifically depends on” relation: a relation used to specify the existence of 
conditions that hold between two particular entities, such that the first entity cannot exist 
without the second entity. For example, the patient role specifically depends on the 
patient; MEMS function of the recording date and time specifically depends on MEMS; 
belief specifically depends on mental function anatomical structure. Formal definition: a 
“specifically depends on” b=Def. a is an entity, b is an entity, and a exists only if b exists 
(Smith et al., 2012). 
5) “generic depends on” relation: a relation specifies the existence of conditions that hold 
between a particular entity and one or more other entities. For example, refill record (i.e., 
pharmacy record) generically depends on computer systems, such as the pharmacy and 
hospital system (EHR) that host it. It exists as long as some records are stored in a 
computer system. Formal definition: a generically depends on b1,... = Def. a is an entity, 
b1,... are entities, and a exists only if one or more of b1,... exists (Smith et al., 2012).  
6) “bears” relation: a relation that can be used instead of “specific depends on” and 
“generic depends on” relations. For example, a person bears a patient role at t; MEMS 
bears MEMS function in recording the date and time every time a cap opens; disorder 
bears breast cancer. Formal definition: a bears b= Def. a is an entity, b is an entity, and 
either b specifically depends on a or b generically depends on a (Smith et al., 2012). 
7) “inheres_in” relation: a relation that holds between a specific dependent continuant 
and an independent continuant that is not a spatial region. For example, the active role of 
the patient to participate in decision-making inheres in the patient at t. Formal definition: 
b bearer_of c at t =Def. c s-depends_on b at t and b is an independent continuant that is 
not a spatial region (Smith et al., 2012). 
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8) “quality_of” relation: a relation that holds between quality and independent continuant 
that is not a spatial region. For example, Lori’s level of education is a quality of Lori. 
Formal definition: b quality_of c at t = Def. b is a quality and c is an independent 
continuant that is not a spatial region and b s-depends_on c at t (Smith et al., 2012). 
9) “realized in” relation: A relation that holds between realizable entity and process. 
Some entities are manifested only when they participate in certain kinds of processes. For 
example, belief is a realized entity that is realized in bodily processes (which include 
mental and behavioral processes) in which there exists some material entity (i.e., mental-
function-related anatomical structure/executive-function-related anatomical structure) 
such that belief specifically depends on it; MEMS function in calculating the date and 
time is a function that inheres in MEMS and is realized in the adherence assessment 
process; the patient’s role is realized in the healthcare process. Formal definition: a 
realized in b=Def. a is an entity (i.e., realized entity), b is a process, and there exists some 
entity c such that a specifically depends on, and a is fully present or exhibited when c 
participates in b (Smith et al., 2012). 
10) “preceded by” relation: a relation that holds between two processes in which one 
occurs before the other and the latter starts when the first ends and it can be transitive. 
For example, the medication initiation phase starts to occur before the continuation phase 
or medication filling/refilling process occurs after the medication prescribing process. 
Formal definition: p’ is preceded by a process p if and only if the last temporal instant of 
p is earlier than the first temporal instant of p’ and a process p’ is immediately preceded 
by a process p if and only if there exists a temporal instant where both the first instant of 
p’ and the last instant of p exist (Smith et al., 2012).  
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11)“has_participant” relation: a relation that holds between a process and a continuant 
entity in which the continuant is somehow involved in the process. For example, 
behavioral change information technology intervention has some platforms or devices as 
participant. Formal definition: P has_participant C=Def. for every particular occurrent of 
p, if p is an instance of P, then there is some c and sometimes t, such that a c instance of 
C at t and p has_participant c at t (Smith et al., 2012). 
3.4 Ontology Integration 
This step occurred side-by-side with previous steps, where reusing the existing 
definition was considered. The OBO Foundry Ontology Library, Ontobee, and the 
Bioportal servers searched to leverage entities that were identified from other ontologies 
into the MAB-Ontology. The criteria selected to be included was a class label where: (1) 
the selected term definition must be consistent with the MAB-Ontology term definition 
(synonym). (2) The ontology of the selected match term must be mapped to BFO. The 
class was imported using Ontofox—“a web-based ontology tool that fetches ontology 
terms and axioms.” Ontofox supports ontology reuse (http://ontofox.hegroup.org/). It 
allows users to input terms, fetch selected properties, annotations, and certain classes of 
related terms from source ontologies and saves the results using the RDF/XML 
serialization of OWL” (Xiang, Courtot, Brinkman, Ruttenberg, & He, 2010).  
3.5 Model Formalization 
Intermediate Representation (IR) is an iterative artifact that contains information 
needed to create an ontology (Gómez-Pérez et al., 1996). Since IR is not an ontology, the 
resulting model was built manually using Protégé (http://protégé.stanford.edu/) to 
formalize the entities and relations into an OWL for computation. Protégé is a tool that 
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provides interfaces for easy structure, navigation, and query of the ontology. It aligns 
with the NCBO toolkit, which allows for easy importing/exporting, merging, leveraging, 
and sharing; for example, with the BioPortal library of more than 270 ontologies. It also 
ensures integration, harmonization, and leveraging opportunities (Noy et al., 2009). Plug-
in reasoners validate its use, which allows inferences related to the ontology to be made 
so as to demonstrate whether the design’s structure can successfully create instances, 
commonly referred to as “consistency checking” (where it conducts a new entity 
assertion that yields instances consistent with the logic of other instances) (Horridge & 
Bechhofer, 2011; Peters & Consortium, 2009). Protégé tools can also allow “subsumption 
testing.” This test determines whether a class can be a subclass of another(Horridge, 
Knublauch, Rector, Stevens, & Wroe, 2004). Additional examples of Protégé reasoning 
encompass “satisfiability” (meaning, does an entity meet first-order logic of a hierarchy 
and properties) and “retrieval” (have all instances of a class been found). Protégé also 
provides plug-in reasoners that accomplish these tasks; they can show structural 
consistency and check/test descriptive logic via information retrieval and by validating 
the ontology’s content(Aranguren, 2005). Pellet, Fact++, HermiT, and increasingly, Elk, 
are the common reasoners used in Protégé(Kazakov, Krötzsch, & Simancık, 2014). 
Lastly, Protégé’s various storage formats (OWL, RDF, XML, and HTML) allow for 
flexibility in how they are shared and applied. Being able to store Protégé in these 
formatting languages helps Protégé-developed ontologies that conform to Semantic Web 
standards set by the W3C (Horridge & Bechhofer, 2011) and offer human-readable 
options. Therefore, all the terms and hierarchies built in the first steps, as well as the 
definitions given for each class and property, were entered into Protégé manually. As 
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mentioned earlier, an Aristotelian definition followed beside the best principles that 
include applying the essential feature, avoiding a circulatory definition, applying for an 
appropriate extension, avoiding obscure and figurative language, and avoiding negative 
terms, when possible (Copi, Cohen, & Flage, 2007).  
3.6 Evaluation 
Ontology evaluation methods classify into three types: Direct evaluation, in which 
the structure and content validate; application-based evaluation, in which an application 
develops using ontology; and analysis-based evaluation, which evaluates the ontology as 
a tool in scientific data analysis (Hoehndorf, Dumontier, & Gkoutos, 2012). This project 
fell under “Direct Evaluation,” in which the domain representation and structure were 
evaluated against the purpose for which it was developed and ensured its consistency.  
3.6.1 Face Validity of Intermediate Representations  
Since committee members are experts in the domains of breast cancer, medication 
adherence behavior, and ontology, they participated in validating the content and 
Intermediate Representations. Two committee members who are experts in breast cancer 
and medication adherence-related knowledge validated the content in the intermediate 
representation model, while the ontology expert validated the model structure, 
consistency of relationship, and formal presentation of the MAB-Ontology. This study 
was exempted by the Institutional Review Board (IRB) (Appendix 1). (a) Content 
validity. The IR model and its content was validated using an iterative face validity 
technique. An informal meeting with committee members was conducted to discuss 
model content. The validation process was carried out to check if the model represented 
the medication-adherence behavior domain (i.e., represented valid entities and valid 
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structure). (b) Structure validity. An expert in ontology validated the model structure in 
an iterative process. The class hierarchy, relationships, and consistency with upper-level 
ontology were validated. The model was adjusted based on the evaluator’s feedback. 
3.6.2 Competency Questions 
Competency questions are a list of natural language questions formulated based 
on the motivation scenario (Grüninger & Fox, 1995). Motivation scenario is defined as an 
artifact that describes the expectation of the proposed ontology that should be satisfied 
after development (Grüninger & Fox, 1995; Iqbal, Mustapha, et al., 2013). Both the 
motivation scenario and competency questions are considered to be documents for the 
requirement specification; they are used to guide the scope of the ontology. That is why 
they are utilized to test the efficacy of the ontology in answering those questions and 
solving the scenario problem. This type of evaluation is used to evaluate the semantic 
query of the ontology—what the system intended to answer. Protégé editing tool provide 
a query interface for assembling and executing queries. First, the ontology query was 
developed, then executed on the ontology to produce an answer to the question. This 
answer was evaluated manually for correctness and comprehensiveness.  
3.6.3 Consistency Checking 
This type of evaluation was used to check for consistency of the ontology. The 
reasoning module of Protégé, such as Hermit and Pellet, can be used to check for logical 
consistency of the ontology. If there is any inconsistency, the reasoners will highlight the 
source of the error in red. Accordingly, it must be corrected until the ontology is logically 
consistent (Ogundele et al., 2015).  
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3.6.4 Compliance with the OBO Foundry Principle  
The ontology that was developed followed the OBO Foundry Principles explained 
in chapter two. At the end, the model was validated for adherence to the principles.  
3.6.5 Compliance with the METHONTOLOGY Methodology 
The ontology-driven approach is based on the METHONTOLOGY methodology. 
An evaluation for adherence to the methodology was carried out, and justification for 
non-compliance was reported.  
Summary 
This chapter presented the methodological approach used for developing a 
medication adherence behavior ontology (MAP-Ontology). Six steps were introduced to 
capture, structure, evaluate, and implement a medication-adherence behavior ontology 
that can be accessed, queried, navigated, and used for several applications, such as in a 
decision support system, to predict adherence risk among specific disease types or as a 
repository for factors influencing medication adherence.  
The chapter discussed how flexibility of the METHONTOLOGY methodology 
allows the BFO principles to be incorporated into the development lifecycle. This step 
was taken to increase interoperability of the developed ontology with other existing 
ontologies. The chapter presented the different searching strategies implemented to 
gather the information needed to build the ontology. This strategy was used to provide a 
broader, more objective perspective on the medication adherence domain. The chapter 
also discussed several evaluation methods used to evaluate each step. 
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CHAPTER FOUR: RESULTS AND DISCUSSION OF MAB-ONTOLOGY 
 Brief descriptions of results based on the methodology approach mentioned in 
chapter three are presented in the following sections. This chapter describes the six steps 
of the METHONTOLOGY approach and the Basic Formal Ontology (BFO) principles 
incorporated in each step. The six steps are: domain specification, knowledge acquisition, 
knowledge structure, integration with other ontologies, implementation in a formal 
language, and evaluation steps. These processes are mapped to the project aims described 
in chapter one: 
1. Develop a formal ontology framework for medication adherence behavior using 
breast cancer as a case study. This model represented medication adherence 
behavior, factors that impact medication adherence from a theoretical perspective, 
methodologies used to assess medication adherence, and technologies used to 
enhance medication adherence.   
a. Identify key foundational medication-adherence behavior domain sources. 
b. Identify definitions and metrics for terms related to medication-adherence behavior. 
c. Organize and structure the acquired knowledge using tables and graphs.    
d. Formalize the conceptual model using the ontology editor Protégé.  
2. Validate the ontological model by experts using the Face Validity Technique.  
4.1 Domain Specification 
4.1.1 The Purpose of the Ontology 
The general purpose of the MAB-Ontology is to serve as a reference that 
comprehensively represents the domain of medication adherence using breast cancer as a 
case study. This developed ontology aims to eliminate or at least minimize terminological 
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confusion and move towards a common and shared understanding that improves 
communication, sharing, interoperability, and reusability. Thus, the MAB-Ontology 
should capture different factors that impact medication adherence in a consistent manner, 
the methods used to measure adherence behavior, and interventions used to improve or 
sustain medication adherence behavior. For example, the negative effects of low self-
efficacy on medication initiation, or the positive impact of persuasive intervention using a 
mobile application on medication adherence. The MAB-Ontology should not only enable 
access to such information, but it should also enhance the query and navigation of this 
information. In brief, MAB-Ontology can be used when information about factors that 
impact adherence are required in intervention development, decision making, detection 
risk for non-adherence, capturing current and future findings from medication adherence-
related publications, etc. 
a. Deriving the Competency Questions. 
Examples of informal competency questions generated for the scope of MAB-Ontology 
are:  
CQ1: Is it possible to search the MAB-Ontology for factors that impact medication 
adherence? 
CQ1a: Is it possible to search the MAB-Ontology for only cognitive-related factors that 
impact medication adherence? 
CQ1b: Is it possible to search the MAB-Ontology for only medication-related factors that 
impact medication adherence? 
CQ1c: Is it possible to search the MAB-Ontology for only disease-related factors that 
impact medication adherence? 
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CQ1d: Is it possible to search the MAB-Ontology for only economic-related factors that 
impact medication adherence? 
CQ1e: Is it possible to search the MAB-Ontology for only demographic-related factors 
that impact medication adherence? 
CQ1f: Is it possible to search the MAB-Ontology for only geographic-related factors that 
impact medication adherence? 
CQ1g: Is it possible to search the MAB-Ontology for only health care system-related 
factors that impact medication adherence? 
CQ1h: Is it possible to search the MAB-Ontology for only health literacy-related factors 
that impact medication adherence? 
CQ1i: Is it possible to search the MAB-Ontology for only lifestyle-related factors that 
impact medication adherence? 
CQ1j: Is it possible to search the MAB-Ontology for only social-related factors that 
impact medication adherence? 
CQ1k: Is it possible to search the MAB-Ontology for only technology use-related factors 
that impact medication adherence? 
CQ1l: Is it possible to search the MAB-Ontology for medication adherence risk factors 
among breast cancer patients?  
CQ1m: Is it possible to search the MAB-Ontology for factors that influence medication 
adherence among patients who are 60 years old and taking tamoxifen?  
CQ1n: Is it possible to search the MAB-Ontology for a patient who discontinues his 
medication due to tamoxifen side effects?  
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CQ1o: Is it possible to search the MAB-Ontology for a patient who discontinues his 
medication due to fasting during some days? 
CQ1p: Is it possible to search the MAB-Ontology for a patient who discontinues his 
medication due to the cost of tamoxifen? 
CQ2: Is it possible to search the MAB-Ontology for behavioral interventions used to 
change/sustain medication adherence? 
CQ2a: Is it possible to search the MAB-Ontology for Information Technology platforms 
that use to change/sustain medication adherence? 
CQ3: Is it possible to search the MAB-Ontology for methods used to measure medication 
adherence?  
CQ3a: Is it possible to search the MAB-Ontology for direct methods used to measure 
medication adherence?  
CQ3b: Is it possible to search the MAB-Ontology for indirect methods used to measure 
medication adherence?  
CQ3c: Is it possible to search the MAB-Ontology for assays used to measure medication 
adherence?  
CQ3d: Is it possible to search the MAB-Ontology for methods used to measure 
medication adherence among patients?  
CQ3e: Is it possible to search the MAB-Ontology for questionnaires used to measure 
only medication adherence behavior?  
CQ3f: Is it possible to search the MAB-Ontology for questionnaires used to measure 
medication adherence behavior, along with barrier impact medication adherence?  
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CQ3g: Is it possible to search the MAB-Ontology for questionnaires used to measure 
both barriers and beliefs that impact medication adherence?  
CQ3h: Is it possible to search the MAB-Ontology for questionnaires used to measure 
only beliefs associated with medication adherence behavior?  
CQ4: Is it possible to search the MAB-Ontology for theories used as a part of a plan 
specification for medication adherence intervention development?  
CQ4a: Is it possible to search the MAB-Ontology for theoretical constructs for each 
theory?  
CQ4b: Is it possible to search the MAB-Ontology for theories that include constructs that 
represent behavior capability belief?  
CQ4c: Is it possible to search the MAB-Ontology for theories that include constructs that 
represent behavior capability belief and behavior consequences belief?  
CQ5: Is it possible to search the MAB-Ontology for patients who are at risk for non-
adherence?  
CQ4d: Is it possible to search the MAB-Ontology for 60 year-old breast cancer patients 
who is at risk for non-adherence?  
CQ6: Is it possible to search the MAB-Ontology for non-adherent patients?  
CQ7: Is it possible to search the MAB-Ontology for medication adherence risk factors? 
b. Use Case Scenario 
 Use case scenario describes expectations that the MAB-Ontology should comply 
with after development. A use case scenario was created to represent users who can 
access the MAB-Ontology to support their tasks. They can make requests to the MAB-
Ontology and the results will be the required output that is needed to further carry out 
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expected tasks. Table 11 shows the use case template adopted from the object-oriented 
technology to represent the basic flow of the event. The motivation behind using this 
template is that it represents information in a concise way and does not require prior 
experience for understanding IT (Iqbal, Mustapha, et al., 2013). 
Table 11 Use Case Scenario Flow 
Description Describes how a user can input a formal query in the Protégé query tab.  
Actors User and Protégé  
Preconditions Installed Protégé  
The MAB-Ontology is loaded into the environment. 
The user is familiar with the formal query language, such as DL. 
Basic flow of events Protégé is initialized. 
The user inputs a query into the query tab using formal language, i.e., 
DL.  
After the query is entered, the user presses the execution button. 
The system searches the MAB-Ontology for the suitable answer. 
The answer/answers are showed on the screen. 
If another query is requested, the procedure will be repeated. 
Post-conditions Successful execution: The correct answer will be received from the 
system.   
Failure to execute: Two cases give “No results”:  
• If the formal query was entered incorrectly (query syntax), then No 
results will be shown.  
• If the query was inputted correctly, but No results displays; this 
means the query is out of the scope of the MAB-Ontology. 
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The Use case Scenario: A program officer planning to design a new intervention 
to improve medication adherence among breast cancer patients uses information 
technology platforms. The data gathered by the program officer at the point of care is an 
indication that there is a high number of fluctuations in the adherence rate among the 
breast cancer population in the first three months. The program officer does not 
understand the reasons for this discrepancy. He or she wishes to identify a list of the 
potential factors that influence the adherence rate among breast cancer patients in the first 
three months. He or she requires this knowledge in order to develop a proper intervention 
plan that will reduce the rate of non-adherence among this population.  
4.1.2 Approaches for Ontology Building 
The middle-out approach to ontology building was used to build the MAB-
Ontology. It is a combination of top-down and bottom-up strategies. It is an integration of 
theoretical modeling and text analysis, in which the most commonly used general terms 
are extracted first, then the more concrete and abstract entities—“terms and relations”—
are extracted from other ontologies and textual resources. This method gives balance in 
terms of the level of detail.  
4.1.3 The Scope of the Ontology  
The scope of the ontology reflects the knowledge domain covered by the MAB-
Ontology. Adherence behavior is defined by the World Health Organization (WHO) as 
“the extent to which a person’s behavior–taking medication, following a diet, and 
executing lifestyle changes, corresponds with agreed recommendations from a healthcare 
provider.” (Sabaté, 2003) Such a definition is applied to different behaviors and 
regulatory topics. It includes adherence to all recommendations, such as lifestyle, diet, 
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physical activity, preventive screening, follow-up, and vaccination. The goal of the 
MAB-Ontology is to represent knowledge related to adherence to medication only. It is 
also not possible to cover all aspects of medication adherence, such as all diseases, 
medications groups, and interventions used to impact medication adherence. Therefore, 
the scope of the MAB-Ontology is on medication adherence among breast cancer patients 
taking endocrine hormonal therapy and using information technology to improve their 
medication adherence. The motivation for this selection has already been discussed in 
chapter one. This ontology includes factors that impact medication adherence, the 
methods used to assess adherence, and the interventions used to improve adherence.  
4.2 Knowledge Acquisition 
As specified in chapter three, several reviews were conducted to extract the 
important terms that needed to be represented in the MAB-Ontology. In this section, a 
brief discussion of the important terms extracted from those reviews are included.    
4.2.1 Source Selection  
This section includes sources that were used to extract the terms needed to 
represent MAB-Ontology. In chapter two, two reviews (Sawesi, Carpenter, & Jones, 
2014; Sawesi, Rashrash, Phalakornkule, Carpenter, & Jones, 2016) were conducted to 
gain background and detect a gap in the literature—the outcomes that the literature uses 
to extract the terms needed to build an MAB-Ontology. In this section, two additional 
literature reviews were conducted to extract terms needed for MAB-Ontology 
representation:  
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1. Medication adherence-related theory 
The extracted articles were analyzed based on the studies’ characteristics: study 
design, country of study, disease type, theory, constructs, target direction of behavior 
(increase adherence, maintain adherence), constructs measurement methods, adherence 
measurement methods, stage of adherence (initiation if less than three months, 
continuation if more than three months), theory object (i.e., explain adherence, 
conceptualize the factors affecting patients’ adherence, theory testing, intervention 
developing), and the number of medications prescribed. Table 12 includes theories 
identified from the extracted articles, the name of the lead author and the date that theory 
was originally described, frequency of occurrence in the selected articles, and the 
objective of the theory in the study. A total of 1,057 out of 19,010 articles were included 
and 47 theories were detected from those articles. The results showed that 51% (n=539) 
of the studies used quantitative methods, 24% were carried out in the USA (n=253), 
diabetes mellitus was the most cited disease type (n=200; 19%), the majority of theories 
were intervention application (n=798; 75%), the majority of studies targeted diabetes 
(n=240; 44%), the majority of studies used theory as an intervention (n=687, 65%), 88% 
(n=930) of studies were used to measured theoretical concepts by using a questionnaire, 
74% (n=782) of the studies measured adherence using a self-report, and the majority of 
the studies (67%, n=708) used theory at the continuation stage. Construct characteristics: 
441 constructs were extracted from the 47 theories. After de-duplication, 220 concepts 
were included for further analysis. Terms were grouped into 40 concepts based on their 
meaning. Fifteen themes were assigned for those constructs as general terms: antecedent 
of behavior consequence belief, behavior capability belief, behavior consequences belief, 
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behavior regulation, behavior reinforcement, emotion, environment influence, goal, habit, 
intention, knowledge, skill, motivation, social influence, technology influence, and 
memory. Each term gives a definition and the full list is inserted in Protégé. Out of 441 
constructs, only 47 related to medication adherence at the initiation phase.        
Table 12 Theories Identified in the Included Review 
Theory/model First author, year Frequency  Role of 
theory 
Health belief model Rosenstock, 1950 108 E, C, T, I  
Theory of reasoned action  Fishbein, 1975 57 E, C, T, I 
Theory of planned behavior  Ajzen, 1991 56 E, C, T, I 
Health promotion model Pender, 1982 63 E, C, T, I 
Social cognitive theory Bandura, 1997 40 E, C, T, I 
Protection motivation theory Rogers, 1983 34 E, C, T, I 
Social ecological model McLeroy, 1988 11 E, C, T, I 
Motivational interviewing Miller, 2002 165 E, C, T, I 
Rogers’ client-centered counseling Rogers, 1957 40 I 
Cognitive dissonance theory Festinger, 1957 3 I 
Stages of change model Prochaska, 1983 158 E, I 
Consciousness raising 
 
2 I 
Self-determination theory Deci, 1985 20 I 
Information-motivation-behavioral skills Fisher, 1992 48 E, C, T, I 
Self-regulation/common sense model  Kanfer, 1986 32 E, C, T, I 
Self-management theory Ryan, 2009 96 E, C, T, I 
Operant conditioning theory Skinner, 1938 2 I 
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Classical conditioning theory Pavlov, 1988 1 I 
Behavioral learning theory  Skinner  31 I 
Behavioral modification theory  Skinner, 1970 2 I 
Orem’s self-care theory Orem, 1959 3 I 
Problem-solving theory  Newell, 1972  21 I 
Adult learning theory Knowles, 1913  16 I 
PRECEDE/PROCEED Green, 1974  2 I 
Diffusion of innovations Rogers, 1962 39 I 
Interpersonal theory Peplau’s 10 I 
Main determinants of health model Dahlgren, 1991 7 I 
Social action theory Ewart, 1991 17 I 
Social marketing theory  Baran, 2003 1 I 
Roy adaptation model  Roy,  1 I 
Elaboration likelihood model  Petty, 1986 1 I 
Learned resourcefulness Rosenbaum, 1983 2 I 
Empowerment theory Zimmerman, 2000 11 I 
Attitude, social influence, and self-
efficacy (ASE) model 
Nuwaha, 2002 9 E, C, T, I 
I-change model  De Vries, 1988 2 I 
The ecological model Bronfenbrenner, 
1977 
16 I 
Extended parallel process model Witte, 1992 2 I 
Model of goal-directed behavior Bagozzi, 1998 2 I 
Goal-framing theory Lindenberg, 2007 1 I 
Goal-setting theory Locke, 1968 16 I 
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Health action process approach Schwarzer, 1992 16 I 
Integrated theory of health behavior change Ryan, 2009 5 E, C, T, I 
Precaution adoption process model Weinstein, 1988 2 I 
Prospect theory Kahneman, 1979 2 I 
Regulatory fit theory Higgins, 2000 11 I 
Relapse prevention  Marlatt, 1980 40 I 
Theory acceptance model  Venkatesh, 1989 25 I 
E=explain adherence, C=conceptualize factors affecting patients’ adherence, T=theory 
testing, I=intervention developing 
1. Methods used to measure medication adherence.  
In this review, 51 articles about breast cancer as a disease contained clear methods 
to measure medication adherence. The main characteristics included are: study design, 
patient group, number of participants, and methods used to measure adherence. Methods 
used to measure adherence were grouped into direct and indirect methods. Direct 
measurement is defined as a medication adherence assessment that uses direct 
observation and/or an analyte assay to detect the presence of a drug in an extended 
organism. It includes methods, such as measuring drug concentration in body fluid, 
usually blood or urine, detecting biologic markers that are given with the drug, and direct 
observation of the patient administering the drug. Indirect methods, on the other hand, are 
defined as a medication adherence assessment in which the medication taking process 
measures using objective and/or subjective intermediary measurement methods. The 
subjective methods include self-reporting methods that depend on the observer’s personal 
judgment and feelings as to how well the medication was taken, such as interviews and 
questionnaires. The objective methods include a prescription record review and pill 
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counting methods. Seventy-five percent (n=38) of studies used subjective measurement 
to measure adherence, of which the self-report measurement (n=29, 76%) was the most 
frequently used method. Among studies using objective methods, medication event 
monitoring systems were the most frequently used methods (n=8, 62%). This study 
provides the necessary measurement-related terms that are to be represented in the MAB-
Ontology.  
To this end, the literature reviews discussed above, along with those in chapter 
two, were used to manually extract terms and phrases and create a list of classes and 
properties (i.e., high-level classes for an upper hierarchy and sub-classes representing 
more specific details). Therefore, all sources were grouped and categorized into six 
source types based on the project’s aims, as mentioned in the previous chapter. (i) 
Medication adherence assessment source type, (ii) medication adherence determinants 
source type, (iii) medication adherence behavioral theories source type, (iv) medication 
adherence data standards source type, (v) biomedical ontology repositories source type, 
and (vi) domain experts source type. For each source type, the related information was 
extracted based on predefined questions. Table13 shows the category of knowledge 
source types, resources description, and the number included under each category (i.e., 
articles, textbooks, websites, repositories, human resources), use of each source type 
(e.g., for definition, categorization, reusability), and examples of the source extracted 
under the mentioned category. For example, under the category medication adherence 
assessment literature, 51 articles were reviewed in order to extract terms, definitions, 
components, interventions, and any other characterization of medication adherence found 
in the research. An example of an article extracted under this category is provided.  
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Table 13 Source Selection Examples 
Knowledge Source 
Type 
Resources and 
Number 
Use Source Example 
Medication 
Adherence 
Assessment 
Literature 
Journal articles 
(51) 
Terms, definitions, 
interventions, 
characterization of 
adherence research  
Steinberg et al., 2014 
 
Determinants of 
Medication 
Adherence 
Literature 
Journal articles 
(26)  
Characterization of 
medication adherence 
among breast cancer 
research 
Sedjo & Devine, 2011 
Theories of 
Adherence Change 
Journal articles 
(1057), books (2)  
Theoretical concepts 
(terms/phrases) 
Arora et al., 2014 
Medication 
Adherence Data 
Standard 
Research, project 
(3), and book (1) 
Categorization, 
taxonomy of MAB 
BCT project (Michie et 
al., 2013), ABC project 
(Vrijens et al., 2012) 
Medication 
Adherence- Related 
Terms 
Ontology 
repositories (n=3), 
Bioportal OBO 
foundry, and 
Ontobee  
Related terms, data 
structure, and levels of 
granularity 
Human disease ontology 
(Schriml et al., 2011), 
drug ontology (Hanna et 
al., 2013), emotion 
ontology (Hastings et 
al., 2011).  
Tacit Knowledge  Domain-related 
experts (3) 
Domain terminology, 
information, and data 
structure.   
JC and JJ 
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4.2.2 Source Analysis 
Figure 9 shows eligible studies included from each source type and the number of 
terms/phrases extracted. The extraction process started by identifying general terms most 
commonly used, then generalizing and specializing them. For each eligible study, the 
information resulted from answering all five questions discussed in the methodology 
chapter; they were then categorized and displayed in tables as shown in Tables 14-19, 
with full tables for all source types attached in Appendix 2. The questions are: (i) How is 
medication adherence described/defined in the source type? (ii) How is medication 
adherence measured in the source type? (iii) How is medication adherence impacted in 
the source type? (iv) What impact is medication adherence in the source type? (v) What 
are the critical themes and concepts concerning MAB research in this source type?  
 
Figure 9 Medication Adherence Source Types to Intermediate Representation 
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Table 14 Medication Adherence Assay Literature Source Type 
Source type  Atkins & 
Fallowfield, 2006 
Huiart et al., 2011 Nekhlyudov et al., 
2011 
How is medication 
adherence 
described/defined in 
the source type? 
Process, 
behavior, skip 
dose. 
Behavior, medication 
management, 
medication taking, 
number of events. 
Behavior, number of 
refills. 
How is medication 
adherence measured 
in the source type?  
Persistence, gap, 
questionnaire, 
self-reporting. 
Electronic monitoring, 
Prescription refill 
records. 
Medication possession 
ratio, objective 
measurement.  
How is medication 
adherence impacted 
in the source type? 
 
Beliefs, age, 
knowledge, 
forgetfulness, 
smoking, side 
effect, ethnicity, 
duration. 
Disease stage, age, 
perceived interference, 
additional prescribed 
medications. 
Medication cost, work 
complexity, religious 
practices, and marital 
status. 
How is intervention 
described and what is 
contained in the 
source type? 
Plan, treatment, 
knowledge, 
interview. 
Technology, 
prescription simplicity, 
feedback, and social 
support. 
Reminder, message, 
intervention. 
What are the critical 
themes, concepts 
concerning MAB 
research in this 
source type?   
Granularity of 
adherence factor, 
intervention 
component, 
measurements. 
Stage of breast cancer, 
adherence range.  
Length of adherence 
treatment class, impact 
type, intervention goal. 
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Table 15 Determinants of Medication Adherence Literature Source Type 
Source type  Kahn et al., 2007 Oguntola et al., 2011 Pellegrini et al., 
2010 
How is medication 
adherence 
described/defined in 
the source type? 
Behavior, self-
management, self-
regulation.  
Planned process, 
misuse, suboptimal 
use. 
Behavior, skipped 
dose, missed dose, 
discontinuation, 
drug management. 
How is medication 
adherence measured 
in the source type?  
Self-reporting, and 
electronic monitoring. 
Monitoring, 
questionnaire. 
Subjective, 
objective.  
How is medication 
adherence impacted 
in the source type? 
 
Patient-related, 
medication-related, 
healthcare-related, 
socioeconomic-related 
factors.  
Beliefs, age, side 
effects, medication 
cost, schedule 
burden, comorbidity, 
disease stage. 
Beliefs, knowledge, 
social impact, 
healthcare 
relations, 
communication.  
How is intervention 
described and what is 
contained in the 
source type? 
Service delivered 
through technology, 
mobile app, the 
Internet. 
Structured interview, 
health belief model, 
education, feedback, 
monitoring. 
Knowledge, 
education, session, 
text message. 
What are the critical 
themes, concepts 
concerning MAB 
research in this 
source type?   
 
Behavior, intervention, 
duration, outcome, 
healthcare engagement, 
direct & indirect assay, 
technology-related, 
patient related factors. 
Disease stage, 
efficacy, impact type, 
stage of cancer. 
Long-term and short-
term.  
Drug class, type of 
cancer estrogen 
receptor-positive 
breast cancer.  
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Table 16 Theory of Adherence Change Source Type 
Source type  Arora (2014)  Boland et al., (2014)  Granholm (2012)  
How is 
medication 
adherence 
described/ 
defined in the 
source type? 
Behavior, process, habit, 
initiation, continuation. 
Adherence, behavior, 
quality of life, missed 
dose. Non-continue.  
Decision-making, 
problem 
recognition, stop 
taking.  
How is 
medication 
adherence 
measured in 
the source 
type?  
Self-reporting, pill count. Indirect, questionnaire Monitoring. 
How is 
medication 
adherence 
impacted in 
the source 
type? 
 
Information searching, prior 
knowledge, novelty, past 
experience, confirmation of 
expectation, perceived 
alternative, evaluation 
process, attitude, antecedent, 
dissatisfaction, perceived 
knowledge, skills, social 
impact, belief, awareness, 
reinforcement, health 
Cognitive dissonance, 
social learning, self-
regulation, social rule, 
experience, social 
norm, cue to action, 
behavioral belief, 
barrier, facilitator, 
modifying factor, 
motivation, coping, 
expectancy, ease of 
Capability, 
behavior, 
intervention, threat, 
intention, goal, 
relapse, 
environment, 
desire, attitude, 
self-determinant, 
feeling, self-care, 
ability, fear, 
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consequence, perceived 
behavioral control, emotion.  
use, communication, 
usefulness, autonomy. 
opportunity, 
socioeconomic.  
How is 
intervention 
described and 
what does it 
contain in the 
source type? 
Treatment theory, 
knowledge, social support, 
emotion, motivation, belief 
change, reinforcement, 
feedback, goal, environment, 
self-regulation.  
Telemonitoring, 
theory, constructs, 
stage of adherence, 
disease type, 
intervention session, 
days covered.   
Mobile, reminder, 
social cognitive 
theory.  
What are the 
critical 
themes, 
concepts 
concerning 
MAB research 
in this source 
type?  
Behavior time, belief, 
emotion granularity, desire, 
intention, awareness, 
decision making, information 
processing, planned study, 
goal of study, intervention.  
Adherence rate, 
comorbidity, 
components, 
theoretical construct. 
Adopter, social 
interaction, 
severity, initiation, 
discontinuation.  
 
Table 17 Medication Adherence Data Standard Source Type 
Source type  WHO dimensions 
(Coulter et al., 2008) 
BCT project (Michie et 
al., 2013) 
ABC project (Vrijens et 
al., 2012) 
How is 
medication 
adherence 
described/defined 
Multidimensional, 
behavior, activity 
taking medication as 
recommended, 
Behavior, typology  Process, typology, 
initiation, 
discontinuation, 
implementation, 
persistence, 
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in the source 
type? 
agreed-on 
recommendations.  
management of 
adherence.  
How is 
medication 
adherence 
measured in the 
source type?  
 
Subjective ratings, 
questionnaires, 
objective strategies, 
biochemical 
measurement, dose-
response curve, 
pharmacy databases. 
n/a Time from prescription 
until first dose is taken, 
time from initiation 
until discontinuation, 
the proportion of 
prescribed drugs taken. 
How is 
medication 
adherence 
impacted in the 
source type? 
Five dimensions (the 
full list is in 
Appendix 2): patient-
related factors, 
socioeconomic 
factors, therapy-
related factors, 
disease related 
factors, healthcare 
system-related 
factors. 
Knowledge, skills, 
social role, belief about 
capability, optimism, 
belief about 
consequences, goals, 
reinforcement, 
intention, memory, 
decision process, 
environment, social 
influence, emotion, 
behavioral regulation. 
Socio-economic-
related, healthcare-
related, condition-
related, therapy-related, 
patient-related, 
demographics, 
medicines use, health 
status, affordability, 
adherence, optimism, 
beliefs, self-efficacy, 
health service use, 
social support, illness, 
perceptions, income. 
What are the 
components of 
medication 
Role-play, education, 
support, 
communication, habit 
Goal setting, problem-
solving, planning, 
behavior discrepancy, 
Education, knowledge, 
video, simplify dose, 
drug delivery systems, 
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adherence 
intervention in 
the source type? 
maintaining, 
comorbidity treating 
as depression, 
motivation.  
monitoring, feedback, 
social support, reward, 
education, incentive. 
consequences, social 
comparison, cue to 
action, learning, habit 
formation, graded task, 
restructuring 
environment, learning, 
punishment, self-belief, 
persuasion.  
patient assistance 
programs, adherence 
enhancing, packaging, 
reminder, pill 
organizing, telephone 
support, text message 
reminder, Internet 
based, low literacy 
intervention, low 
resources intervention, 
aged intervention.  
What are the 
critical themes, 
concepts 
concerning MAB 
research in this 
source type?   
 
Behavior, subjective 
measurement, 
objective 
measurement, 
patient-related 
factors, treatment-
related, disease-
related, healthcare 
system-related, 
socioeconomic-
related, intervention 
component 
granularity. 
Knowledge granularity, 
belief granularity, 
social impact 
granularity, emotion 
granularity, 
reinforcement, 
environment 
granularity, goal, 
component.   
Intervention content 
granularity, adherence 
typology, adherence 
measurement 
granularity, factors 
granularity. 
 n/a: not applicable 
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Table 18 Medication Adherence-Related Terms Source Type 
Source type  OBO foundry 
http://www.obofound
ry.org  
Bioportal  
https://bioportal.bioont
ology.org 
Ontobee 
http://www.ontobe
e. org  
How is medication 
adherence described/ 
defined in the source 
type? 
Patient compliance, 
attitude to health, 
behavior.  
Patient compliance, 
attitude to health, 
health behavior, 
behavior, 
pharmacology, 
medication 
management.  
Patient compliance, 
attitude to health, 
behavior, 
medication taking, 
drug 
administration, 
medical 
intervention. 
How is medication 
adherence measured 
in the source type?  
Degree of medication 
taking, direct-
observed therapy, 
medication tracking 
device.   
Direct-observed 
therapy, medication 
tracking device.   
Direct-observed 
therapy, medication 
tracking device.  
How is medication 
adherence impacted 
in the source type? 
n/a Incorrect dose 
administration, omitted 
dose, error drug 
administration, 
overdose, under dose, 
ease of use of 
medication. 
n/a   
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What are the 
components of 
medication adherence 
intervention in the 
source type? 
n/a Medication therapy 
management, medical 
device usage for 
medical intervention, 
medication knowledge, 
take medication at 
correct time, take 
medication as 
prescribed. 
n/a 
What are the critical 
themes, concepts 
concerning MAB 
research in this 
source type?   
Upper-level, 
leveraging. 
 
Adherence type, direct, 
indirect measurements, 
drug error, mode of 
delivery, type of 
intervention, 
management process. 
Disposition 
measurement, 
process quality.  
n/a: not applicable 
Table 19 Tacit Knowledge Source Type 
Source type  Experts 1 (JJ) Expert 2 (JC) 
How is medication 
adherence described/defined 
in the source type? 
Initiation, continuation 
and discontinuation 
Initiation and continuation. 
How is medication 
adherence measured in the 
source type? 
n/d n/d 
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How is medication 
adherence impacted in the 
source type? 
 
Knowledge category, 
motivation 
 
Patient-related: demographic, 
psychological, physical; therapy-
related: complexity, side effects; 
condition-related: disease stage, 
severity, comorbidity; social and 
economic factors: language, 
literacy, social support, living 
conditions, cost; healthcare-related: 
patient-provider relationship. 
How is intervention 
described and what does it 
contain in the source type? 
n/d n/d 
What are the critical themes, 
concepts concerning MAB 
research in this source type? 
Process, knowledge 
granularity, motivation. 
Granularity of factors, assay. 
 n/d: not discussed  
4.3 Knowledge Structuring Using Set of Intermediate Representations 
The terms and phrases extracted from the previous step were organized, 
structured, and represented informally using tables and graphs.  
4.3.1 Building a Glossary of Terms 
Terms extracted and listed in the previous step were de-duplicated and synonym-
specified, with a definition of the terms adopted or created, type of terms defined (e.g., 
noun or verb), and source of the definition cited. Table 20 is an example of a glossary of 
terms; a full table with terms extracted is in Appendix 2.  
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Table 20 Building a Glossary of Terms 
Term/Phrase Descriptive 
Factor(s) 
Definition Type  Definition 
Source 
Behavior Behavioral 
process, 
activity 
Patterned activity of a whole 
organism in a manner dependent 
upon some combination of that 
organism’s internal state and 
external conditions. 
Noun MFO  
http://www.on
tobee.org/  
Medication 
adherence   
Medication-
taking 
behavior; 
behavioral 
response to 
medication, 
medication 
compliance  
Behavior associated with the 
consumption or use of a chemical 
substance with presumed 
curative, preventive, or medicinal 
value in accordance with the 
provider’s recommendation 
concerning the timing, dosage, 
frequency, and duration. 
Noun  Sawesi 
Duration of 
treatment 
course  
Length of 
therapy 
The period from start to the end 
of a treatment course. 
Noun  APOLLO_SV  
http://www.on
tobee.org/  
Adherence 
rate 
 Percentage of doses taken as 
prescribed from initiation of the 
medication or start of 
observation, until stopping the 
medication or ending the 
observation.  
Noun Hugtenburg, 
Timmers, 
Elders, 
Vervloet, & 
van Dijk, 2013 
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Habituation  Habit  A condition resulting from 
repeating the consumption or use 
of a chemical substance presumed 
curative, preventive, or having a 
medicinal value with a desire (but 
not a compulsion) to continue 
taking the medication for the 
sense of improved well-being or 
to prevent disease recurrence, 
which it engenders; no tendency 
to miss or skip the dose; postpone 
the dose; or stop the dose for 
whatever reason without provider 
recommendation.  
Noun Sawesi 
Impact  Affect, 
effect, 
influence 
A relation that holds between two 
entities: one has influence over 
the other, such as a connection 
between behavioral determinant 
and the behavior in question. This 
impact can be positive, negative, 
or neutral. 
Verb Sawesi  
Determinant Factor Anything that contributes 
causally to a result. 
Noun https://www.m
acmillandictio
nary.com/us  
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New 
prescription 
New 
medication 
A prescription that includes a new 
medication or therapy that has not 
been used before by the patient to 
treat the current disease or 
condition.  
Noun Sawesi 
Defined 
number of 
days 
 Number of days in which the 
prescription is presumed to be 
dispensed after it has been 
ordered. The commonly used 
days are 30 or 60.  
Noun  
 
 
 
Sawesi 
Management 
of adherence 
process 
Monitoring, 
supporting 
The process of monitoring and 
supporting patients’ adherence to 
medications by healthcare 
systems, providers, patients, and 
their social networks. 
Noun  Vrijens et al., 
2013 
Behavioral 
intervention 
Behavioral 
technique 
Psychological or behavior 
intervention is a combination of 
program elements, strategies, or 
modalities designed to influence 
psychological or behavioral 
processes or outcomes. 
Noun  Eagle_i 
resource 
ontology 
http://www.on
tobee.org  
Drug 
concentration 
measurement 
 An assay that is used to measure 
the drug concentration in body 
fluid, such as blood and urine. 
Noun  Sawesi  
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Medication 
possession 
ratio (MPR)  
 Ratio of the number of days for 
which a patient has medication 
on-hand divided by the total 
number of days a patient was 
observed. Used for refill 
adherence. 
Noun  Raebel, 
Schmittdiel, 
Karter, 
Konieczny, & 
Steiner, 2013 
Prescription Written 
instruction  
A document that represents verbal 
or written orders given by an 
authorized person instructing a 
patient to obtain and use a 
medical device, prescription, or 
undergo a procedure. 
Noun NCI 
Thesaurus  
http://www.on
tobee.org  
Patient Sick person A role that inheres in a person 
and is realized by the process of 
being under the care of a 
physician or healthcare provider. 
Noun  OBI  
http://www.on
tobee.org 
Healthcare 
encounter 
Patient 
present at 
healthcare 
system 
A temporarily-connected 
healthcare process that has as its 
participants an organization or 
person realizing the healthcare 
provider role and a person 
realizing the patient role. The 
healthcare provider role and 
patient are realized during the 
healthcare encounter. 
Noun OBI 
http://www.on
tobee.org 
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Belief   A mental disposition that is 
realized in a mental process.  
Noun Sawesi  
Occurrent 
belief  
Thinking A mental process that realizes the 
dispositional belief. It is a process 
of bringing belief to the 
conscious.  
Noun Sawesi  
 
4.3.2 Knowledge Representation Using Triples 
The terms extracted and listed in the glossary have been structured in triples of 
Subject-predicate and object. These triples model those of the dictionary, wherein the 
meaning of the terms define using statements. The subject refers to the entity to be 
described, while the predicate defines a type of relation that exists between the subject 
and object. It is the subject attributes, with the object being an entity or value that 
describes the subject via being in relation with it. Figure 10 shows an example of this: 
Medication adherence behavior influenced by medication adherence determinants. 
Medication adherence behavior is an entity that is being described, influenced is relation 
with what exists between the entities; whereas, the medication adherence determinant is a 
value of this relationship. An instance of a triple could be a subject of other triples. For 
example, medication adherence behavior regulated by medication adherence intervention. 
Additionally, an object of one triple can be the subject of another, such as medication 
adherence determinant targeted by medication adherence intervention, or a subject of one 
triple can be an object of another, such as medication adherence intervention regulates 
medication adherence behavior. In this example, an inverse relation was used, but other 
relations could serve the same explanation, as shown in Table 21.  
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Figure 10 Knowledge Representation in Triples 
Table 21 Knowledge Representation Using Triples. 
Subject Object Predicate 
Patient  Has  Breast cancer 
Breast cancer  Is a  Disease 
Disease  Has subtype Breast cancer disease 
Breast cancer  Has stages Breast cancer stages 
Breast cancer stages  Treated by  Breast cancer treatment 
Breast cancer treatment  Specified by Breast cancer treatment protocol 
Breast cancer treatment 
protocol 
Includes  Specified medication 
recommendation 
Specified medication 
recommendation 
Has specified  Medication dose specification, 
medication time specification, 
medication duration specification, 
medication frequency 
specification 
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Medication dose specification, 
medication time specification, 
medication duration 
specification, medication 
frequency specification 
Participates in  Medication adherence process 
Medication adherence process Is a  Behavior process 
Behavior process Has participant some Patient  
Patient  Participates in  Healthcare process 
Healthcare process  Has participant some Physician  
Medication  Prescribed to  Patient  
Physician  Orders Prescription  
Prescription  Contains Instruction about medication 
Instruction about medication  Targeted some/ is about Patient 
Patient  Bears  Belief  
Belief  Is a   Mental state  
Mental state   Has subtype some  Belief  
Belief   Targeted by  Psychological and behavioral 
intervention  
Behavioral intervention Influences  Patient adherence to medication 
Patient adherence to 
medication 
Is about Patient  
Patient  Takes Medication 
Medication  Has subtype Tamoxifen  
Tamoxifen  Has role  Selective estrogen receptor 
modulators (SERMs) 
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Selective estrogen receptor 
modulators (SERMs) 
Realizes in   Preventing estrogen from binding 
(estrogen antagonist)  
Preventing estrogen from 
binding (estrogen antagonist)  
Has output     Reduces the risk of breast cancer 
recurrence  
Reduces the risk of breast 
cancer recurrence 
Is a   Finding   
Finding  Is about  Patient  
Patient  Participates in  Information technology-based 
intervention 
Information technology-based 
intervention 
Has part some  Technology mode of delivery  
Technology mode of delivery  Has participant some Technology  
Technology   Bears some  Information technology platform 
Information technology 
platform 
Has part some   Information technology platform 
objective  
 
4.3.3 Building the MAB Hierarchy 
The triples created in the previous step facilitated knowledge representation in a 
hierarchy. As mentioned earlier, it acts like a dictionary. However, such a dictionary-like 
ontology can be understood only by a single system (as in the case of the English 
dictionary): only people who know English can understand the meaning. It is the same 
with the ontology: other systems cannot understand the meaning of the word and share it. 
Therefore, in order to facilitate interoperability, an upper-level of information is needed. 
Therefore, these triples need to be restructured and mapped with the BFO upper-level 
ontology. Not only does it need map terms to an upper level, but it also must adhere to 
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the BFO principles mentioned in chapter three. Therefore, the next step involves 
restructuring the extracted knowledge based on the reality—a philosophical perspective 
use towards defining the nature of each term as it exists in reality.  
4.3.4 Building the MAB Hierarchy based on BFO 
To define medication adherence, there is a need for defining the entities involved 
in this process based on BFO structure. As shown in Figure 10, behavioral determinants 
play a central role in medication adherence and behavioral interventions designed to 
target these psychological determinants. Therefore, it is important to define the nature of 
these entities using BFO structure.  
4.3.4.1 Continuant Entity 
I. Independent Continuant Entity 
a. Material Entity. 
MAB-Ontology involves several entities that fit under this category. In this 
section, a few examples are provided, while the full entities are formally represented in 
Protégé and are attached in Appendix 3. The hierarchy of classes adopted from other 
ontologies were extracted using OntoFox, http://ontofox.hegroup.org/.  
1. Human, human being, or homo sapiens 
Patients, healthcare providers, or others involved in the treatment process are 
categorized under this class according to the role they play or have. The hierarchy of 
homo sapiens was adopted from the NCBI Organismal classification. 
http://www.ontobee.org/ontology/NCBITaxon. For example, human breast cancer 
patient=Def. A human who bears the breast cancer patient role. Healthcare provider 
=Def. A human who bears the healthcare provider role. Oncologist= Def. A healthcare 
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provider who bears the oncologist’s role.  Adherent patient=Def. A patient who has a 
medication adherence percentage greater than 80%, meaning there is material entity a 
(patient), process p (measurement of medication adherence), scalar measurement m (rate 
of adherence-80%), measurement unite label (percent) l, value (80) v and adherent patient 
• participates in p 
• p has output m 
• m has label l 
• m has value v 
2. Drug tablet 
Drug tablet= Def. “A solid object, typically a discoid, spheroid, or elliptic-
cylindrical shape or approximation thereof that bears a clinical drug role.” This class has 
been adopted from Drug Ontology http://www.ontobee.org/ontology/DRON and includes 
several subclasses. For example, Anastrozole Oral Tablet= Def. A drug product that bears 
some active-ingredient role and has a granular part of some Anastrozole. Therefore, 
Anastrozole 1 MG Oral Tablet can be defined as= Def. An Anastrozole oral tablet where 
there exists some material entity b (anastrozole), role r (active ingredient role), quality q 
(mass), measurement unit m, value v (equal 1) and Anastrozole 1 MG Oral Tablet: 
• has part b 
• bears r and q 
• q has m 
• m has v 
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3. Device 
Device=Def. “A material entity that is designed to perform a function in a 
scientific investigation but is not a reagent.” This definition was borrowed from Ontology 
for Biomedical Investigations http://www.ontobee.org/ontology/OBI to include MAB-
Ontology-related devices. For example, Medication Event Monitoring System 
(MEMS)=Def. A device that bears MEMS function and is realized in the process of the 
medication adherence measurement process. This means there is a material entity m, 
function f, process p and Medication Event Monitoring System: 
• bears f 
• participates in p 
4. Material anatomical structure 
Material anatomical structure=Def. An anatomical entity that has mass adopted 
from the UBERON ontology http://purl.obolibrary.org/obo/UBERON. This class 
includes the subclass Multi-cellular anatomical structure=Def. “A material anatomical 
entity that has more than one cell as a part,” which includes several subclasses that 
represent the body organ. The reason for including this class is to relate disease to its 
location; for example, breast cancer is located in the breast. Also, to include mental 
functioning anatomical structure as subclass (will be discussed under disposition). It is 
adopted from Mental Functioning Ontology http://www.ontobee.org/ontology/MF. 
Mental functioning anatomical structure=Def. An anatomical structure in which there 
inheres the disposition to be the agent of a mental process. This means that there is a 
material entity a (mental functioning anatomical structure), disposition d (mental 
disposition), process p and, the mental functioning anatomical structure  
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• bears d 
• d realized in p 
II. Specific Dependent Continuant Entity 
a. Realizable Entity 
1. Role 
Patient role=Def. A role which inheres in a person and is realized by the process 
of being under the care of a physician or healthcare provider. Adopted from Ontology of 
Biomedical Investigations http://www.ontobee.org/ontology/OBI. This means that there 
is role r (patient role), material entity a (patient), process p (healthcare process), and 
patient role 
• inheres in a 
• a participates in p 
Drug role=Any substance that, when absorbed into a living organism, may modify 
one or more of its functions. Adopted from Chemical Entities of Biological Interest 
http://www.ontobee.org/ontology/CHEBI. For example, estrogen receptor antagonist 
role=Def. A role that inheres in Tamoxifen and realizes in some process, such as the 
estrogen-binding process. This means that there is a role r (drug role), material entity a 
(Tamoxifen), process p (estrogen binding process) and drug role   
• inheres in a 
• a participates in p 
Oncologist role=Def. A role that inheres in the physician by which the physician 
diagnoses and treats patients with cancer. This means that there is a role r (oncologist 
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role), material entity a (physician), process p (cancer treatment process), and oncologist 
role r 
• inheres in a 
• a participates in p 
b. Disposition.   
Disease=Def. A disposition (i) to undergo pathological processes that (ii) exist in 
an organism because of one or more disorders in that organism. This class has been 
adopted from the Ontology for General Medical Science 
http://www.ontobee.org/ontology/OGMS to define breast cancer, the disease class 
categorized to include a class named disease of cellular proliferation= Def. A disease that 
is characterized by abnormally rapid cell division. This definition has been adopted from 
Human Disease Ontology (DOID) http://www.ontobee.org/ontology/DOID. Under this 
class, cancer class is represented and defined as= Def. A disease of cellular proliferation 
that is malignant and primary, characterized by uncontrolled cellular proliferation, local 
cell invasion, and metastasis. Cancer has two subclasses: cell type and organ system. 
Accordingly, breast cancer is defined as=Def. A cancer that is located in the breast. This 
means there is a disposition c (cancer), anatomical entity m (breast), and breast cancer  
• subtype of c 
• inheres in m  
Cognitive or psychological factors: Psychological determinants, which include 
belief, motive, desire, fear, knowledge, intention, perception, feeling, thought, etc., are 
defined in the literature as mental states (Apperly, 2010; Call & Tomasello, 1999; De 
Villiers, 2007; Perugini & Bagozzi, 2004). A mental state is a state of mind that an agent 
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is in (Symons, Peterson, Slaughter, Roche, & Doyle, 2005): having a belief, desire, 
motive, etc., is being in the state. The question here is, under what BFO category does the 
mental state belong? Is it occurrent or continuant? If, for example, a mental state is 
categorized as an occurrent entity, do all the above-mentioned determinants satisfy the 
condition to be a member of that class of mental states? To answer this question, there 
needs to be a need for understanding the nature and distinguishing features that are 
unique only to this mental-state class. Philosophers argue that a mental state has two 
important features namely, intentionality and consciousness. 
1. A mental state is intentional; it—“has intentionality” (Searle, 1979).  
Two definitions were found related to intentionality. (i) One meaning of 
intentionality is aboutness or directedness (Bourget & Mendelovici, 2016). It is 
impossible to have a belief without referring to something or being about something. If a 
patient believes that medication causes side effects, then his or her belief is about the 
medication. This intentionality does not necessary exist, as the person may have a belief 
about something that does not exist in reality, such as, my son believes that Spiderman 
lives in California. His belief about Spiderman, even though Spiderman does not exist, is 
a mental state. (ii) Another meaning for intentionality is carrying information about 
something (Dretske, 1980). Pain and other symptoms are considered mental states. It 
does not make sense to say what pain is about, but it does make sense to say that pain 
carries information about what is happening in this patient’s body. This information does 
not need to exist. Some patients may have phantom sensations after breast amputation. 
Belief can also carry information, but other entities cannot, such as desire. In this case, an 
intentional mental state can be define as “a mental state that is either about some entity or 
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carries information about some entity.” These entities do not need to exist. Given this 
definition, all the entities mentioned above satisfy this condition and can be a member of 
a mental state class. But such a definition will allow other entities to be members of this 
class, such as non-living things. Books and pictures, for example, carry information about 
something. Are they considered mental states? Therefore, this feature is not unique to 
mental states.  
2. A mental state is a state of consciousness or awareness.  
It means that they do not persist through periods of loss of consciousness or sleep. 
Feeling pain, for example, is consciousness; once the person falls sleep or goes under 
anesthesia, he or she is not aware of the pain. It is the same with emotions. A person can 
be anxious and depressed while conscious. He or she may, however, lose this awareness 
for some time when being distracted by an important call or visit by a loved one. This 
duration of unconsciousness is what philosophers call a “genuine duration” (James, 1904) 
that occurs when conscious is interrupted by other events, then resumes after the 
distraction has been suppressed. Philosophers claim that consciousness is “something that 
it is like to be in” (Fabrega, 2000; Ornstein, 1972; Quilty-Dunn, & Mandelbaum, 2017). 
For example, a person may be in a cheerful or joyful state. Once a question is asked about 
what state patient “A” is in today, simply answer, patient “A” is in a state of depression, a 
bad mood, etc. This feature works for some psychological determinants mentioned above, 
but not all. For example, knowledge—a justified true belief (Schmitt, 2006)—is not 
conscious and cannot cease to exist simply because one falls sleep or lacks awareness. 
The person may forget some knowledge but does not exhibit a genuine duration. A 
person may have knowledge for the entirety of his or her life that cannot be interrupted 
 164 
 
by some objects or events that distract attention and later resume that knowledge once the 
distraction has terminated. Belief, too, is not conscious and has no “genuine duration.” 
Intention (the tendency to act–not intentionality) also persists through time. A person 
may have the intention to do something for years and does not lose that intention when he 
or she falls asleep or has a genuine duration. Also, for consciousness to be “something to 
be in,” it does not work for all of mental states. For example, belief, knowledge, and 
desire. You cannot say this person is in a belief state or a knowledge state. The literature 
claims that consciousness is occurrent and part of all mental processes (Hastings, Smith, 
Ceusters, Jensen, & Mulligan, 2012). Since consciousness is a dynamic process (Aikens 
et al., 2014) and an inseparable part of all mental processes (Hastings, Smith, Ceusters, 
Jensen, & Mulligan, 2012), then mental state is a process. However, the state obtains not 
happening or taking place. How can a state be an occurrent? Based on what has been 
mentioned in chapter three, to be an occurrent, entities must unfold themselves in time. 
States do not unfold or evolve through time; they exist in the instantiation of properties in 
objects, as shown in Figure 11. Objects do not change their state over time; instead, a 
series of states are followed—one state is followed by another. Following this case of 
consciousness must mean following in time; one event follows another in temporal order. 
States have no temporal parts; for example, temperature and height. It makes no sense to 
say the early or latter part of the patient having the temperature or height he does. An 
event, on the other hand, has temporal parts and cannot be wholly present throughout 
each moment of its existence. Instead, for every moment an event is happening, there are 
temporal parts that exist. This is not true with state. Consider a state that instantiates 
property over a particular period of time. For each moment the state exists, the property 
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and the particular are wholly present, and if the particular ceases to have this property, 
then it undergoes a change of state. The change itself is occurrent, but the state is not an 
occurrent. 
A mental state cannot be occurrent or at least occurrent cannot be its unique 
feature. For example, philosophers have said that belief is conscious and is categorized as 
a process (Österholm, 2010). When a belief is formed through perception, judgment, 
thinking, or other mental processes, it is stored in the memory and executed when 
needed. A belief can guide action by using it in reasoning, planning, and making a 
decision. For such an entity to serve this role, it is supposed to be a continuant and persist 
through time. Pitt (2016), in his paper, “Conscious Belief,” states that “to believe that p is 
to think that p while taking p to be the case—while accepting or endorsing that p.” He 
claims that such conscious endorses the content that p is a conscious belief. But how can 
the same belief be conscious (occurrent belief) and unconscious (continuant belief)? 
Belief is not just a matter of taking something as being the case for a period of time, 
relating belief to knowledge, and the similar role it plays in impacting an individual’s 
behavior and reasoning. Why is there no such an occurrent knowledge, while there is an 
occurrent belief? People bring their knowledge to mind when they need to. It is the same 
for belief. What does it mean to bring “A” to the mind or consciousness? This refers to 
the fact that there is an entity—“belief”—that participates in occurrent conscious, and by 
its participation, it is realized. Such an occurrent conscious could be a cognitive process, 
such as thinking, reasoning, judging, or decision-making. So, when we measure belief, 
we measure its realization either through behavioral observation or by asking an 
individual about his belief about x. This individual will answer the question based on his 
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or her belief (i.e., the continuant belief). Therefore, the claim that all mental states are 
consciousness and occurrent would be implausible, because it denies claim that there are 
some mental states that are not occurrent or conscious. 
 
Figure 11 Linda’s Belief Instantiates at Different Times 
To this end, it is impossible to define the above-mentioned determinants as mental 
states, or find an appropriate category for mental state under BFO, as the nature and 
feature of mental status are controversial and not clearly defined in the literature. 
Therefore, in this dissertation, each entity is treated and defined individually, based on its 
nature, if occurrent and continuant, without grouping each under the same category, such 
as mental state.  
Based on BFO, entities must be either occurrent or continuant, and since a 
cognitive entity as a belief is not occurrent based on the above explanation, it categorized 
under continuant. Two options are considered for this project to categorize belief under 
BFO: (i) belief that “A” is a proposition that is stored in long-term memory. This means 
that belief is an object (material entity). (ii) Belief that “A” is a realizable entity that 
inheres in an independent continuant entity whose instances require process in order to be 
realized. 
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First, belief is an object. It is not unusual to see belief as something an individual 
may have. One way to interpret this is to consider belief as a proposition or statement 
“A” that is stored in the mental system, or as some in the literature name it, the belief 
box(Schiffer, 2006). So, to believe that “Tamoxifen can prevent breast cancer recurrence 
if taken for at least 5 years” is to have a representation/proposition with content that 
“Tamoxifen can prevent breast cancer recurrence if taken for at least 5 years” is stored in 
the brain and is ready to be activated when needed, such as when the patient is prescribed 
Tamoxifen and has to decide whether or not to take it. Although some neuroimaging 
literature neglects that there is any brain structure that can be mapped to the mental 
process, others prove the opposite. The amygdala, for example, has proven to be the “fear 
area,” and the anterior cingulate is the “conflict area”(Poldrack, 2010). For a belief to be 
a cognitive representation, it needs to be stored somewhere in the brain. Let’s say (belief 
area). But the problem here is in what form can the belief be represented? The 
representation—“patient belief that Tamoxifen can prevent breast cancer recurrence if 
taken for at least 5 years”—can be represented in many forms, such as beliefs that 
Tamoxifen can prevent breast cancer recurrence if taken for 4, 3, or 2 years, or more than 
one year. Likewise, the patient may believe that Tamoxifen is an antineoplastic and 
inhibits estrogen. The list could be expanded. The question is how many representations 
for a single proposition? If there is only one representation and the other is derived, 
which one? And, how could we know? Also, in what structure is this belief represented? 
Some cognitive scientists claim that belief representation can be in the form of language 
(Harman, 1973), while others say map-like representation (Camp, 2007) or sensorimotor 
representation (Gelder, 1990). If one of these representational structures is accepted, then 
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it will take the form of a yes-no phenomenon. The belief either exists or not, but what 
about the “in-between” belief? The belief in something and it acting differently as a 
result. For example, a patient who asserts that he or she can take medication on time, no 
matter what, and yet shows behavior indicative of the inability to control their behavior. 
Does the brain have both of those structures? Also, what about whether there is an 
individual who has a pattern behavior of knowing for a specific belief x but has a 
different underlying structure? Do we still consider that this individual believes that x?   
Second assumption, belief is a disposition. To believe some particular proposition 
is to be disposed toward a certain act (i.e., behavior or thought) under certain 
circumstances. For example, to believe that Tamoxifen causes side effects is to be 
disposed not to fill the prescription if the physician prescribed it, to ask the physician for 
an alternative upon visiting him or her, to stop taking Tamoxifen if it is time for 
administration, or “to bring what you believe to conscious”—judgment or thinking—
using this belief to answer the question about your belief. A person can be disposed to 
thinking about Tamoxifen’s benefits if he or she is going to make a specific-related 
decision, answer a question in a questionnaire, or judge with someone, build a new belief, 
etc. Therefore, belief is a multi-tracking entity in which an individual can be realized in 
many ways while holding the belief that x. To this end, even if the individual uses 
consider belief as a disposition, the material entity that bears such a disposition is still 
needed, therefore, belief is classified as a disposition. A disposition means that it is a 
realizable entity (realized by process) and specifically depends on (i.e., inheres in) some 
independent entity –material entity (i.e., belief area- or mental-functioning anatomical 
structure (term adopted from Mental Functioning Ontology (Hastings et al., 2012; 
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Schurz, Aichhorn, Martin, & Perner, 2013)). Mental functioning anatomical structure, as 
defined under material entity, above, is that part of an individual that bears mental 
disposition to be a participant in one or more actions (thought or behavior). Mental 
functioning anatomical structure can include subtypes, such as neurotransmitter, assumed 
to be a bearer of belief disposition (Harris, Sheth, & Cohen, 2008). If this disposition 
ceases to exist, then its bearer (i.e., the neurotransmitter) will physically change. Formal 
definition=Def. Belief is a disposition that realizes in process (behavioral or mental 
processes) and inheres (i.e., specifically depends on) in mental functioning anatomical 
structure, and belief is such that, if it ceases to exist, then its bearer is physically changed. 
Figure 12 shows this process, which means there are disposition d (belief), material entity 
a (mental functioning anatomical structure), process p (behavioral or mental processes) 
and belief 
• Inheres in a 
• Realized in p 
 
Figure 12 The Belief Structure Under BFO 
Belief includes several subcategories that are categorized based on the results of 
the above-mentioned review into: Capability belief, behavioral consequences belief, 
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normative belief, and risk-related belief. Definitions of those classes and their 
subcategories are entered into Protégé.  
Desire, memories, capability, power, skills, habit, phobia, fear and other 
psychological determinants are treated in the same way as belief and are analyzed 
individually to satisfy the BFO category. Unfortunately, due to space constraints, it is 
impossible to cover all psychological determinants separately. Therefore, a brief 
description of some of them will be provided. Desire, for example, is similar to belief, as 
is disposition. Action-based theory of desire (Anscombe, 2000) claims that, having a 
desire is comparable to having tendencies to act in or think in certain ways. For example, 
the patient has a desire to prevent breast cancer from spreading or recurring; this is 
because he or she is disposed to taking medication on time and thinking positively about 
the medication. Desire may not manifest. Similar to the fragility of glass, the glass may 
not break if the physical circumstances do not exist. A patient may have had a desire to 
get a second opinion four months ago; however, that desire did not manifest. The desire a 
person has may be stored somewhere in the person’s mind most of the time, and it mostly 
generates thoughts, feelings, and actions. Capability is a disposition, too. The capability 
to read instructions related to one’s medication is the disposition to read, the ability to 
understand, or speak the written word. Memory can also be categorized as a disposition 
or enduring dispositional memory in which an individual retains, as long as he or she has 
the capacity to remember.  
Skill is also the disposition to engage in certain acts and use those skills, such as 
problem-solving and decision-making. Intent is a disposition where an individual has to 
pursue some goal in a particular circumstance. Intention can exist without undergoing or 
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producing any effect or change. Similar to fragility, belief, desire, and intention can be 
present for an indefinite period of time and not manifest or be realized until triggered by 
an appropriate event or elicitor.  
Motive can also be categorized as a realizable entity that represents a need, desire, 
or drive within an individual that motivates him or her to action (adopted from Life 
ontology https://bioportal.bioontology.org/). For motive subclasses, Maslow’s hierarchy 
was adopted(Maslow & Lewis, 1987). It includes physiological need, safety need, motive 
for social belonging, motive for self-actualization, and motive for self-esteem. Each class 
has subclasses. For example, the need for health–(a subcategory of safety need)–
motivates individuals to take their medication. Therefore, psychological determinants 
represented as a mental disposition under bodily disposition (adopted from Mental 
Functioning Ontology (Hastings et al., 2012)), are shown in Figure 13.   
 
Figure 13 The Mental Disposition Structure Under BFO 
III. Generic Dependent Continuant Entity 
Many entities could be measured using standardized tests, such as those that 
measure medication adherence, determinants of medication adherence, and age. The 
output of measurement methods includes some information-content entities 
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(measurement datum) that concretized in some form of material entity, such as paper 
assessment questionnaires given out to the patient. Such a test can be linked by relation 
(e.g., measures) to the quality or process that is measured. The relation “is concretized 
as” is one between measurement datum (generic dependent continuant) and 
concretization of measurement datum (specifically dependent continuant) upon which it 
existentially depends. For example, when the questionnaire is printed on paper, the ink 
color and pattern formed by the ink splotches are qualities of the ink used on paper. This 
quality depends on independent continuant (i.e., ink). The quality (color of ink) exists 
only if the bearer exists (ink) and does not need a process to be realized. This category–
the generic dependent entity–is discussed in the next sections, along with the process 
(Figure 14).  
 
Figure 14 Measurement Under BFO 
4.3.4.2 Occurrent Entity 
A. Process 
Several processes are included in MAB-Ontology, such as the behavior process, 
physiological process, mental process, and treatment process. Some will be explained in 
this section, while the full classes are represented in Protégé. To define medication 
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adherence, other entities need to be specified, such as medication recommendations (e.g., 
duration, dose, and time for medication administration), methods used to evaluate the 
patient’s medication adherence, the process that is part of the medication adherence 
process, and the barrier to medication adherence. In the previous section, mental 
disposition was both represented and discussed in terms of how it can be instantiated and 
linked to medication adherence; other entities, however, may cause medication non-
adherence. Measuring these entities will be discussed in this section.  
1. Medication adherence 
In general, medication adherence is a subclass of the behavior process based on 
Mental Functioning Ontology http://www.ontobee.org/ontology/MFO. The behavior 
process is defined as “Patterned activity of a whole organism in a manner dependent upon 
some combination of that organism’s internal state and external conditions (Hastings et 
al., 2012).” Therefore, a definition given to the medication adherence behavior is, 
“behavior associated with the consumption or use of a chemical substance with presumed 
curative, preventive, or medicinal value in accordance with the provider’s 
recommendation concerning the timing, dosage, and frequency.” Figure 15 shows this 
process, which means that there is a process p (medication adherence process), material 
entity m (patient), dose specification d, dose frequency specification f, duration 
specification s, time specification t, value v and medication adherence process 
• has participant m, d, f, s, t 
• d, f, s, t has v 
When a physician treats a patient, he or she follows a protocol, such as the one 
developed by the World Health Organization (WHO), which serves as a guideline in the 
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management of breast cancer according to T.N.M—“T.N.M. Staging of tumors according 
to three components: primary tumor (T), regional nodes (N), and metastasis (M) (Geara 
et al., 2006),” or he or she uses practical experience. The protocol specifies the drug, 
dose, frequency, and duration for each disease stage or type. The physician may consider 
how the determinants impact medication taking, risk factors, demographic characteristics, 
types of hormone receptors, menopausal status, etc., in the treatment process. Therefore, 
a specification of this recommendation is important. A class named “cancer treatment 
regimen specification” was created that is an extension of the Ontology for Biomedical 
Investigating (OBI) plan specification and is defined as “a plan specification that 
prescribes actions whose goal is to cure and prevent a patient’s breast cancer from 
reoccurring. A cancer treatment regimen specification takes into account the standard 
protocol, determinants and risk factors, specific patient characteristics (e.g., age, weight, 
menopausal status, family history), as well as the patient’s preference.” This class 
included several classes as part of such a dose specification, frequency specification, 
duration specification, dietary specification, etc. Dose specification is that part of a 
cancer treatment specification that states the dose to be prescribed to the patient (e.g., 5 
ml). Duration specification is a scalar specification that is part of a plan specification that 
specifies a length of time the patient should take the medication for a single dose (30 
minute for infusion) and for the entire course (e.g., 30 days, 2 months, 1 year). Frequency 
specification is a “value specification that is part of a plan specification and specifies the 
frequency of the drug supply.” This includes subclass as: drug dispensing frequency 
specification, which is “a frequency specification that specifies the frequency of drug 
dispensing (e.g., 12 dispensings per year.” Drug administering frequency specification, 
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which is “a frequency specification that specifies how often a drug taken (i.e., 1 tablet per 
day, 2 tablets per day).” 
The process that implements the treatment specified in the cancer treatment 
regimen specification is referred to as the planned treatment process. It fits under the 
healthcare process class from Ontology for General Medical Science (OGMS) 
http://www.ontobee.org/ontology/OGMS and is defined as “a planned process that 
has_specified_input; some concretizes some cancer treatment regimen specification.” 
The concretization of the planned process could be a plan in the physician’s brain or a 
written note that is part of the patient’s medical record. Figure 16 shows the process of 
treatment regimen.
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Figure 15 Medication Adherence Process 
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Figure 16 Treatment Process
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2. Medication adherence measurement 
Medication adherence rate (measurement datum) is about the quality of process 
(such as increased adherence, regular adherence, irregular adherence). Quality under 
BFO is a continuant and has no temporal parts. Therefore, it cannot inhere in occurrents, 
and it is not possible to make any statement on whether a medication adherence is regular 
by inspecting a snapshot of this process at a particular moment in time. While, under 
BFO quality of a continuant entity, it is possible to describe a change quality has in their 
bearers over time, such as changes in temperature against time (temperature chart) or 
changes in an individual’s weight over times (as increases or decreases). When 
measuring continuant quality, such as the weight of patient “A,” this weight is quality 
that inheres in an individual at a specific time. It is easy to create a chart for the weight of 
this patient against time. So, we can represent increasing and decreasing weight and/or 
regular or irregular weight for the same patient over different times. In terms of the 
occurrent part, however, there is no such counterpart. We cannot say process one is an 
instance of universal “A” at t1 and universal “B” at t2. Instead, we can say that there is a 
process p that has two occurrent parts: “a,” which is an instance of universal “A” and “b,” 
which is an instance of universal “B.” BFO assumes the process is a change, and changes 
cannot change; therefore, they cannot have quality-like entities that inhere in occurrents. 
Each process has at least one participant (continuant entity) and one duration (extent of 
the time interval between beginning and ending). The process can have many 
subprocesses in which each has some participant and duration. To this end, two classes 
are created, namely, dose administration process and medication adherence process. (a) 
The dose administration process is defined as “a process that has as participants an 
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organism and a drug product and that results in a specified portion of the drug product (a 
single dose) being located in the organism.” This means that there is a dose 
administration process p, dosage specification s1, dose administration duration 
specification s2, dose timing specification s3, drug product specification s4, and patient p, 
drug d, and dose administration process p 
 has participant s1-4, p, d 
• s1-4 is about d 
(b) The medication adherence process is defined as a behavior process that has at least 
two dose administration processes. So, to define 30 days, medication adherence process 
is to say that “a process that has part 30 dose administration process (single dose/day of 
tamoxifen). If the medication is taking twice daily, then we can say that it is a process 
that has 60 doses taking process.” Any missing dose, therefore, is “a process that lacks 
part of some dose administration process.”  
Dealing with the quality of the medication adherence process (e.g., regular 
adherence rate, irregular adherence rate) under BFO is challenging. Therefore, to 
represent such a quality under BFO, there were five analyzed options to choose from: 
(i) Representing the process attributes as if they were attributes of the continuant 
participants by following the Vital Sign Ontology (VSO), which represents the process 
quality as a continuant quality that inherence in independent continuant entity, so the 
adherence rate will be one that inheres in an individual. This way could be reasonable for 
the simple process. However, it becomes complicated when dealing with a change in the 
adherence rate and in relation to the other entity (substance or process), such as a change 
in the duration of adherence due to a side effect of the medication. Therefore, there is a 
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need to capture the knowledge of the effect or change a side effect can have on 
medication adherence or to relate such a change back to the side effect. This requires 
explicit representation of process attributes. It is also necessary to record such changes in 
medical records to tailor interventions based on the reason for such changes.  
(ii) Represent the quality of process under class quality and have process qualities as 
subclasses by following the phenotypic quality ontology (PATO), so that the process 
quality for medication adherence is defined as a quality that inheres in the medication 
adherence process. By using this method, medication adherence attributes, such as 
regular, irregular, rate, frequency, duration, accelerating, abnormality, and having an 
extra or missing sub-process part can be represented. And the process be connected with 
the rate or modifier, such as increased adherence rate, irregular adherence, or missing 
adherence. However, this method contradicts the BFO definition of quality. Quality is a 
dependent continuant that presents as a whole at one point in time and can change over 
time. For example, the height of an individual changes as he or she grows. If there is a 
process quality based on BFO, it should depend on the process as a whole and can extend 
over time (process duration) based on whether it cannot be wholly presented at a given 
time or change over time (there is no medication adherence rate at 3:30). Instead, there is 
a medication adherence rate for the medication adherence process that starts at 3:30 pm. 
(iii) Represent the process attributes as a result of drawing a conclusion based on data by 
extending the “conclusion based on data” class from the ontology of biomedical 
investigations (OBI) to include the medication adherence rate and include its sub-
category as a regular or irregular rate that can be linked to the adherence process by 
relation (is about). By using such a technique, the medication adherence process will 
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assume a normal or regular process. Any information regarding irregular data will appear 
under the information content entity as a finding or conclusion based on finding only and 
will not be represented under process as a type or quality. 
(iv)  Directly represent complicated medication adherence process hierarchies by creating 
a process profile under BFO for medication adherence in which every instance should be 
universal (for example, an adherence rate of 70% during a duration of 30 days of the first 
year, an 80% adherence rate for 6 months during the third year of the medication 
adherence process, etc.). Therefore, the process attributes (such as increased, decreased, 
missing one dose, two doses per day, one refill per period of time, so on) is represented as 
an instantiation relation. Creating a process profile contains classifications of the process 
universals instantiate each subtype of the process, however, may lead to a complex list, as 
for every instance, a universal should exist. For example, in terms of the process of 
medication adherence, there is a rate process profile that contains a cyclical process 
profile that contains a regular cyclical process profile. In turn, it will have a 30 doses per 
30 days duration, a 60 doses per 30 day duration, etc. An irregular process profile, on the 
other hand, contains 29 doses per 30 days duration, 28 doses per 30 days duration, etc. 
Representing process quality in such a way is complicated if it compared with the 
continuant quality that can be represented simply. For example, the “20 mg mass of 
Tamoxifen” is represented by having a universal class of mass, a universal class of tablet, 
a universal class for measurement, and the relationship between each. 
(v) Lastly, create a new class for process attributes and define it as occurrents that 
describe a process without committing this class to any existing entity in reality at this 
point. Once the definition of the process attributes has been achieved and is assigned in 
 182 
 
an upper-level ontology, an update to the ontology will take place accordingly. So, under 
this type, a medication adherence process is classified into a single process and cyclic 
process. Adherence to medication as a cyclic process may take an entire lifetime and for 
tamoxifen, it takes up to 10 years. The quality of the medication adherence process 
represented under occurrent is a class named “process attribute” and is connected with 
the relation “is process attribute of.” Under this class, several attributes can be 
categorized, such as process duration (regular and irregular), process occurrent (missing 
dose), and process frequency (adherence rate). Although the last way is preferred to 
represent the medication adherence attribute, it contradicts the BFO/OBO-principles. 
Therefore, representing process attributes as if they were attributes of the continuant 
participants, as well as a conclusion based on data, are the ways that have been adopted to 
represent the medication adherence process attribute.  
Medication adherence can be measured using different methods (Figure 17):    
(i) Drug concentration assay is an assay that measures concentration of the active 
ingredient of a drug product in a specified body fluid, such as the blood and urine of an 
individual in order to assess whether or not the patient can take the medication regimen. 
The results can be represented as “contains 1.3ng/ml,” or “no drug detected.” The output 
of this assay is scalar measurement datum that is about body fluid (i.e., evaluant), which 
is part of the patient or it can be direct-linked with the patient. This scalar measurement 
has a specified value and measurement-unite label (ng/ml) based on the value specified. 
Figure 18 describes this process and provides an example. The formal definition of Drug 
concentration assay =Def. Medication adherence assay, is such that there exists some 
drug d, analyte role r1, evaluant role r2, body fluid specimen (e.g., blood or urine) b, 
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measurement device v, measure function f, drug concentration assay objective g, drug 
concentration measurement c, and drug concentration assay  
• realizes r1 , r2, f  
• r1 inheres in d  
• r2 inheres in b  
• f inheres in v 
• has specified input d, b, v 
• d part of b 
• has specified output c  
• c is about b  
• and is directed toward achieving goal g 
(ii) Direct observation is a medication adherence assay in which the subject is monitored 
and the medication consumption recorded. The output of this assay is categorical 
measurement (e.g., “drug taken” or “not taken”), which is about the patient (i.e., 
evaluant). Figure 19 shows this process. The formal definition of direct observation=Def. 
Medication adherence assay which is such that there exists some patient p, drug d, human 
h, evaluant role r1, observer role r2, direct observation objective g, categorical 
measurement datum m, and medication administration observation  
• has specified input p, d, and h 
• d part of p 
• realizes r1 and r2 
• r1 inheres in p  
• r2 inheres in h 
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• has specified output m 
• m is about p 
• is implemented towards achieving goal g 
(iii) Dosing event recording is a medication adherence assay that uses monitoring 
devices, such as the Medication Event Monitoring System (MEMS) incorporated into the 
packaging of a prescription medication. These devices contain a microprocessor that 
records the time and date whenever the patient opens the cap of the medication container, 
assuming that the patient has taken that dose at that specific time. The output of this assay 
is time measurement data and count measurement datum that records time and the 
number of doses taken by the patient (i.e., evaluant). Figure 20 exemplifies this process.  
The formal definition of dosing event recording=Def. Medication adherence assay, is 
such that there exists some patient p, drug d, evaluant role r, monitoring device (e.g., 
Medication Event Monitoring System) m, monitoring device function f, number of drugs 
taken d, dosing event recording objective g, and the dosing event recording 
• has specified input p, d, and m 
• realizes r and f 
 r inherence in p 
 f inherence in m 
• has specified output n 
• and is directed toward achieving goal g 
(iv) Pill counting is a medication adherence assay that counts the number of doses that 
have been taken between two scheduled appointments or clinic visits. The output of this 
assay is a count datum that is about some container (i.e., evaluant). Figure 21 shows this 
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assay. The formal definition of pill counting=Def. Medication adherence assay which is 
such that there exists some drug d, drug container c, evaluant role r, drug counting device 
k, drug counting device function f, measurement of the remaining number of drug n, pill 
counting objective g, and the pill counting 
• has specified input d, c, and v 
 d part of c 
• realizes r and f 
• r inherence in c 
• f inherence in v 
• has specified output n 
• and is directed toward achieving goal g 
(v) Self-reported medication adherence assessment is a medication adherence assay in 
which an individual was asked to respond to characterize his or her medication adherence 
behavior. A medication adherence self-report includes questions that range from simple, 
single-item questions regarding missed doses, to complex multi-item assessments that 
incorporate reasons for non-adherence. The output of this measurement is about the 
patient (evaluant). This class included several subclasses:    
1. Patient interview: is a self-reported medication adherence assessment in which the 
patient is asked to estimate his or her medication-taking behavior and whether he or she 
follows the prescribed regimen. Its specified output is an adherence categorical 
measurement datum, which is a measurement of the patient’s adherence behavior and is 
recorded using a category “adherent” or “non-adherent,” (Figure 21). The formal 
definition of patient interview=Def. Self-reported assay, which is such that there exists 
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some patient p, human h, evaluant role r1, interviewer role r2, categorical measurement 
datum m, self-reported objective g, and the self-reported medication adherence 
assessment 
• has specified input p and h 
• realizes r1 and r2 
• r1 inherence in p 
• r2 inherence in h  
• has specified output m 
• and is directed toward achieving goal g 
2. Adherence assessment with questionnaire: is a self-reported medication adherence 
assessment that use a series of questions to gatherer information from the patient about 
his or her medication adherence behavior or barrier to adherence. The answers to these 
questions are turned into scores to assess adherence. The questionnaire can be used by an 
observer assessing the patient or the patient’s self-reporting adherence behavior. Figure 
22 shows the process with an example. The formal definition of adherence assessment 
with questionnaire =Def. Self-reported assay, which is such that there exists some patient 
p, questionnaire q, evaluant role r, scalar measurement datum m, adherence assessment 
with questionnaire objective g, and the self-reported medication adherence assessment 
• has specified input p and q 
• realizes r 
• r inherence in p 
• has specified output m 
• and is directed toward achieving goal g 
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(vi) Prescription filling and refilling assay is a medication adherence assay in which the 
time of the filled prescription has been assessed in order to measure the number of days 
in which the patient has medication on-hand (possession ratio) or the total number of 
days the patient is without medication (gap) in an observation period. The output of this 
assay is a time measurement datum (e.g., 01/01/2018) that is about evaluant (i.e., patient). 
Figure 23 shows this type of assay. The formal definition of prescription filling and 
refilling assay =Def. Medication adherence assay which is such that there exists some 
patient p, pharmacist s, observer role r1, pharmacy computer c, pharmacy record d, 
concretization of pharmacy record q, evaluant role r, ratio measurement datum m, 
prescription filling and refilling objective g, and the prescription filling and refilling 
assay 
• has specified input p, s, and q 
 realizes r  
 has specified output m 
 and is directed toward achieving goal g
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Figure 17 Medication Adherence Assay 
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Figure 18 Drug Concentration Assay 
Note: -- -- -- represents instances classes.  
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Figure 19 Direct Observation Assay 
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Figure 20 Dosing Event Recording  
Note: -- -- -- represents instances classes. 
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Figure 21 Pill Counting 
Note: -- -- -- represents instances classes.  
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Figure 22 Self-Reported Medication Adherence Assessment 
Note: -- -- -- represents instances classes. 
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Figure 23 Prescription Refill Assessment 
Note: -- -- -- represents instances classes. 
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3. Behavioral intervention.  
Adherence intervention is categorized under Ontology for Biomedical 
Investigation (OBI) planned process (Peters & Consortium, 2009) (Figure 24). 
“Adherence behavior intervention specification” is a subclass of OBI plan specification 
and is defined as=Def. A plan specification that prescribes actions whose goal is to 
improve, prevent, or maintain the behavior process. A medication intervention 
specification takes into account the specific patient’s psychological determinants; 
duration of medication taking (i.e., long-term vs. short-term); medication-taking phases 
(i.e., initiation vs. continuation); mode of delivery; the behavioral theory(ies) used to 
explain the determinants’ effect on behavior; and the standard protocol for developing, 
implementing, and evaluating the type of intervention used.  
“Medication adherence intervention” is the process that carries out the adherence 
intervention specification and is defined as=Def. A planned process that 
has_specified_input some concretizes some cancer treatment regimen specification. 
“Behavior change technique” is defined as=Def. A planned process that is part of 
the medication adherence intervention and is designed based on one or more behavioral 
theories with a goal to influence one or more psychological determinants of behavior.  
“Medication adherence intervention objective specification” is defined as =Def. 
An objective specification that describes the endpoint of medication adherence 
intervention.  
“Intervention delivery process” is defined as=Def. A planned process by which 
the planned behavior intervention is delivered to an individual or group of individuals 
using either the personal or impersonal mode.  
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“The formal definition of planned behavior intervention” is defined as=Def. A 
planned process which is such that there exists some human a, technology tool t, mode of 
delivery role r, concretization of behavior intervention specification c, intervention 
delivery process d, behavior change method m, behavior intervention specification s, 
behavior intervention objective g and the planned behavior intervention process  
• initiated by a  
• has specified input some concretizes s 
• s concretized as c 
• has part m, d, and 
• d realizes r  
•  r inheres in t 
• directed toward achieving the goal g of p 
An example of medication adherence intervention designed to improve self-belief, 
using a mobile application (patient partner), is shown in Figure 25. The categories of 
intervention are adopted from the behavior change technique, while the mode of delivery 
is built based on the review carried out by Sawesi, Rashrash, Phalakornkule, Carpenter, 
& Jones (2016). 
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Figure 24 Behavior Change Intervention 
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Figure 25 Medication Adherence Intervention 
Note: -- -- -- represents instances classes. 
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4. Measuring Medication Adherence Determinants 
Findings about adherence determinant can be represented in two ways: (i) Expand 
the planned process to include class “medication adherence barrier assessment” that has a 
goal to assess medication adherence, so the result is a scalar measurement datum that has 
a measurement unite label and value. (ii) The clinical history-taking class from the 
Ontology of General Medical Science OGMS http://www.ontobee.org/ontology/OGMS 
has been expanded to include a new class, adherence history taking. as shown in Figure 
26. The class is defined as “Clinical history taking that records the past event and 
circumstances that are or may be relevant to a patient’s current medication-taking state 
with an account of actual and perceived determinants of adherence.”  
Adherence determinate finding can then be the outcome of this process. The class 
adherence history taking is defined as= a clinical history taking in which there exists 
some information entity i (adherence finding), some material entity (patient) m, and 
measurement datum d and adherence history taking 
• has output i 
• has part d 
• is about m
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Figure 26 Adherence Determinate Finding
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5. Drawing a conclusion based on data  
To say that this patient did not take his or her medication because of a negative 
belief about the effects of the medication or because of the cost of treatment, or even the 
burden of a schedule, is to draw an inference based on some findings (data item) that this 
reason causes that behavior. Therefore, there is a need for a class that represents this 
implication or inference. A class was named that drawing a conclusion based on data and 
was adopted from Ontology of Biomedical Investigation 
http://www.ontobee.org/ontology/OBI. Drawing a conclusion based on data is=Def. A 
planned process p in which new information is inferred from existing information. That 
means that there is a planned process, which is such that there exists some data item 
(measurement data) m, conclusion c (conclusion based on data). and planned process 
• has participant d  
• has output c 
Therefore, a subclass named causal determinant of non-adherence assessment is 
created and defined as drawing a conclusion based on data from assays that evaluate the 
disposition or quality inherent in an organism and comparing it with an evaluative result 
or another organism’s data to make conclusions about this difference. The output of this 
process is an information-entity-named conclusion about causal adherence determinant, 
which is defined as a conclusion about a determinant that expresses the result of 
reasoning about something being a causal determinant or a risk factor. For a variable to 
be a causal determinant, a correlation must exist and precedes the outcome. This 
determinant can change and, when changed, can cause change in risk for the outcome. 
Therefore, as shown in Figure 27, causal determinant of non-adherence assessment is 
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defined as=Def. A drawn conclusion based on data d, in which there exists some 
information entity (conclusion about causal adherence determinant) i, measurement data 
(adherence determinant measurement data) m, assay (adherence determinant assay) a, 
disposition d, human h and, causal determinant of non-adherence assessment 
• has participant m 
• m output of a  
• m about d 
• d inheres in h 
• has output i 
Increasing the medication adherence rate 
The medication adherence process has duration. If the goal was to measure a daily 
event, such as by using a medication event-monitoring system, then the duration of the 
process would be recorded daily (one day). Making a conclusion or inference about the 
patient adherence rate is based on the accumulated data that is taken daily, weekly, 
monthly, or yearly; it is a class-named medication-adherence-pattern assessment, which 
is defined as drawing a conclusion based on data in which the adherence data aggregated 
is evaluated based existing knowledge to generate a conclusion that patient adherence is 
increasing, decreasing, or no changes occur. This class has an output class-named 
adherence-pattern conclusion, which is an information content entity that is inferred from 
the adherence measurement rate. Therefore, as shown in Figure 28, the medication 
adherence pattern assessment=Def. A drawn conclusion based on data such that there 
exists some information content entity (conclusion based on adherence rate) i, 
measurement data (adherence rate measurement datum) m, planned process (adherence 
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assay) p1, process (adherence process) p1, human (patient) h and, medication adherence 
pattern assessment: 
• has participant m 
• m output of p1  
• m about h 
• h participates in p1 and p2 
• m is measurement of p1 
• has output i 
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Figure 27 Conclusion Based on Data About Causal Belief 
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Figure 28 Conclusion Based on Data About Adherence Pattern
 206 
 
4.4 Model Integration  
Several terms in MAB-Ontology were built based on other ontologies’ categories. 
For instance, medication adherence assessment, drawing conclusion-based data, and 
behavior intervention were built by expanding the planned process class in the Ontology 
of Biomedical Investigation (Peters & Consortium, 2009). The mental function 
anatomical structure and the psychological factors were built based on the Mental 
Functioning Ontology (Hastings et al., 2012) and Emotion Ontology (Hastings et al., 
2011). Breast cancer was built based on the Disease Ontology (Schriml et al., 2011). The 
breast cancer treatment regimen built based on the Drug Ontology (Hanna et al., 2013).  
Leverage Ontology Summary:  
Seven ontologies were used for leveraging. Table 22 below, summaries the 
included ontologies. 
Table 22 Listing of Leveraged Ontology 
Source Terms Description Data type 
Basic Formal 
Ontology 
35 Upper-level ontology used to support 
domain ontologies to enhance 
interoperability and connection with other 
biomedical ontologies.  
Controlled 
terminology/ 
ontology 
Ontology of 
Biomedical 
Investigation 
3380 A domain ontology for biomedical data 
annotating.   
Controlled 
terminology/ 
ontology 
Human Disease 
Ontology 
17632 An ontology representing human disease 
classifications and organized by etiology. 
Controlled 
terminology/ 
ontology 
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Ontology for 
General 
Medical 
Science 
124 A domain ontology for representing 
diagnosis and treatment of disease, 
carcinomas, and other pathological 
entities. 
Controlled 
terminology/ontology 
The Drug 
Ontology 
434663 A domain ontology used to enhance 
comparative effectiveness researchers 
studying claims data. 
Controlled 
terminology/ontology 
Mental 
Functioning 
Ontology 
692 A domain ontology focused on mental 
functioning aspects.  
Controlled 
terminology/ontology 
Behavior 
Change 
Technique 
Taxonomy 
114 A taxonomy-classified behavioral 
intervention.  
Taxonomy 
 
4.5 Model Formalization  
The resulting model was built manually using Protégé to formalize the entities 
and relations discussed above into an OWL for computation. A term definition was given 
for each class and property entered in Protégé, as shown in Figure 29. The process starts 
by extracting BFO ontology and other upper classes borrowed from other ontologies 
using OntoFox, as shown in Figure 30. Then MAB-Ontology classes and the relationship 
used were entered into Protégé. The resulting ontology included 629 classes, 529 
individuals, 51 object property, and 2 data property. Figure 31 shows the object 
properties and data properties included in the MAB-Ontology.  
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Figure 29 MAB-Ontology Viewed in Protégé 
 
Figure 30 Class extraction process using OntoFox 
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Figure 31 Object Properties and Data Properties in the MAB-Ontology 
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4.6 MAB-Ontology Evaluation 
In order to meet the last step of the ontology construction process, evaluation 
methods were carried out.  
4.6.1 Face Validity of Intermediate Representation 
This method was carried out by experts who assessed whether the domain was 
represented properly by the entities and relationships established so that both the 
ontology’s key entities and a formal description of the domain knowledge could be 
detected.  
a. Content validity. The included information was validated against both the 
structure and entity validity. Structure validity ensures that entities and relations in MAB-
Ontology cover the domain in a proper manner, while entity validity is intended to 
eliminate and add entities. An informal meeting was conducted with domain experts, Dr. 
JJ and Dr. JC, in which several rounds were taken. Several data items were included, 
based on Dr. JJ’s model validation. Figure 32 shows a representation of those items in 
Protégé. The outcomes of the face-validity conducted with Dr. JC include: comorbidity 
class removed from treatment-related and assigned under disease-related. Cognitive 
impairment was also removed from patient-related and was added to the disease-related 
class. A class of treatment, based on the cancer’s stage, was added under treatment plan 
specification. Breast cancer patients were categorized, based on their menopausal-to 
postmenopausal status: female breast cancer patients and premenopausal female breast 
cancer patients, because their breast cancer treatment is specific, were based on 
menopausal status. Breast cancer was also categorized, based on hormone receptors, as 
shown in Figure 33. 
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Figure 32 Factors Impact Medication Adherence Process 
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Figure 33 Breast Cancer Patient and Disease Categories   
b. Structure validly. Informal face-validity performed with an expert in BFO 
structure to validate consistency of the entities included in the MAB-Ontology with 
upper-level ontology. The iterative process outcomes were: simplifying the model 
representation, defining the breast cancer treatment process, adding class conclusion 
based on data, and defining age under measurement datum. Change relations “realizes 
some concretizes some” into “has_specified_input some concretizes some.” Based on Dr. 
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WD’s philosophy, plan specification is a generic-dependent entity; it cannot be realized 
in a planned process, only a realizable entity can be realized in a process.  
4.6.2 Competency Question 
The MAB-Ontology was validated against the sample list of questions, as shown 
below. MAB-Ontology successfully answered all the questions.   
CQ1: Is it possible to search the MAB-Ontology for factors that impact 
medication adherence? MAB-Ontology successfully represents the 69 instances of factors 
that influence adherence to the endocrine therapy/regimen, as shown in Figure 34. These 
factors were extracted from the literature review discussed in chapter two, part one.  
 
Figure 34 Adherence Influencing Factors 
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CQ1a: Is it possible to search the MAB-Ontology for cognitive-related factors 
that impact medication adherence? MAB-Ontology successfully represents the 21 
instances that represent the psychological factors influence adherence to endocrine 
therapy, as shown in Figure 35.  
 
Figure 35 Psychological Determinants of Medication Adherence 
MAB-Ontology successfully answered all competency questions from CQ1b to 
CQ1l in the same way as CQ1a.  
CQ1m: Is it possible to search the MAB-Ontology for factors that influence 
medication adherence among 60 year-old patients who take tamoxifen? Yes, MAB-
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Ontology successfully retrieved factors that impact patients under those categories, as 
shown in Figure 36.  
 
Figure 36 Determinants Influence 60 Year-old Patients Taking Tamoxifen 
CQ1n: Is it possible to search the MAB-Ontology for a patient who discontinues 
tamoxifen due to the side effects? MAB-Ontology successfully answered this question. 
First, patients 1, 2, and 3 are premenopausal. That means they are taking tamoxifen as 
aromatase inhibitors as prescribed for postmenopausal women. Patient 1 is the only 
patient to discontinue his tamoxifen and mentioned side effects as a reason. Patient 2 is at 
risk for non-adherence, because she is fasting some days (i.e., religious reasons), as 
shown in Figure 37.  
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Figure 37 Patient Discontinues Tamoxifen Due to Side Effects 
MAB-Ontology successfully answered all competency questions from CQ1o-
CQ1b in the same way as CQ1n.  
CQ2: Is it possible to search the MAB-Ontology for behavioral change techniques 
used to change/sustain medication adherence? MAB-Ontology successfully answered this 
question, as shown in Figure 38.   
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Figure 38 Behavioral Change Techniques Used to Change Medication Adherence 
CQ2: Is it possible to search the MAB-Ontology for Information Technology 
platforms used to change/sustain medication adherence? MAB-Ontology successfully 
answered this question, as shown in Figure 39.  
 
Figure 39 Information Technologies Used to Change Medication Adherence 
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CQ3: Is it possible to search the MAB-Ontology for methods used to measure 
medication adherence? MAB-Ontology successfully answered this question, as shown in 
Figure 40.  
 
Figure 40 Methods Used to Measure Medication Adherence 
CQ3a: Is it possible to search the MAB-Ontology for direct methods used to 
measure medication adherence? MAB-Ontology successfully answered this question as 
shown in Figure 41.  
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Figure 41 Direct Methods Used to Measure Medication Adherence 
MAB-Ontology successfully answered all competency questions from CQ3b and 
CQ3c and they gave the same results as CQ3a.  
CQ3d: Is it possible to search the MAB-Ontology for methods used to measure 
medication adherence among patient 1? MAB-Ontology successfully answered this 
question, as shown in Figure 42.  
 
Figure 42 Methods Used to Measure Medication Adherence Among Patient 1 
CQ3e: Is it possible to search the MAB-Ontology for questionnaires used to 
measure adherence to endocrine therapy/regimen? MAB-Ontology successfully 
represented 45 questionnaires used to measure adherence to the endocrine regimen 
(Figure 43). 
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Figure 43 Questionnaires Used to Measure Adherence to Endocrine Therapy 
CQ3d: Is it possible to search the MAB-Ontology for questionnaires used to 
measure only medication adherence behavior? MAB-Ontology successfully answered 
this question, as shown in Figure 44.  
 
Figure 44 Questionnaires Used to Measure Only Medication Adherence Behavior 
CQ3e: Is it possible to search the MAB-Ontology for questionnaires used to 
measure medication adherence behavior and the barriers that impact medication 
adherence? MAB-Ontology successfully answered this question, as shown in Figure 45.  
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Figure 45 Questionnaires Measure Medication Adherence Behavior and Barriers 
MAB-Ontology successfully answered CQ3f, CQ3g and they had the same 
answers as the CQ3e&d.  
CQ4: Is it possible to search the MAB-Ontology for theories used as a part of a 
plan specification for medication adherence intervention development? MAB-Ontology 
successfully represented 49 medication adherence-related theories, as shown in Figure 
46. Behavioral theory is part of a plan specification when designing an intervention. 
Based on the review of 1,057 articles, 49 behavioral theories associated with medication 
adherence behavior were included in this project.  
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Figure 46 Behavioral Theories Used for Medication Adherence Intervention  
CQ4a: Is it possible to search the MAB-Ontology for theoretical constructs of the 
theory of planned behavior? MAB-Ontology successfully answered this question, as 
shown in Figure 47. Each theory has its constructs as parts. Interventions may target only 
one construct. For example, improve self-efficacy.  
 223 
 
 
Figure 47 MAB-Ontology for Theory of Planned Behavior Constructs 
CQ4b: Is it possible to search the MAB-Ontology for theories that include 
constructs that represent behavior capability belief? MAB-Ontology successfully 
answered this question (28 out of 49 theories), as shown in Figure 48.  
 
Figure 48 Theories That Include Constructs Represent Behavior Capability Belief 
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MAB-Ontology successfully answered the competency question CQ4c in the 
same way as CQ4b.  
CQ5: Is it possible to search the MAB-Ontology for patients who are at risk for 
non-adherence? MAB-Ontology successfully answered this question, as shown in Figure 
49. 
 
Figure 49 Patients at Risk of Non-adherence 
CQ5a: Is it possible to search the MAB-Ontology for a 60 year-old breast cancer 
patient who is at risk for non-adherence? MAB-Ontology successfully answered this 
question, as shown in Figure 50. 
 
Figure 50 Sixty Year-old Breast Cancer Patient at Risk for Non-adherence 
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CQ6: Is it possible to search the MAB-Ontology for non-adherent patients? 
MAB-Ontology successfully answered this question based on an 80% cutoff for 
adherence rate, as shown in Figure 51. 
 
Figure 51 MAB-Ontology for Non-adherent Patients 
CQ7: Is it possible to search the MAB-Ontology for medication adherence risk 
factors? MAB-Ontology successfully represents the 21 risk factors that influence the 
patient adherence process, as shown in Figure 52. 
 
Figure 52 MAB-Ontology for Medication Adherence Risk Factors 
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4.6.3  Use Case Scenario 
A program officer planning to design a new intervention to improve medication 
adherence among breast cancer patients uses information technology platforms. The data 
gathered by the program officer at the point of care is an indication that there is a high 
number of fluctuations in the adherence rate among the breast cancer population in the 
first three months. The program officer does not understand the reasons for this 
discrepancy. He wishes to identify a list of potential factors influencing the adherence 
rate among breast cancer patients in the first three months. He requires this knowledge in 
order to develop a proper intervention plan that will reduce the rate of non-adherence 
among this population. The answer to this question is shown in Figure 53. 
 
Figure 53 Factors That Influence Adherence in the First Three Months 
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4.6.4 Consistency Checking 
Pellet identified no inference class violations for equivalency or unsatisfiability 
for the MAB-Ontology, as shown in Figure 54.   
 
Figure 54 Consistency Checking 
4.6.5 Compliance with OBO Foundry.  
OBO design principles were followed in building MAB-Ontology where possible. 
The majority of the principles were considered throughout data collection, analysis, and 
evaluation. Table 23 shows the OBO principles and the rational for the adherence or non-
adherence.  
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Table 23 Adherence to the OBO Foundry Principles. 
OBO FP ID Principle Type Rationale MAB-Ontology 
FP 001 Open  The ontology must be open and 
accessible to be used without 
any restriction. 
Protégé OWL generates 
automatically. 
FP 002 Common format Ontology expressed in a 
common shared syntax.  
Protégé generates OWL, 
RDF, and XML. 
FP 003 Identifier space Each class and relation should 
have a unique URI identifier. 
Protégé generates 
unique URIs for all 
entities. 
FP 004 Versioning The ontology provider has 
procedures for identifying 
distinct successive versions.  
Protégé versioning. 
FP 005 Clearly 
delineated 
content 
The ontology has clearly-
specified and clearly-delineated 
content.  
Natural language used 
for terms, definitions. 
FP 006 Textual 
definitions 
Terms should be defined so that 
their precise meaning within the 
context is clear to 
a human reader. 
Literature, other existing 
ontology, no two terms 
share a definition. An 
Aristotelian definition 
was used. 
FP 007 Relations Uses unambiguously defined 
relations following the pattern of 
Definitions in OBO Relation 
Ontology. 
Use of OBO Relations 
Ontology (RO). 
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FP 008 Documented Publications for users and 
developers. 
Dissertation publication; 
planned article 
publications. 
FP 009 Plurality of 
users 
URIs used in a variety of 
projects. 
n/a/a/t 
FP 010 Commitment to 
collaboration 
Consistency with OBO Foundry 
ontologies and use of relevant 
terms from neighboring 
ontologies. 
Adherence to OBO 
principles, leveraging 
with other ontologies. 
 
FP 011 Locus of 
authority 
Maintain integrity and 
further development. 
Author’s name will be 
provided on ontology 
website.  
FP 012 Naming 
conventions 
Enhance communication,  
simplify, support integration, 
facilitate automated tools. 
Consistently naming 
entities. 
FP 016 Maintenance in 
light of 
scientific 
advances 
Ensure the improvement of 
ontology over time. 
Domain engagement and 
update schedule. 
 
4.6.6 Compliance with METHONTOLOGY 
Besides following the OBO principles in developing MAB-Ontology, 
METHONTOLOGY methods played an essential role in MAB-Ontology construction. 
The compliance to the METHONTOLOGY’s steps and strategies was evaluated. Table 
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24 shows the basic steps the METHONTOLOGY method includes. The result indicates 
that all the steps were satisfied, except for the maintenance stage as it is an iterative step. 
Table 24 Adherence to the METHONTOLOGY Method  
METHONTOLOGY Validation (yes-no) Added Value 
Specification Yes  Adopted to medication adherence. 
Knowledge acquisition Yes  Classify factors based on treatment 
phase. 
Conceptualization Yes  Intermediate representation using 
VUE. 
Formalization Yes  Human language-based definition, 
using Aristotelian definition. 
Integration Yes  Leverage with other ontologies.  
Implementation Yes  Using Protégé. 
Evaluation Yes  Competency question, face-validity. 
Documentation  Yes  Tables, text, figures, poster, and 
dissertation. 
Maintenance  n/a Iterative cycle.  
n/a=not applicable at this phase.  
4.6.7 Expandability Testing  
The developed model was tested for expandability and reusability by using it in 
another domain. Using the MAB-Ontology to include factor-impact-technology use was 
one of the aims of this work at the proposal level. However, and due to the fact that they 
are two separate domains, a decision was made to design one domain and expand it to 
include the other. Technology adoption ontology (TAB-Ontology) was built using the 
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same approach used for MAB-Ontology. The ontology scope was to represent factors that 
have an impact on technology adoption, specifically mobile-based technology. The 
motivation behind this is featured in the first chapter. Several competency questions were 
developed to clarify the ontology’s scope. The following are some and the list could be 
expanded.  
Q1: Is it possible to search TAB-Ontology for a list of factors that impact technology 
adopting at the initiation phase?  
Q2: Is it possible to search TAB-Ontology for the factor that has a negative value among 
people older than age 50?  
Q3: Is it possible to search TAB-Ontology for the human who discontinues the 
technology? 
Knowledge extraction was built based on the data extracted from review carried 
out by Sawesi, Rashrash, Phalakornkule, Carpenter, & Jones (2016). A total of 113 
classes and 69 individuals were created and integrated with the MAB-Ontology using the 
same structure, with some modifications, as shown in Figure 58. Three classes were 
created under class human to define the type of technology user named: technology 
adopter, technology user, and technology discontinuer. Technology adoption class was 
represented as a subclass of the behavior process. The methods used to assess factors that 
impact medication adherence were expanded to include methods use to assess factor-
impact technology-use. The relations used between the instances were the same as those 
used for MAB-Ontology instances (Relation Ontology).  
Evaluation of the model was carried out in two ways: (1) Face-validity with a 
domain expert. An informal meeting with Dr. JJ was done to validate the ontology 
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structure and content validity. An adjustment was made, based on feedback. (2) 
Competency Question: An evaluation based on answering the competency questions was 
implemented.   
Q1: Is it possible to search TAB-Ontology for a list of factors that impact 
adopting technology? The model successfully answered this query and extracted all the 
factors that impacted technology adoption, as shown in Figure 55. 
 
Figure 55 TAB-Ontology 
Q2: Is it possible to search TAB-Ontology for the factor that has a negative value 
among people older than age 50? TAB-Ontology successfully answered the query and 
extracted the factors in question, as shown in Figure 56.  
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Figure 56 Factors with Negative Value 
Q3: Is it possible to search TAB-Ontology for the human who discontinues the 
technology? TAB-Ontology successfully answered the question, as shown in Figure 57. 
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Figure 57 Technology Discontinuation 
Results of the TAB-Ontology demonstrated that MAB-Ontology is expandable. 
TAB-Ontology classes were integrated among MAB-Ontology by adding new class 
categories and sub-classes in existing classes. 
The reasoning for this is that it can be done using a single query, such as question 
number (Q1), as well as using a combination of some or all of the dimensions of the 
influencing factor. More complex queries could be used. 
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Figure 58 Expanding MAB-Ontology
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CHAPTER FIVE: CONCLUSION AND FUTURE WORK 
5.1 Conclusion 
Medication adherence is a complex domain. It poses difficulty for clinical 
research. Several technology-based interventions have been developed to maintain and 
enhance the medication adherence process. However, a lack of common terms to define 
medication adherence behavior and its determinants that impact patients who participate 
in this process is evident in the literature when these areas are examined. This, in turn, 
limits the ability to develop interventions and measure the effectiveness of these 
interventions. From an informatics viewpoint, data sharing is challenging, due to 
heterogenicity, complicity, and a lack of standardization.   
To provide insight into the aforementioned challenge and support knowledge 
accumulation, this work has applied ontological engineering to develop an overarching 
framework to clarify the multiple dimensions of medication adherence domain, based on 
reviewing 1,304 articles. The determinants impact adherence to medication, along with 
technology adoption extracted from 49 theories, to represent factor-impact adherence to 
medication and technology use based on theory. The relationship between terms was 
implemented. Precise interpretation is a necessary prerequisite for automatic search, 
retrieval, and processing of adherence data. This approach describes the information 
related to adherence domain in such a way that domain users can easily obtain relevant 
information based on their need. MAB-Ontology focuses on three major areas: 
determinants that impact adherence to medication, methods used to measure adherence, 
and technology interventions used to enhance medication adherence. The latter is based 
on the theoretical constructs extracted from behavioral theories used to study, change, 
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and sustain medication adherence This ontology was developed using a methodology that 
merges the approach (METHONTOLOGY and FBO Principles), which made 
development of the MAB-Ontology more effective and intuitive. This approach is 
illustrated to provide guidance on how to develop an ontology in the medication 
adherence domain. The proposed approach was used to capture, organize, and define 
knowledge to develop a derived ontological framework to integrate dimensions of 
medication adherence and relationships. BFO was used to facilitate domain 
interoperability between MAB-Ontology and other systems. Finally, the proposed 
ontology framework was validated through face-validity, a series of competency 
questions, case scenario, and against METHONTOLOGY and OBO/BFO principles.  
5.2 Impact of the Research 
1. This study provides a unified method for developing a computerized-based adherence 
model that can be applied among various disease groups and different drug 
categories.  
2. The METHONTOLOGY approach addressed the details of identifying the ontology 
domain scope, classes, and properties, along with demonstrating the usefulness of 
developing an ontology based on BFO principles. Building an MAB-Ontology based 
on BFO should facilitate the process of its expanding to support other tasks and its 
interoperability with other ontologies. 
3. This approach has been developed to deliver explicit knowledge related to medication 
adherence that can be utilized in areas such as healthcare decision-making, 
intervention development, detection risk for non-adherence, capturing current and 
future findings from medication adherence-related publications, and so on.  
 238 
 
4. An intervention developer can query and navigate through the MAB-Ontology to 
select adherence to medication factors among specific patients or age groups in order 
to build a tailored intervention. The researcher will be able to study different factors 
that impact technology use in order to design a technology-based intervention.   
5.3 Challenges in the Development of MAB-Ontology 
1. The first limitation of this work is that the MAB-Ontology was created by a single 
person; a collaborative approach that reflects diverse viewpoints is preferred. 
2. Manual extraction of data from existing research was tedious, time-consuming, and 
challenging. It requires both domain and tool expertise.  
3. Developing an ontology using software tools, such a Protégé for knowledge 
representation, was challenging and requires practice with the tool before building the 
model.  
4. Building an ontology based on an upper-level ontology requires deep philosophical 
skills in order to represent the nature of terms as they exist in reality. Terms, such as 
belief, desire, and intention, lack clear definition in the literature. Such ambiguity of 
terms/definitions makes it difficult for an ontology developer to decide under which 
BFO category they belong.  
5. There is no candidate category in a BFO ontology for process quality, as BFO has no 
occurrent counterpart. Ontologies aligned with BFOs need to include process quality 
or be attributed to represent, for instance, the increase and decrease in adherence rate 
and regular and irregular adherence processes. Therefore, in order to represent 
changes in process, either by representing them as an attribute of the material entity 
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or as a complicated process with no reference to these attributes, this infers that there 
is no mechanism of comparison of process based on their attributes. 
6. Access to real-time observations and evidence-based practice data could be used to 
represent the domain vocabulary more precisely according to demand.  
5.4 Future Work 
The MOB-Ontology was developed as a proof-of-concept and to demonstrate the 
advantages of data sharing. The following work can be done to improve the ontology:  
1. The MAB-Ontology can be expanded by considering other out-of-scope areas, such 
as adherence to physical exercise and considering other chronic diseases and drug 
categories.  
2. A real use case based on this work could be used to validate the implementation of 
MAB-Ontology in healthcare-related areas.  
3. Knowledge capturing and analysis could be done automatically. The advanced text 
mining method with natural language processing (NLP) could be an alternative to 
extracting knowledge from scientific publications and entering them into the 
ontology. 
4. Further development of end users’ interface using Semantic web technology, such as 
OWL API, is important.  
5. MAB-Ontology can be extended to represent medication adherence based on 
healthcare-provider perspectives to gain a comprehensive picture that one viewpoint 
may not cover. 
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APPENDICES  
Appendix 1 
INDIANA UNIVERSITY INSTITUTIONAL REVIEW BOARD (IRB)  
APPLICATION FOR NON-HUMAN SUBJECTS’ RESEARCH  (RESEARCH NOT 
SUBJECT TO FDA OR COMMON RULE DEFINITIONS OF HUMAN SUBJECTS RESEARCH)                                                                                                                       
Principle Investigator:   MacDorman     
Please type only in the gray boxes.  To mark a box as checked, double-click the box, select “checked,” and 
click “OK.”  
SECTION I:  PROJECT TYPE  
STOP!   Before completing this form, refer to the IU Human Subjects Office website for additional 
information on determining if the activity is considered Human Subjects Research at 
http://researchadmin.iu.edu/HumanSubjects/hs_submissions.html. Investigators conducting 
research falling into the categories below do not need to submit an application to the IRB unless 
specifically requested by a sponsor or collaborator.   
 Project meets the definition of human subjects research; however, Indiana University is not 
considered engaged in this research in accordance with the Office for Human Research Protections 
(OHRP) Guidance on Engagement of Institutions in Human Subjects Research available at 
http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.    
Project is NOT a systematic investigation designed to expand the knowledge base of a scientific 
discipline or other scholarly field of study through the attempt to answer research question(s) and 
draw conclusions. Please proceed to Section II.  
IU Researcher(s) receive de-identified information (not Health Information) from another source or 
institution which requires confirmation that no IU IRB Review is needed. Please proceed to Section II.  
Research Involving Data on Decedent PHI.  Please indicate that the following criteria are satisfied:  
The use is solely for research on the identifiable health information of decedents.  
The PHI sought is necessary for the purposes of the research; and  
Upon request, the covered entity disclosing the data may require the investigator to provide 
documentation of the death of the individual(s) about whom information is being sought.  
De-Identified Health Information.  The research involves the use or disclosure of de-identified health 
information.  
This project type may only be selected if the following is true:  The health information excludes all 
of the following: (1) Name; (2) All geographic subdivisions smaller than a state, including street 
address, city, county, precinct, zip codes if the geographic unit of combining all the same three initial 
digits contains more than 20,000 people; (3) All elements of dates (except year) for dates directly 
related to an individual, including birth date, admission date, discharge date, date of death; and all 
ages over 89 and all elements of dates (including year) indicative of such age, except that such ages 
and elements may be aggregated in a single category of age 90 or older; (4) Telephone numbers; (5) 
Fax numbers; (6) Electronic mail addresses; (7) Social security numbers; (8) Medical record numbers; 
(9) Health plan beneficiary numbers; (10) Account numbers; (11) Certificate/license numbers; (12) 
Vehicle identifiers and serial numbers, including license plate numbers; (13) Device identifiers and 
serial numbers; (14) Web universal resource locators (URLs); (15) Internet protocol (IP) address 
numbers; (16) Biometric identifiers, including finger and voice prints; (17) Full face photographic 
images and any comparable images; and (18) Any other unique identifying number, character, or 
code.  
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 Coded Private Information or Biological Specimens.  The research involves only coded private 
information or specimens.  To qualify for this type of review, the private information or specimens 
cannot be linked to specific individuals by the investigator(s) either directly or indirectly through 
coding systems.  To qualify, both of the following conditions must be met:  
 The private information or specimens were not collected specifically for this proposed research 
project through an interaction or intervention with living individuals.  NOTE: If this condition 
is not met, then your research involves human subjects and requires a human subjects research 
submission. AND  
The investigator(s) cannot readily ascertain the identity of the individuals to whom the private 
information or specimens pertain because: (mark which option(s) applies)  
The key to decipher the code will be destroyed before the research begins.  
The investigator(s) and the holder of the key will enter into an agreement prohibiting the 
release of the key to the investigator(s) under any circumstances, until the individuals are 
deceased.  
  1 IRB Form v3/31/2016  
1610704702 determined IU IRB Review Not Required 7-Nov-2016 
 Other.  Please explain:       
  
For additional information on research with coded private information or biological specimens, please refer 
to the OHRP Guidance on Research Involving Coded Private Information or Biological Specimens 
(October 16, 2008) at: http://www.hhs.gov/ohrp/policy/engage08.html.   
SECTION II:  PROJECT DESCRIPTION  
1. Provide a brief description, in lay terms, of the purpose of the proposed project and the procedures to 
be used.  
A modified Delphi Study to assess a developed model of medication adherence. A model will be validated by a 
dissertation committee's members. Multiple rounds may take place based on their comments.       
2. Provide a list of all data points that will be collected below or attach a data collection sheet.  
A data collection sheet will be attached.  
  
Statement of Principle Investigator.  By submitting this form, the Principle Investigator acknowledges 
that he/she has personally reviewed this report and agrees with the above assessment.  
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Appendix 2 
Literature Source Type: Examples Before Analysis 
Source Type  
Assay 
How is medication 
adherence described/ 
defined in the source 
type? 
How is medication 
adherence measured 
in the source type? 
How is medication adherence 
impacted in the source type? 
 
How is 
intervention 
described and 
what contains in 
the source type? 
What are the critical 
themes, concepts 
concerning MAB 
research in this 
source type?   
(Williams et 
al., 2011) 
Process, behavior, 
skip dose, non-
adherence, non-
persistence, 
discontinuation. 
Direct, indirect, 
questionnaire, self-
reporting. 
Patient-related factors: patients’ 
beliefs toward TAM and AIs, 
patients’ knowledge about the 
disease, forgetfulness, smoking, 
age, and race or ethnicity. 
Therapy-related factors: therapy 
duration, side effects. 
Plan, treatment, 
knowledge, 
interview. 
Granularity of 
adherence factor, 
Intervention 
component, 
assessment methods.  
(Meichenbaum 
et al., 1987) 
Behavior, medication 
management, 
Electronic 
monitoring, 
Disease stage, age, patient related, 
and perceived interference, 
Prescription 
simplicity, 
Stage of breast 
cancer, adherence 
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compliance, 
persistence, 
adherence, 
medication taking. 
prescription refill 
records. 
additional prescribed medications. feedback and 
social support. 
range. 
(Nasseh et al., 
2012) 
Behavior, medication 
taking, persistence, 
adherence, skipping 
dose. 
Medication 
possession ratio, 
objective 
measurement. 
Age, healthcare system-related 
factors: patient- provider 
relationship. Socioeconomic 
factors: medication cost, work 
complexity, religious practices, 
and marital status. 
Reminder, plan, 
intervention. 
Length of study, 
treatment class, 
impact type, 
intervention goal. 
(Nekhlyudov 
et al., 2011) 
Behavior, medication 
taking, self-
management, self-
regulation, treatment 
monitoring, not 
taking. 
Direct measurement, 
indirect 
measurement, self-
reporting, and 
electronic 
monitoring, 
Patient-related factors, medication-
related factors, treatment-related 
factors, healthcare-related factors, 
socioeconomic-related factors. 
Service 
delivered 
through 
technology, 
mobile app, 
internet, email, 
Behavior, direct 
assay, indirect 
assay, Intervention 
content, duration, 
outcome, healthcare 
engagement, 
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questionnaire, pill 
count, insurance data, 
possession ratio. 
video game, 
telemonitoring, 
message, text, 
reminder, 
education, 
Motivation for 
health behavior 
change, long-
standing 
adherence. 
technology-related 
factor, patient 
related factor. 
(Bodenreider 
et al., 2006) 
process, planed 
process, drug 
management, 
behavior, adherence, 
persistence, non-
persistence. 
Self-reporting, and 
electronic 
monitoring, 
questionnaire. 
Beliefs, age, side effect, 
medication cost, schedule burden, 
comorbidity, disease stage. 
Structured 
interview, health 
belief model, 
education, 
feedback, 
monitoring 
Disease stage, 
efficacy, impact 
type, stage of 
cancer. Long term 
and short term. 
  
 
245 
(Kaplan et al., 
2011) 
Behavior, skipped 
dose, missed dose, 
discontinuation, drug 
management. 
Self-reported, 
medication 
monitoring system, 
subjective, objective. 
Beliefs, knowledge, social impact, 
healthcare relation, 
communication. 
Knowledge, 
education, 
session, text 
message. 
Drug class, type of 
cancer estrogen 
receptor–positive 
breast cancer. 
(Winstead et 
al., 2012) 
Behavior, process, 
habit, initiation, 
continuation. 
Direct measurement, 
indirect 
measurement, self-
reporting, and 
electronic 
monitoring, pill 
count, prescription 
refill. 
Awareness, attitude, information 
searching, prior Knowledge, 
novelty, past experience 
Treatment 
theory, 
consequences 
actions, 
awareness, 
information 
searching.  
Knowledge, 
social support, 
emotion, 
motivation, 
reinforcement, 
feedback. 
Behavior time, 
belief, emotion 
granularity, desire, 
intention, 
awareness, decision 
making, information 
processing, planned 
study, goal of study, 
intervention.   
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(Trust, 2012) Decision making, 
problem recognition, 
stop taking. 
Monitoring. confirmation of expectation, 
expertise, perceived alternative, 
evaluation process, dissatisfaction, 
perceived knowledge skills, social 
impact, belief, reinforcement, 
antecedent, health consequence, 
self-efficacy, perceived behavioral 
control, emotion.  
Telemonitoring, 
internet, 
monitoring, 
Study design, 
type of study, 
theory, 
constructs, stage 
of adherence, 
disease type,  
days covered. 
Adherence rate, 
comorbidity, 
components, 
theoretical 
construct. 
(Brendryen, & 
Kraft, 2008) 
Adherence, behavior, 
quality of life, missed 
dose. Non-continue. 
Subjective ratings, 
questionnaires, 
objective strategies, 
Biochemical 
measurement, dose–
response curve, 
Pharmacy databases. 
Cognitive dissonance, social 
learning, self-regulation, 
experience, social norm, 
behavioral belief, social rule, 
barrier, facilitator, external 
variable, modifying factor, cue to 
action. 
Mobile, 
reminder, social 
cognitive theory. 
Adopter, social 
interaction, severity. 
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(Coulter, 
2008) 
Multidimensional, 
Behavior, activity 
taking medication as 
recommended, 
agreed on 
recommendation. 
Medication event 
monitoring systems, 
objective electronic 
measurement, 
Morisky scale 
directly observed 
therapy, therapeutic 
drug monitoring, 
measurement of 
biologic marker, 
electronic 
compilation, dosing 
histories, counts of 
returned tablets / 
untaken dosage 
forms, prescription 
records.  
Capability, behavior, intervention, 
threat, intention, goal, 
environment, desire, attitude, self-
determinant, feeling, self-care, 
ability, opportunity, 
socioeconomic, fear, engagement, 
maintenance, relapse. 
Role-play, 
education, 
support, 
communication, 
habit 
maintaining, 
comorbidity 
treating as 
depression, 
motivation. 
Behavior, subjective 
measurement, 
objective 
measurement, 
patient related 
factor, treatment-
related, disease-
related, healthcare 
system-related, 
socioeconomic- 
related, intervention 
component 
granularity. 
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(Andrade et 
al., 2006) 
Behavior, Typology. refills, self-report 
patient questionnaires 
and diaries, 
assessment of 
patients’ clinical 
responses and/or 
physiological marker 
or effect. 
 Goal setting, 
outcome, 
problem solving, 
action planning, 
review behavior 
goal, behavior 
discrepancy, 
commitment, 
monitoring, 
feedback, self-
monitoring, 
social support, 
knowledge. 
Knowledge 
granularity, belief 
granularity, social 
impact granularity, 
emotion granularity, 
reinforcement 
granularity, 
environment 
granularity, goal, 
component.   
(Buntin et al., 
2011) 
Process, typology, 
initiation, 
discontinuation, 
implementation, 
 Knowledge, skills, social role, 
belief about capability, optimism, 
belief about consequences, 
reinforcement, intention, goal, 
Education 
material to 
promote 
medication 
Intervention content 
granularity, 
adherence typology, 
adherence 
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persistence, 
management of 
adherence.  
memory, decision process, 
environment, social influence, 
emotion, behavioral regulation. 
knowledge, 
video to 
promote 
adherence, what 
do instruction if 
dose is missed, 
development of 
less complex 
medication.  
measurement 
granularity, factors 
granularity. 
(Culter et al., 
2018) 
  Socio-economic factors, healthcare 
team and system-related factors, 
condition-related factors, therapy-
related factors, patient-related 
factors, demographics, medicines.  
expenditure, and 
satisfaction, 
Technology 
platforms, 
mobile 
application, text 
message, video.  
adherence typology, 
adherence 
measurement 
granularity, factors 
granularity. 
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(Nasseh et al., 
2012) 
Patient compliance, 
attitude to health, 
behavior. 
Direct observed 
therapy, medication 
tracking device. 
motivation, coping, expectancy, 
usefulness, ease of use, autonomy, 
communication, punishment, 
reinforcement. 
packaging 
methods, 
reminder, pill 
organizing, 
telephone 
support, text 
message 
reminder, 
internet based, 
low literacy and 
resources 
intervention, 
aged 
intervention. 
belief, emotion 
granularity, desire, 
intention. 
(Iuga, & 
McGuire, 
2014) 
Patient compliance, 
attitude to health, 
health behavior, 
Direct observed 
therapy, medication 
tracking device. 
Incorrect drug dose administration, 
omitted dose, error drug 
administration, over dose, under 
Medication 
therapy 
management 
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behavior, 
pharmacology, 
medication 
management. 
dose, ease of use medication. medical device 
usage for 
medical 
intervention,  
medication 
knowledge, take 
medication at 
correct time, 
take medications 
as prescribed. 
(Coulter et al., 
2008) 
Patient compliance, 
attitude to health, 
behavior, medication 
taking, drug 
administration, 
medical intervention 
Direct observed 
therapy, medication 
tracking device 
High cost of transportation, 
inability or difficulty accessing a 
pharmacy, lack of healthcare 
insurance, medication cost, 
cultural and lay beliefs about 
illness and treatment, family 
dysfunction low income, religious  
Video game, 
internet, social 
media, tele-
monitoring, 
motivation, 
social impact, 
past adherence 
Behavior, direct 
assay, indirect 
assay, Intervention 
content, duration, 
outcome, healthcare 
engagement, 
technology-related 
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  and healthcare team / history, 
technology 
satisfaction. 
factor, patient 
related factor. 
(Bailey, 
McMullin, & 
Coble, 2001) 
Adherence type, 
direct measurement, 
indirect 
measurement. 
Electronic 
monitoring, 
prescription refill 
records. 
Provider and those of the patient, 
weak capacity of the system to 
educate patients and provide 
follow-up, lack of knowledge of 
adherence and effective 
interventions for improving it, 
overworked. 
 Disease stage, 
efficacy, impact 
type, stage of 
cancer. Long term 
and short term. 
(Bramwell et 
al., 2010) 
Adherence type, 
direct measurement, 
indirect 
measurement, drug 
error, mode of 
delivery, type of 
Medication 
possession ratio, 
objective 
measurement. 
healthcare providers, lack of 
incentives and feedback on 
performance short consultations, 
lack of incentives and feedback on 
performance, inability to establish 
community support and self-
reward, learning, 
habit formation, 
graded task, 
incentive, self-
reward, 
restructuring 
Drug class, type of 
cancer estrogen 
receptor–positive 
breast cancer. 
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intervention, 
management process. 
management capacity. physical 
environment, 
self-role, 
punishment, 
self-belief, 
persuasion, 
learning. 
(Ajzen, 2002) Adherence typology, 
direct and indirect 
granularity. 
Direct measurement, 
indirect 
measurement, self-
reporting, and 
electronic 
monitoring, 
questionnaire, pill 
count, insurance data, 
possession ratio. 
Goal setting, outcome, problem 
solving, action planning, review 
behavior goal, behavior 
discrepancy, commitment, 
monitoring, feedback, self-
monitoring, social support, 
knowledge, education, 
consequences, social comparison, 
cue to action, reward, learning, 
habit formation, graded task, 
regimens, 
development of 
combination 
drugs, 
development of 
patient-drug 
delivery 
systems, 
establishment of 
patient 
Behavior time, 
belief, emotion 
granularity, desire, 
intention, 
awareness, decision 
making, information 
processing, planned 
study, goal of study, 
intervention.   
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incentive, self-reward, 
restructuring physical 
environment, self-role, 
punishment, self-belief, 
persuasion, learning. 
assistance 
programs,  
use of adherence 
enhancing. 
 
(Khan et al., 
2007) 
Process, behavior, 
skip dose, non-
adherence, non-
persistence, 
discontinuation. 
Self-reporting, and 
electronic 
monitoring, 
questionnaire. 
Education material to promote 
medication knowledge, video to 
promote adherence, instruction if 
dose is missed, less complex 
medication regimens, development 
of combination drugs, 
development of patient- drug 
delivery systems, assistance 
programs, adherence enhancing 
packaging, reminder, pill 
organizing, text message reminder.  
game, internet, 
social media, 
tele-monitoring, 
motivation, 
social impact, 
past adherence 
history, 
technology 
satisfaction. 
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(Winstead et 
al., 2012) 
Behavior, medication 
management, 
compliance, 
persistence, 
adherence, 
medication taking. 
Self-reported, 
medication 
monitoring system, 
subjective, objective. 
requires significant behavioral 
changes. Socio-economic-related: 
low level of education, lack of 
family or social support network, 
unstable living conditions, 
unemployment, homeless, 
burdensome schedule, limited 
access to healthcare facilities, long 
distance from treatment center. 
role-play, 
education, 
support, 
communication, 
habit 
maintaining, 
comorbidity 
treating as 
depression, 
motivation. 
 
(Walters, 
2007) 
Behavior, medication 
taking, persistence, 
adherence, skipping 
dose. 
 Substance abuse, smoking, visual 
impairment, hearing impairment,  
cognitive impairment, impaired 
mobility or dexterity, swallowing 
problems. Condition-related: 
chronic conditions, lack of 
symptoms, severity of symptoms, 
Goal setting, 
outcome, 
problem solving, 
action planning, 
review behavior 
goal, behavior 
discrepancy, 
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rate of progression, severity of 
disease, co-morbidity; as 
depression, psychotic disorder, 
mental retardation/developmental. 
commitment, 
monitoring, 
feedback, self-
monitoring, 
social support, 
knowledge, 
education, 
consequences, 
social 
comparison, cue 
to action, 
reward, learning, 
habit formation, 
graded task, 
incentive. 
(McCowan et 
al., 2008) 
Behavior, medication 
taking, self-
 system-related: provider-patient 
relationship, poorly developed 
reward, 
restructuring 
awareness, decision 
making, information 
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management, self-
regulation, treatment 
monitoring, not 
taking. 
health services with inadequate or 
non-existent reimbursement by 
health insurance plans, poor 
medication distribution systems, 
disparity between the health 
beliefs of the healthcare. 
physical 
environment, 
self-role, 
punishment, 
self-belief, 
persuasion. 
processing, planned 
study, goal of study, 
intervention.   
(Ma et al., 
2008) 
process, planed 
process, drug 
management, 
behavior, adherence, 
persistence, non-
persistence. 
 use, health status, affordability, 
adherence, optimism, beliefs, self-
efficacy, health service 
use, barriers and 
social support, illness 
perceptions, income. 
  
(Hershman, 
2010) 
Behavior, skipped 
dose, missed dose, 
discontinuation, drug 
management. 
Self-reported, 
medication 
monitoring system, 
subjective, objective. 
Beliefs, knowledge, social impact, 
healthcare relation, 
communication. 
Knowledge, 
education, 
session, text 
message. 
Drug class, type of 
cancer estrogen 
receptor–positive 
breast cancer. 
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(Sawesi et al., 
2016) 
Behavior, process, 
habit, initiation, 
continuation. 
Direct measurement, 
indirect 
measurement, self-
reporting, and 
electronic 
monitoring, pill 
count, prescription 
refill. 
Awareness, attitude, information 
searching, prior Knowledge, 
novelty, past experience. 
Treatment 
theory, grouping 
and 
consequences 
actions, 
awareness, 
information 
searching.  
Knowledge, 
social support, 
emotion, 
motivation, 
belief change, 
reinforcement, 
feedback, goal, 
environment, 
self-regulation. 
Behavior time, 
belief, emotion 
granularity, desire, 
intention, 
awareness, decision 
making, information 
processing, planned 
study, goal of study, 
intervention.   
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(Brendryen, & 
Kraft, 2008) 
Understanding 
reason is medication 
needed and 
consequences of poor 
compliance (+/-). 
Understanding of 
instructions about 
medications (+/-) 
Understandings of 
side-effects (+/-) 
Understanding 
benefit of treatment 
(+/-) Patient beliefs. 
Electronic 
monitoring, 
prescription refill 
records. 
Disability, drug and alcoholic 
abuse. Therapy-related: 
complexity of medication, 
regimen; number of prescriptions, 
treatment required mastery of 
certain technique, duration of 
therapy. 
 
Structured 
interview, health 
belief model, 
education, 
feedback, 
monitoring. 
outcome, healthcare 
engagement, 
technology-related 
factor, patient 
related factor. 
(Van den Berg 
et al., 2007) 
Burdensome 
schedule, rout of 
administration  
Feeling stigmatized. 
Ratio, objective 
measurement. 
Age, patient related, and perceived 
interference, additional prescribed 
medications. 
Simplicity, 
feedback and 
social support. 
Intervention 
component, 
assessment methods. 
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(Herbst et al., 
2014) 
Visual impairment, 
hearing impairment, 
cognitive 
impairment, 
immobility or 
dexterity, dysphagia. 
Direct, indirect, 
questionnaire, self-
reporting. 
frequent change in medication 
regimen, lack of medication 
benefit of therapy, medications 
with social stigma attached to their 
use, actual or perceived unpleasant 
side effects, treatment interferes 
with lifestyle. 
Plan, treatment, 
knowledge, 
interview. 
Stage of breast 
cancer, adherence 
range. 
(Tildesley et 
al., 2010) 
Complexity of 
medication regimen, 
duration of therapy, 
frequent change in 
regimen, lack of 
immediate benefit of 
therapy, social 
stigma, actual or 
perceived unpleasant 
side effect. 
electronic 
monitoring, 
questionnaire, pill 
count, insurance data, 
possession ratio. 
treatment-related factors, 
healthcare-related factors, 
socioeconomic-related factors. 
Technology 
platforms, text, 
mobile 
application, 
video game, 
social media, 
tele-monitoring, 
motivation, 
social impact, 
past adherence.  
outcome, healthcare 
engagement, 
technology-related 
factor, patient 
related factor 
 261 
 
Appendix 3 
 Glossary of Terms: Examples Included in Protégé  
Terms/ Phrases Description Definition Type (noun/ 
verb) 
Definition 
Source 
Behavior  Patterned activity of a 
whole organism in a 
manner dependent upon 
some combination of that 
organism's internal state 
and external conditions. 
Noun MFO 
http://www.onto
bee.org/  
Medication 
adherence   
Medication 
taking 
behavior; 
behavioral 
response to 
medication, 
medication 
compliance.  
Behavior associated with 
the consumption or use of 
chemical substance with 
presumed curative, 
preventive or medicinal 
value in accordance with 
the provider’s 
recommendation 
concerning the timing, 
dosage, frequency, and 
duration. 
Noun  Sawesi 
Medication 
initiation  
Primary 
adherence, 
adoption. 
Medication adherence 
that is associated with the 
new prescription for a 
given course of treatment. 
Noun Sawesi 
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Medication 
continuation 
Secondary 
adherence, 
medication 
implementati
on, 
medication 
execution, 
medication  
Maintenance. 
Medication adherence 
behavior that is 
associated with the 
continuation of an 
existing prescription or 
order for a given course 
of treatment. 
Noun Sawesi 
Medication 
non-initiation  
Primary non-
adherence, 
dispensation 
delay. 
Medication adherence 
behavior in which the 
new prescription did not 
initiate or dispense within 
a defined number of days 
after the medication was 
ordered. Usually within 
30-90 days.  
Noun Sawesi 
Suboptimal 
adherence 
Inadequate 
adherence. 
Medication adherence 
behavior associates with 
incorrect dosing, 
incorrect time, incorrect 
frequency, and incorrect 
duration.  
Noun Sawesi 
Medication 
discontinuation 
Stop taking 
medication 
Medication taking 
behavior that is 
Noun  Vrijens et al., 
2012 
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associated with the act of 
stop taking the treatment 
for whatever reasons. 
Medication 
discontinuation 
for database 
analysis 
Termination, 
end of 
therapy. 
Failure to have a 
medication dispensing 
within a defined 
number of days after 
exhaustion of the days’ 
supply of the previous 
dispensing some time 180 
days used (often includes 
exhaustion of any 
stockpiled medication 
accumulated from 
previous dispensings). 
Noun Sawesi  
Adequate 
medication 
continuation 
Adequate 
adherence, 
Adherence, 
Ongoing 
adherence 
Compliance, 
adequate 
secondary 
adherence 
Medication continuation 
adherence with either an 
overall (1) gap in days of 
medication possession 
not exceeding 20% of the 
days between the date of 
initial dispensing and the 
date of the end of the 
measurement period (gap 
measures) or (2) number 
Noun  Raebel et al., 
2013 
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of days of medication 
possession of no less than 
80% of the days between 
the Date of initial 
dispensing and 
Date of the end of the 
Measurement period 
Inadequate 
medication 
continuation 
Partial 
adherence, 
poor 
adherence, 
inadequate 
adherence, 
non-
compliance, 
inadequate 
secondary 
Adherence 
Medication adherence 
with either an overall (1) 
gap in days of medication 
possession exceeding 
20% of the days between 
the date of initial 
dispensing and the date of 
the end of the 
measurement period or 
(2) number of days of 
medication possession of 
less than 80% of the days 
between the date of initial 
dispensing and the date of 
the end of the 
measurement period. 
Noun  Raebel et al., 
2013 
Cut-point   The value on an ordinal 
scale beyond which 
Noun Sawesi 
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values are regarded as 
abnormal adherence. The 
cut-points commonly 
Used are:  
Gap: Cmg >20%, Npmg 
>20% 
Possession: Mpr <80% 
Pdc <80%. 
Medication 
persistence 
 The duration of time from 
initiation to 
discontinuation of 
therapy or last dose 
taking. It is dichotomous 
(yes/no). 
Noun Nekhlyudov et 
al., 2011 
Early-stage 
persistence 
Point-of-
time, 
persistence, 
early 
persistence, 
persistence 
A new prescription was 
dispensed (medication 
initiated) and at least one 
Refill of that prescription 
was Dispensed over a 
time period consistent 
with (implying) current 
use of the drug.  
Noun  Nekhlyudov et 
al., 2011 
Time period  Time period allowed or 
considered between the 
one dispending and the 
Noun  Sawesi  
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following expected refill 
or time period 
Allowed after last refill in 
the measurement period. 
Early-stage 
non-persistence 
Early non-
persistence 
Failure to have the new 
prescription refilled over 
a time period consistent 
with current use of the 
drug.  
Noun  Nekhlyudov et 
al., 2011 
Later-stage 
persistence 
Second stage 
persistence, 
refill 
compliance, 
persistent/per
sistence 
Two or more refills (i.e., 
the new prescription was 
Dispensed and at least 2 
refills of that prescription 
were Dispensed) over a 
time period consistent 
with current use of the 
drug. The time period can 
Span several refills that 
occur over 6 months, 12 
months, or longer.   
Noun  Nekhlyudov et 
al., 2011 
Later-stage 
Non-
persistence 
Second stage 
non-
persistence, 
suboptimal 
persistence, 
Failure to have two or 
more refills over a time 
period consistent with 
current use of 
The drug. Can imply 
 Nekhlyudov et 
al., 2011  
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not 
persistent, 
non-
persistence 
either that the patient has 
discontinued the 
medication or that usage 
is inconsistent over time.   
Duration of 
treatment 
course  
Length of 
therapy 
The period from the start 
to the end of a treatment 
course. 
Noun  Apollo_sv  
http://www.onto
bee.org/  
Adherence rate  Percentage of doses taken 
as prescribed from 
initiation of medication or 
start of observation until 
stop medication or end of 
observation.  
Noun Hugtenburg et 
al., 2013 
Habituation  Habit  A condition resulting 
from repeating the 
consumption or use of a 
chemical substance 
presumed curative, 
preventive or medicinal 
value with a desire (but 
not compulsion) to 
continue taking the 
medication for the sense 
of improved well-being 
or prevent disease 
Noun Sawesi 
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recurrence which it 
engenders; and no 
tendency to miss or skip 
the dose; postpone the 
dose; or stope dose for 
whatever reason without 
provider 
recommendation. 
Direction of 
effect  
Type of 
effect 
Determinants were 
classified according to 
their positive, negative, 
neutral effect on 
adherence. 
Noun  Kardas et al., 
2013  
Determinant Factor Anything that contributes 
causally to a result. 
Noun https://www.ma
cmillandictionar
y.com/us  
New 
prescription 
 A prescription that 
include a new medication 
or therapy that has not 
been used before by the 
patient to treat current 
disease or condition.  
Noun Sawesi 
Defined 
number of day 
 Number of day in which 
prescription presumed to 
be dispensed after it has 
Noun  
 
 
Sawesi 
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been ordered. The 
commonly used days are 
30 or 60 days.  
 
Intention-non-
adherence 
 A medication adherence 
behavior preceded by a 
rational decision to 
deviate from treatment 
regimen. Or has an 
appraisal process as part.  
Noun  Sawesi 
Non-intention-
non-adherence 
 A medication adherence 
behavior that is largely 
driven by circumstance 
out of an individual’s 
control such as 
forgetfulness, lack of 
resources.   
 
Noun  
Sawesi 
 
Management of 
adherence 
process 
 The process of 
monitoring and 
supporting patients’ 
adherence to medications 
by healthcare systems, 
providers, patients, and 
their social 
networks. 
Noun  Vrijens et al., 
2013 
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Behavioral 
intervention 
 Psychological or behavior 
intervention is a 
combination of program 
elements, strategies, or 
modalities designed to 
influence psychological 
or behavioral processes or 
outcomes. 
Noun  Eagle_i resource 
ontology 
http://www.onto
bee.org  
Adherence use 
mems 
 ‘‘adherent’’ when at least 
a single mems cap 
opening occurred on a 
given day. 
Noun  Ayelward et al., 
2014 
Non-adherence 
use mems 
 When all prescribed 
mems cap openings were 
missed on any given day 
(e.g., patient prescribed to 
take morning and evening 
dose and didn’t open the 
electronic pill container. 
Noun  Ayelward et al., 
2014 
Direct 
measurement 
of medication 
adherence 
 Determination of 
medication adherence by 
directly observe 
consumption process or 
assaying the presence of 
medication in body fluid.   
Noun  Sawesi  
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Indirect 
measures of 
adherence  
 Determination of 
medication adherence by 
measuring related 
parameters other than 
object characteristics and 
convert them into 
measurement of the 
characteristics in question 
(medication adherence).  
Noun  Sawesi  
Objective 
measurement 
of adherence 
 Determination of 
medication adherence 
based on impartial 
measurement, observable 
phenomenon and not on 
personal feeling or bias. 
Noun Sawesi  
Subjective 
measurement 
of adherence  
 Determination of 
medication adherence-
based observer’s personal 
judgment and on how 
well the drug was taken.  
Noun Sawesi 
Drug 
concentration 
in blood  
 A measurement method 
that determine the 
concentration of drug in a 
blood serum sample. 
Noun  Sawesi  
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Drug 
concentration 
in urine 
 A measurement method 
that determine the 
concentration of drug in a 
urine sample. 
Noun  Sawesi  
Evaluation of 
presence of 
biomarker 
given with drug 
 A measurement method 
that record medication 
adherence based on an 
ingestible sensor 
imbedded in tablet (tablet 
co-encapsulated) that 
digitally records 
medication ingestion by 
sending a signal to a 
patch worn by patient. 
The information then 
transfers to physician 
device.  
Noun Sawesi 
Direct 
observation of 
patient taking 
medication 
 Determination of 
medication adherence by 
direct watching and 
recording patient taking 
medication.  
Noun  Sawesi  
Secondary 
database 
analysis 
 Is analysis of data that 
was collected for another 
primary purpose.  
Noun  Sawesi  
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Medication 
possession ratio 
(MPR)  
 Ratio of the number of 
days for which a patient 
has medication on hand 
divided by the total 
number of days a patient 
was observed. Used for 
refill adherence  
Noun  Raebel et al., 
2013 
Medication 
possession ratio 
modified 
(MPRM)  
 Ratio of the days’ supply 
of medication dispensed 
during specified 
observation period 
excluding last refill, 
divided by number of 
days between first and 
last dispensing. Used for 
refill adherence. 
Noun Raebel et al., 
2013 
Medication 
refill adherence 
 Total days’ supply 
divided by number of 
days in observation 
period. For refill 
adherence. 
Noun Raebel et al., 
2013 
MEDSUM  Number of daily doses 
dispensed in a period 
divided by number of 
Days in period. 
Noun Bryson et al., 
2007 
 274 
 
Proportion of 
days covered 
(PDC) 
 Total number of days’ 
supply dispensed during 
specified observation 
period divided by number 
of days (from first to end) 
in patient’s observation 
period. For refill 
adherence and 
persistence.  
Noun  Bryson et al., 
2007 
Continuous 
measure of 
medication 
acquisition 
(CMA) 
  Total days’ supply of 
medication obtained 
throughout study period 
divided by number of 
days from first dispensing 
until study completion 
date (number of days in 
observation period). For 
refill adherence.  
Noun  Raebel et al., 
2013 
Continuous, 
single interval 
measure of 
medication 
acquisition 
(CSA) 
  Single-interval measure 
of medication 
availability; provides an 
adherence value for each 
patient between 
dispensings (not 
Overall study period).  
Noun  Raebel et al., 
2013 
 275 
 
Compliance 
rate or 
compliance 
ratio (CR) 
  Sum of days’ supplies 
minus days’ supply 
obtained at last 
dispensing divided by 
number of days from 
First up to (not including) 
last dispensing date.  
Noun  
 
Raebel et al., 
2013 
Refill 
compliance rate 
(RCR)  
 The total days’ supply 
was multiplied by 100 
and divided by the 
number of days from first 
to last medication 
dispensation. 
Noun  Hess et al., 2006 
Refill 
compliance 
(RECOMP)  
 Total number of drug 
days that apply within an 
observation period plus 
oversupply divided by the 
number of days in the 
observation period. 
Noun  Hess et al., 2006 
Medication- 
total 
(MED_TOT) 
 Total supply of pills 
dispensed divided by the 
total number of days 
elapsed. 
Noun  Andrade et al., 
2006 
Medication 
interval 
 Ratio of days’ supply 
obtained at the beginning 
Noun  Raebel et al., 
2013 
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(MED_INT) of a specific time interval 
to the days elapsed before 
the subsequent refill. 
Refill 
compliance rate 
(RCR)  
 The total days’ supply 
was multiplied by 100 
and divided by the 
number of days from first 
to last medication 
dispensation. 
Noun  Dunbar et al., 
2010 
New 
prescription 
medication gap 
(NPMG) 
  Time between date 
provider first prescribes 
medication until first of 
the following: end of 
follow-up, censoring due 
to patient being switched 
to alternate therapy or 
medication discontinued 
by prescriber. For 
initiation, persistence and 
refill adherence. 
Noun  Raebel et al., 
2013 
Continuous 
measure of 
medication 
gaps (CMG) 
Or cumulative 
 Number of days in which 
the medication was not 
available (gap) between 
each prescription fill, 
divided by the number of 
Noun  Raebel et al., 
2013 
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medication gap 
(CMG) 
days between the first and 
last medication fill during 
the study period. For 
refill adherence.  
Continuous 
multiple 
interval 
measure of 
over supply 
(CMOS) 
 Total number of days’ 
supply (if gap) or surplus 
divided by days in 
observation period or 
total days to next fill. 
Noun  Lam et al., 2015 
Cumulative gap 
ratio 
 Number of days in which 
the medication was not 
available (gap) between 
each prescription fill, 
divided by the number of 
days between the first and 
last medication fill during 
the study period. 
Noun  Andrade et al., 
2006 
Medication out 
(MED_OUT or 
MEDOUT) 
 Total number of days 
without medications 
divided by the total days 
of observation. 
Noun  Bryson et al., 
2007 
Days between 
fill adherence 
rate (DBR) 
 The total days’ supply 
was subtracted from the 
number of days between 
Noun  Raebel et al., 
2013 
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dispensations divide by 
the number of days 
between dispensations.  
Prescription Written 
instruction  
A document that 
represents verbal or 
written order given by an 
authorized person 
instructing a patient to 
obtain and use a medical 
device, prescription or 
undergo a procedure. 
Noun NCI thesaurus  
http://www.onto
bee.org  
Patient Sick person Patient is the involved 
participant in the 
Treatment process. 
Noun   
Healthcare 
encounter 
Patient 
present at 
healthcare 
system 
A temporally-connected 
healthcare process that 
has as participants an 
organization or person 
realizing the healthcare 
provider role and a 
person realizing the 
patient role. The 
healthcare provider and 
patient are realized during 
the healthcare encounter. 
 OBI 
http://www.onto
bee.org 
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Physical 
examination   
 A sequence of acts of 
observing and measuring 
qualities of a patient 
performed by a clinician; 
measurements may occur 
with and without 
elicitation. 
 OGMS  
http://www.onto
bee.org 
Clinical history 
taking  
 An interview in which a 
clinician elicits a clinical 
history from a patient or 
from a third party who is 
reporting on behalf of the 
patient. 
Verb  OGMS  
http://www.onto
bee.org 
Prescribe   Is to issue a medical 
prescription or 
recommend with 
authority.  
Verb  Oxford 
dictionary 
Start new 
medication  
 Instantiate new 
prescription.   
Verb Sawesi 
Change current 
medication 
 Substitute the current 
medication with another.  
Verb Sawesi 
Continue 
current 
medication  
 Issue refill or recommend 
continuation. 
Verb Sawesi 
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Discontinue 
medication by 
physician 
 Advise to stop the current 
medication for medical 
reason.  
Verb Sawesi  
Behavioral 
intervention  
 An intervention that use a 
combination of program 
elements or techniques, 
strategies, and modalities 
to influence 
psychological or 
behavioral processes or 
outcomes. 
Noun  ERO 
http://www.onto
bee.org 
Breast cancer   A thoracic cancer that 
originates in the 
mammary gland. 
Noun  DODI 
http://www.onto
bee.org 
Tamoxifen   An antineoplastic 
nonsteroidal selective 
estrogen receptor 
modulator (serum). 
Tamoxifen competitively 
inhibits the binding of 
estradiol to estrogen 
receptors, thereby 
preventing the receptor 
from binding to the 
estrogen-response 
Noun  NCI thesaurus  
http://www.onto
bee.org 
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element on dna. The 
result is a reduction in 
dna synthesis and cellular 
response to estrogen. In 
addition, tamoxifen up-
regulates the production 
of transforming growth 
factor b, a factor that 
inhibits tumor cell 
growth, and down-
regulates insulin-like 
growth factor 1, a factor 
that stimulates breast 
cancer cell growth. 
Aromatase 
inhibitors 
 Any compound that 
inhibits aromatase and 
reduces production of 
estrogenic steroid 
hormones. 
Noun  Biomodels  
https://bioportal.
bioontology.org/ 
 
Breast cancer 
stage  
 A staging of breast cancer 
for example by the 
American Joint 
Committee on Cancer, 
stage 7, or other coding 
system. 
Noun EFO 
http://www.onto
bee.org  
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Neoadjuvant 
endocrine 
therapy 
 Treatment given as a first 
step to shrink a tumor 
before the main 
treatment, which is 
usually surgery, is given. 
Examples of neoadjuvant 
therapy include 
chemotherapy, radiation 
therapy, and hormone 
therapy. It is a type of 
induction therapy. 
Noun  Fleming et al., 
2017 
Hormone-
receptor-
positive 
 Cancer cell with receptors 
for estrogen or 
progesterone as it needs 
these hormones to grow.  
Noun  Ingle et al., 2003 
Needs 
recognition 
 Is an adoption stage in 
which an individual 
recognizes the difference 
between the desired state 
and the actual condition.  
 Http://academic.
udayton.edu/joh
nsparks/tools/no
tes/conprobrec.p
df   
Perceived 
threat  
 A belief that a threatening 
health problem is serious 
and has potential negative 
consequences for 
lifestyle. This belief 
 Http://medical-
dictionary.thefre
edictionary.com/
health+beliefs%
3a+perceived+th
 283 
 
triggers awareness of the 
problem and stimulate 
individual to participates 
in a behavior to prevent 
or minimize the threat.   
reat 
 
Perceived 
severity   
 
 A perceived threat that 
refers to the individual's 
belief about the 
seriousness or severity of 
a disease. 
 Https://chirr.nlm
.nih.gov/perceiv
ed-
susceptibility. 
php 
Perceived 
susceptibility  
 
 A perceived threat that 
refers to the subjective 
belief about the risk of 
contracting a condition. 
 
 Https://chirr.nlm
.nih.gov/perceiv
ed-
susceptibility. 
php 
Needs 
awareness 
process  
 A process in which an 
individual exposed to 
internal or external 
trigger and perceived 
need toward technology.   
  
Internal stimuli   A stimulus that results 
from thoughts or 
physiological sensations 
that trigger a need. 
 Https://www.b2
bmarketing.net/e
n/resources/blog
/5-steps-
understanding-
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your-customers-
buying-process. 
External 
stimuli 
 A stimulus from an 
outside/environment that 
touches upon one of the 
five senses and trigger a 
need. 
 Http://rachel.gol
earn.us/modules
/en-
boundless/www.
boundless.com/
marketing/defini
tion/stimuli/inde
x.html 
Perceived 
needs  
 A cognitive 
representation of 
feeling or state of strongl
y wanting something.  
 Http://dictionary
.cambridge.org/
dictionary/englis
h/need 
Information 
search 
 A process in which the 
information seeker gets 
involved to satisfy his 
need either by activating 
the knowledge stored in 
his/her memory or by 
acquisition of information 
from the environment 
using different sources.   
  
Perceived 
uncertainty  
 A subjective perception 
of need of information 
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 about object or situation. 
It is a state of lack of 
information.   
In-memory 
search process  
 
 An information searching 
process in which an 
information seeker 
examining memory for 
available information. 
 Lee, y. (2006). 
Determinants of 
consumers' 
information 
search patterns 
in online 
marketing 
communication. 
Prior 
knowledge  
 A knowledge that occurs 
in an individual’s 
memory and it is 
multidimensional 
construct that comprised 
of three dimensions. 
  
Perceived 
familiarity of 
technology 
 A prior knowledge an 
individual knows or 
perceives about the 
attributes of the 
technology.  
 Http://journals.s
agepub.com.pro
xy.ulib.uits.iu.ed
u/doi/pdf/10.117
7/109634800326
1218 
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Perceived past 
experience  
 A prior knowledge an 
individual gained from 
the previous usage of the 
 https://www.res
earchgate.net/pr
ofile/deborah_ke
rstetter/publicati
on/223955678_p
rior_knowledge
_credibility_and
_information_se
arch/links/53f24
1a70cf2bc0c40e
731d5.pdf?origi
n=publication_li
st 
Perceived 
expertise 
 A prior knowledge that 
refers to an individual 
ability to perform 
product-related tasks 
successfully. 
 Khosrowjerdi, 
m., & iranshahi, 
m. (2011) 
Perceived 
novelty 
 The degree of contrast 
between present 
perception and past 
experience. 
 Https://pdfs.sem
anticscholar.org/
bdd8/00f3863b6
c6902f5e174e0b
40f86544f3e2d.
pdf 
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Perceptual 
process  
 An information searching 
process in which 
information seeker 
selects, organizes and 
interprets information 
received via his/her sense 
from different 
environmental sources 
when he/she has no prior 
knowledge and limited 
experience and expertise 
about a product 
(technology). The 
searching sources could 
be personal sources (e.g., 
Word of mouth from 
friends/family) and/or 
impersonal sources (e.g., 
internet/social media). 
  
Perceptual 
selection 
 A perceptual process in 
which a sensory data 
selected for more 
processing. 
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Perceptual 
categorization 
 A perceptual process in 
which selected sensory 
data mentally structured 
in coherent way. 
  
Perceptual 
interpretation 
 A perceptual process in 
which a meaning to the 
information received and 
categorized is assigned. 
  
Perceived 
technology 
attribute 
knowledge 
 A new knowledge about 
the product or/and its 
medium (e.g., application 
on phone) from an 
outside source via either 
acquisition or imitation. 
  
Perceived 
concrete 
attributes 
 A perceived knowledge 
of product that refers to 
the physical 
characteristics of a 
product or its medium 
and can be assessed base 
on some criteria such as 
color, size, or shape. 
  
Perceived 
abstract 
attributes 
 A perceived knowledge 
of product that refers to 
the pseudo-physical 
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characteristics which is 
intangible such as design, 
function, social and 
psychological benefits. 
Use initiation   An adoption stage occurs 
in response to cognitive 
representation (prior 
knowledge, perceived 
knowledge, beliefs, 
feeling and attitude).   
  
Evaluation 
process 
 
 A process in which a user 
evaluates his/her prior 
knowledge or the 
perceived knowledge and 
make belief, attitude and 
feeling toward the 
product.   
  
Performance 
expectancy 
Perceived 
benefit; 
benefit 
expected of 
technology, 
extrinsic 
motivation 
The degree to which an 
individual believes that 
using the system will help 
him or her to attain gains 
in job performance. 
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Perceived 
usefulness 
Job-fit; task-
technology 
fit 
The degree to which an 
individual believes that 
using a system would 
enhance his or her job 
performance. 
 TAM1/TAM2/I
DTPB/ MODEL 
OF PC; TTF 
Relative 
advantage 
 The degree to which an 
innovation is perceived as 
better than what already 
exists. 
  
Response 
efficacy 
 The extent people believe 
a recommended behavior 
effectively deters or 
alleviates possible harm. 
(tangible or intangible 
harm). 
 PMT 
Long-term 
consequence 
Outcome of 
outcome 
(e.g., using 
technology 
will improve 
adherence 
which will 
prevent 
cancer 
recurrence) 
A belief about the 
outcomes of behavior that 
have a pay-off in the 
future.  
 MPCU 
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Concern 
expectancy  
 The degree to which an 
individual believes that 
using the system 
associated with some 
drawback.  
 Model of pre-
implementation 
acceptance 
Response cost   The degree to which an 
individual believes that 
using a system associated 
with unpleasant, 
unexpected 
consequences.   
 PRT  
Note: for after 
acceptance 
phase 
Perceived risk   The degree to which an 
individual believes that 
there is an ease associated 
with the use of the 
system. 
 UTAUT 
Effort 
expectancy  
 The degree to which an 
individual believes that 
there is an ease associated 
with the use of the 
system. 
 UTAUT 
Perceived ease 
of use  
 
 The degree to which a 
person believes that using 
a particular system would 
be free of effort. 
 TAM/TAM2/ID
TPB/IDT 
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Complexity 
(antonym of 
ease of use)   
 
 The degree to which an 
innovation is perceived as 
relatively difficult to 
understand and use. 
 IDT/MPCU 
Compatibility  The degree to which an 
innovation is perceived as 
being consistent with the 
existing values, needs, 
and past experiences of 
potential adopters. 
 IDT/DTPB 
Job relevance  The degree to which 
target system is 
applicable to the 
individual’s job. 
 Tam2 
Social 
influence 
 The degree to which an 
individual perceives that 
important others believe 
that he or she should use 
the new system. 
 UTAUT 
Subjective 
norm  
 A social influence that 
refers to the person’s 
perception that most 
people who are important 
to him think he should or 
not perform the behavior.  
 TRA/TPB/TAM
2/IDTPB 
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Social factors  A social influence that 
represents cues individual 
receives from a member 
of his/her social structure 
which prompt him/her to 
behave in certain way.  
 MPCU 
Image  The degree to which use 
of an innovation is 
perceived to enhance 
one’s status in one’s 
social system. 
 TAM2 
 
Perceived 
behavioral 
control  
 Individual belief about 
ability to perform a given 
behavior. It encompasses 
of self-efficacy and 
controllability.  
 TPB/IDTPB 
Control over 
behavior 
Control 
belief/control
lability 
An individual belief 
about the presence of 
factors that may facilitate 
or impede performance of 
the behavior.  
 TPB 
Perceived 
facilitating  
Facilitation The degree to which an 
individual believes that 
an organizational and 
technical infrastructure 
 SCT/MPCU/ID
TPB 
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exists to support use of 
the system. 
Perceived 
barrier 
 Person’s perception on 
the obstacles to 
performing a 
recommended action.  
 HBM 
Self-efficacy  Individual confidence in 
his ability to perform a 
given behavior and 
overcome barrier. It 
encompasses skill and 
confidence that individual 
can effectively and 
consistently use.  
 SCT/HBM/PMT 
Perceived 
autonomy  
 The degree to which an 
individual perceives his 
or her actions. 
As a result of his or her 
own free will, without 
external interference in a 
certain situation. 
  
Perceived 
voluntariness 
 The degree to which an 
individual perceives his 
or her self not under the 
influence or control of 
 IDT/TAM2/UT
AUT 
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another person when 
making decision.  
Attitude toward 
technology 
 
 A cognitive 
representation results 
from an individual’s 
evaluation of the product 
or the behavior based on 
his/her beliefs, prior 
behavior, or feeling to 
form a favorable or 
unfavorable perspective.   
  
Affect toward 
technology 
 An affective 
representation that 
represents an individual’s 
feelings toward behavior 
or product such as feeling 
of satisfying, joy, elation, 
or pleasure, or 
depression, disgust, 
displeasure, or hate 
associated by an 
individual with a 
particular act. 
 The model of pc 
utilization.  
Http://www.swd
si.org/swdsi201
0/sw2010_prece
edings/papers/pa
104.pdf 
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Decision 
making process 
 A process in which an 
individual chooses to 
adopt or reject the 
technology based on 
his/her cognitive 
representation (prior 
knowledge, belief, 
attitude and feeling). 
  
Intention to 
initiate use  
 Is a cognitive 
representation of act in 
which an individual 
perceived likelihood or 
“subjective probability 
that he or she will engage 
in a given behavior/adopt 
the technology. 
  
Behavior 
modification 
(initiation use)  
 A process by which an 
individual use the system 
as intended.   
  
Perceived 
performance 
experience 
 A knowledge that is 
gained from the 
performing a behavior. 
  
Use 
continuation 
 An adoption stage occurs 
based on prior 
performance experience 
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as well as belief, feeling, 
and attitude. 
Expectation 
confirmation 
 
 An evaluation process in 
which an individual 
evaluates his/her 
performance experience 
to confirm or update his 
prior belief, attitude. 
  
Perceived 
satisfaction 
 An affective 
representation that result 
from an individual 
assessment after having 
direct experience with a 
product or service in 
terms of whether that 
product or service has 
met his/her needs and 
expectations. 
 http://www.scial
ert.net/fulltext/?
doi=jas.2014.86
0.872&org=11 
 
Perceived 
confirmation of 
expectation 
 
 The degree to which an 
individual’s initial 
expectation about the 
performance of a system 
is being confirmed after 
having an experience 
with the system. 
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Intention to 
continuation 
 Is a cognitive 
representation of act in 
which an individual 
perceived likelihood or 
“subjective probability 
that he or she will 
continue engaging in a 
current behavior/ 
continue using the 
technology.” 
  
Intention to 
discontinue 
 
 Is a cognitive 
representation of act in 
which an individual 
perceived likelihood or 
“subjective probability 
that he or she will 
discontinue using the 
technology.” 
  
Technology 
adoption  
 A behavioral process that 
occurs in response to the 
cognitive representation. 
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